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ABSTRACT

Rhesus macaques represent a valuable model in biomedical research and in development
of vaccines and therapeutics. Due to the lack of reagents, the general properties of IgG and
corresponding cellular receptors (FcγR) in this species are poorly characterized. We engineered
recombinant IgGs containing each of the four rhesus macaque heavy constant region (CH)
subclasses. To define FcγRs that mediate IgGs, we identified and characterized three FcγR
classes, and generated recombinant cDNA constructs. cDNA IgH constructs were created by
fusing – by sequence overlap extension PCRs – a gene segment encoding the murine variable
heavy domain specific for the hapten NIP, an established specificity system for assessing
antibody effector functions, with rhesus macaque CH fragments. The complete IgH constructs
were transfected into J558L cells, a murine IgH-lost myeloma cell line expressing anti-NIP light
chain. Secretion of engineered IgGs was determined by ELISAs using NIP-BSA and anti-

monkey IgG-specific antibodies. Molecular cloning methods were applied to identify and clone
FcγR genes, and recombinant FcγR cDNA constructs were created by the recombinant DNA
method. Four engineered IgH cDNA constructs were successfully created. Recombinant IgGs, in
the intact Ig form and retaining the original anti-NIP specificity, were successfully produced.
Compared to those in humans, FcγRs in rhesus macaques share high homology, yet also feature a
relatively high level of intra-species polymorphism and possess different N-linked glycosylation
patterns. FcγR constructs and expression vectors were successfully generated. The chimeric
recombinant IgGs are powerful tools for defining IgG functional properties and studying CH
structure/function relationship. These molecules can also be used as immunogens for generation
of antibodies capable of unequivocally detecting individual IgG subclasses. The findings on
FcγRs validate rhesus macaques as a model for studying antibody responses, and underscore the
need to take into account of the genetic heterogeneity. The FcγR constructs and vectors serve as
a tool for further studies of IgG/FcγR interactions.
We also reported here our findings from a separate study that the main female hormone,
17β-estradiol, is capable of restoring antibody responses to an influenza vaccine in a
postmenopausal mouse model, suggesting that immunogenicity and efficacy of influenza
vaccines should be evaluated in postmenopausal women.

INDEX WORDS: Rhesus macaque, Antibody, Immunoglobulin, IgG, IgG1, IgG2, IgG3, IgG4,
Fc receptor, FcγR, CD64, CD32, CD16, Allele, Polymorphism, Effector functions, Recombinant
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CHAPTER 1
INTRODUCTION AND STUDY OBJECTIVES

1.1. Rhesus macaques as a biomedical research model for human diseases
1.1.1. Rhesus macaques are widely modeled for human diseases and are considered the best
animal model for HIV/AIDS-related studies
The macaque model has been in the past century used for over 70 human infectious
diseases (Gardner and Luciw, 2008). From pandemics and notable global infections, such as
acquired immunodeficiency syndrome (AIDS), influenza, hepatitis, and tuberculosis, to a variety
of infections typically seen in pediatrics or in tropics, as well as diseases caused by newly
emergent infectious or other viral, bacterial, fungal, or parasitic pathogens, including potential
bioterrorism diseases, and oncogenic and chronic degenerative neurologic disorders, have been
studied in these animals. Other non-infectious diseases, such as Parkinson’s and Alzheimer’s
diseases and age-related disorders (Herodin et al., 2005; Carlsson et al., 2004), have also been
modeled in this versatile model.
Studies using animal models, including those with macaques, are crucial part for
understanding human disease mechanisms so as to improve diagnostics, to rationally design
vaccines, and to develop therapies. Use of the macaque model has proved to be an invaluable
resource for understanding pathogenesis of human diseases. This model has also represented
essential tools in vaccinology and passive immunization studies, such as for assessing the safety
and efficiency of new vaccines, including these properties of different adjuvants being used to
boost vaccine-induced immune responses (Sibal and Samson, 2001). Furthermore, macaques
have served as models for evaluation of efficacy of novel therapeutic applications, the
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mechanisms of action and pharmacokinetics of therapeutic antibodies, as well as strategies to
prevent allograph rejection in transplantation research.
The macaque species most commonly used as human disease models is rhesus macaques
(Macaca mulatta). Rhesus macaque animals are extensively available and are closely related
anatomically, physiologically, and phylogenetically to humans (Shedlock et al., 2009; Gardner
and Luciw, 2008). As a nonhuman primate (NHP) model, rhesus macaques are further valued by
their capacity of being naturally infected (and expressing disease symptoms) with NHP
etiologies similar to those causing related diseases that are difficult to study in humans (Gardner
and Luciw, 2008). In particular, rhesus macaques experimentally infected with simian
immunodeficiency virus (SIV) [considered the viral substitute of the AIDS-causing human
immunodeficiency virus (HIV), which does not replicate in most animal species (Lackner and
Veazey, 2007)], were shown to recapitulate human HIV infection immunologically,
virologically, and pathologically, as well as to develop AIDS-like disease (Shedlock et al., 2009;
Thomas, 2009). Rhesus macaque species, to date, is considered the most suitable model for
studying HIV pathogenesis as well as for testing potential therapies and developing vaccines
against HIV/AIDS (Shedlock et al., 2009; Nath et al., 2000). Indeed, this species has played a
key role in characterizing HIV viral immunobiology and in correlating the host innate and
adaptive immune responses with in vivo protection induced by HIV/AIDS vaccine candidates
(Shedlock et al., 2009; Gardner and Luciw, 2008). The recent availability of the rhesus macaque
genome sequence (Gibbs et al., 2007) and microarray chips of macaque-specific genes has
certainly increased the potential use of rhesus macaques in biomedical research.
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1.1.2. The rhesus macaque model: Incomplete characterizations of Ig/FcR immune system
components and mechanisms
When using the rhesus macaque model, particularly for evaluation of vaccines and
antibody (Ab)-based therapeutic applications, much of the attention has been focused on
assessing the host immune responses. In such responses, the two main molecular players are Ab
[also known as immunoglobulin (Ig)], and their cellular Fc receptor (FcR). These molecules
together carry out the various so-called cell-killing effector functions that aim to destroy and
“clear” pathogens. Indeed, Ab responses, particularly those of neutralizing Abs, correlate with in
vivo protection and represent the major protective components against SIV and HIV infections
(Schmitz et al., 2003). Many therapeutic agents directed at Igs or FcRs are under development
for treatment of various human diseases, including cancer and autoimmune disorders.
Nevertheless, apart from the general similarity of the overall biology of infection between SIVinfected rhesus macaques and HIV-infected humans, as well as the evolutionary relatedness
between these two species, the Ig/FcR immune system components and mechanisms of rhesus
macaque model relevant to studies of human diseases are not completely characterized. In the
absence of known human disease mechanisms, the design and interpretation of experimental data
generated from the rhesus macaque model are based on the similarity of the disease pathogenesis
and manifestation between these two species (Shedlock et al., 2009). It is the scientific
assumption that crucial immune molecules in rhesus macaques could be highly conserved with
those of humans, both structurally and genetically, and that their interactions could generally
mimic those in humans. However, this premise has not been fully evaluated.
Early studies show that rhesus macaque Igs share a high degree of homology with their
human counterpart (Calvas et al., 1999). This finding suggests that these molecules would be less
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immunogenic (at least compared to murine counterpart) in humans, and consequently, might
induce a low level of the so-called human anti-mouse antibody (HAMA) response (Laffly and
Sodoyer, 2005). Indeed, rhesus macaque monoclonal Abs (mAbs) have been proposed as an
alternative to humanized rodent mAbs, which causes a high HAMA response when used for
therapeutic purposes (Ehrlich et al., 1988; van Meurs and Jonker, 1986). On the other hand, antihuman Ab reagents in many cases poorly or rarely cross-react with rhesus macaque effector
cells, suggestive of less conserved antigenic determinants (epitopes) between the corresponding
molecules of the two species. Some immune cell surface molecules between the two species,
while structurally similar, are even sufficiently distinct antigenically to invoke an immune
response. For instance, rhesus macaques elaborate specific humoral immune responses against
the human CD4 cell surface molecule (Lodgberg et al., 1994; Newman et al., 1992). Indeed, it
had been suggested that rhesus macaques had the potential to be employed for production of
specific Abs recognizing antigens and receptors on the surface of human immune cells
(Lodgberg et al., 1994). Subsequently, several “primatized” mAbs containing variable regions
from a macaque species (although it was not rhesus, but cynomolgus macaque) and an IgG
human constant region have been developed. Among these mAbs are anti-CD4 [Keliximab; for
rheumatoid arthritis (Newman et al., 2001; Reddy et al., 2000)], anti-CD23 [for allergies
(Nakamura et al., 2000)], and anti-CD80 [Galiximab; for autoimmune and inflammatory
diseases, like psoriasis (Gottlieb et al., 2004; Schopf 2001)].
Like with Abs, studies of murine Ig Fc cell surface receptors (FcRs) have traditionally
provided important insights for better understanding human FcR biology. However, the human
FcR system is complicated and extensively different from that of mice. Humans possess several
FcRs with which no homologues are found in mice, such as FcγIIa, FcγRIIc, FcγIIIb, and FcαR
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(Pleass and Woof, 2001). As FcR biology varies greatly among species, insights from a more
“human” FcR model system – such as those from an NHP species instead of mice – would be
more practically translatable into human FcRs. As discussed above, owning to their close
anatomical, physiological, and phylogenetical relatedness to humans (Gardner and Luciw, 2008),
rhesus macaque species is already used extensively for immunological research. Rhesus macaque
FcR biology research, however, is largely unexplored (Rogers et al., 2008, 2006, and 2004).
Indeed, several FcγRs found in mice, including FcRs for IgA and IgM, have not even been fully
characterized in NHP species (Rogers et al., 2004).
Therefore, the various Ig and FcR systems and related pathogen-clearance mechanisms
are still largely unexplored in the rhesus macaque model. In particular, little is presently known
about the structure of Ig and FcR molecules in rhesus macaques, and the extent of similarity to
their human counterpart is not completely defined. No current information about the functional
properties and structure-function relationships that characterize rhesus macaque IgG molecules,
as well as interaction of IgG subclasses and corresponding FcγR classes, is available. It is not
known at what extent the various components of the rhesus macaque immune system mimic
corresponding components of the human immune system upon antigen exposure, particularly
that directing against HIV and SIV. Also, the relative level of IgG subclasses present in rhesus
macaque serum is not known. As many therapeutic Abs – either approved or in trials or
development – are of IgG Ab class, comprehensive understanding of interaction between IgG
subclasses and corresponding FcγRs would enable the rational design and production of novel
therapeutic Abs, as well as prognosis for treatment success.
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1.1.3. The need for comprehensive characterization of rhesus macaque Ig/FcR immune system
components and mechanisms
Owing to almost 25 million years of evolution (Shedlock et al., 2009), human and rhesus
macaque species might possess important structural and thus, functional, differences related to
their Ig and FcR components that have not been completely characterized. The incomplete
characterization has limited the scope of biomedical research performed with this model.
Importantly, these differences might mislead data interpretation and translation to human
diseases. Indeed, recent studies suggest that the safety and performance of drugs or vaccines
observed in NHP animals, particularly rhesus macaques, are not necessarily similar to or
translatable into humans. For instance, while the CD28 super-agonist Ab TGN1412 had showed
no adverse effects in macaques, it caused, with 500 times less in dose and within an hour of
administration, life-threatening conditions in healthy human volunteers in a 2006 clinical study
(Attarwala, 2010). More recently, a leading HIV vaccine candidate that demonstrated apparent
protection in rhesus macaques appeared to fail to protect humans (Thomas, 2009). Molecularly,
recent studies revealed that there are more active immune genes in rhesus macaques than in
humans (Gibbs et al., 2007). Several key differences that exist between rhesus macaques and
humans related to their major histocompatibility complex (MHC), as well as Ig and FcR
molecules, both structually and functionally, have also been recently revealed (Rogers et al.,
2008; Gibbs et al., 2007; Rogers et al., 2006; Scinicariello et al., 2006; Daza-Vamenta et al.,
2004; Scinicariello et al., 2004).
Collectively, these findings suggest that interspecies differences between rhesus
macaques and humans regarding immune gene expression and immune responses might
contribute – by means that are currently not fully understood – to pathogenesis and progression
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of infection (Shedlock et al., 2009). Failure to recognize these differences may lead to erroneous
expectations or confounding interpretation of data generated by using this model for evaluation
of vaccines or therapeutic Abs.

1.2. Antibody molecules: Overview, structural and functional features, genetic basis,
classification, and IgG class and subclasses
1.2.1. Antibody molecules: Overview
Antibodies (Abs), or Igs, are host glycoproteins naturally produced in vertebrates in
response to invading foreign particles or organisms (antigens), or to, in abnormal or pathological
circumstances, other agents in the body. Igs are the antigen-specific and multifunctional adaptor
molecules expressed by B lymphocytes as either membrane-bound or secreted products.
Membrane-bound Igs, also known as B cell receptors, act as cell-surface receptors for specific
antigens, which mediate cell signaling and cell activation (like activation of phagocytes, natural
killer cells, or the complement cascade). Secreted Igs, which are synthesized by antigenspecifically proliferated and terminally differentiated B cell clones (Parham, 2000), circulate in
the blood. These circulating Igs serve as the soluble effector molecules, which are capable of
individually and specifically binding and neutralizing pathogens/toxins at a distance, or marking
them for elimination through activating mechanisms that effect their destruction and clearance
(effector functions). Igs, therefore, play a critical role in the protection and defense of a host
organism against pathogens and malignancies.
Every individual Ig recognizes and binds to just one single antigen, which could be
protein and/or carbohydrate particles present on microorganisms and viruses, or could be
distinctive molecules expressed on the surfaces of tumor cells. Because of this exquisitely-
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specific and high-affinity binding characteristics, Igs are ideal molecular tools for basic research
and diagnostics. Igs have been widely used, both in vitro and in vivo, for detecting, localizing,
and purifying both known and unknown molecular targets. As will be discussed further, Igs have
also greatly been increasingly used as therapeutic agents over the last several decades. Indeed,
Igs are among the most powerful immune-therapeutic agents currently available, and neutralizing
Igs are the most sought-after molecules of actions induced from vaccinating against a variety of
infectious pathogens.
Igs belong to the eponymous Ig “superfamily” (IgSF) that constitute the humoral branch
of the immune system in most vertebrates, including fishes, amphibians, reptiles, birds, and
mammals (Clark, 1997). IgSF molecular members adopt a tertiary globular structural motif
known as IgSF domain, or Ig domain, that result from independent folding of their polypeptide
chains, as their basic building block (Schroeder and Cavacini, 2010). In an Ig molecule, the
variable domains localize at the amino termini and confer the antigenic specificity, whereas the
constant domains reside within the carboxyl terminus and define the different effector functions.
The recognition of this domain structure/function property of Igs has facilitated the manipulation
of the Ig genes and thus, their recombinant protein products of predefined specificity and/or
desired species (Clark, 1997). Indeed, generation and production of chimeric recombinant
molecules used for therapeutic purposes or for basic research studies, including those of the
structural basis of Ig functions, have been great success.

1.2.2. Structural features and Ig L and H domains
All Igs, independent of their antigenic specificity, generally have a common structure that
has been conserved through evolution. It is a Y-shaped symmetrical structure composed of four
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Fig. 1.1. Schematic representation showing two-dimentional general structure of a conventional
antibody, or immunoglobulin (Ig), molecule. This representation displays both amino acid (A)
and nucleotide level (B), showing the structure and arrangement of Ig heavy and light chains, the
relative positioning of inter-chain disulfide bonds, the paired domains and the classical Ab
fragments, as well as illustrating germ-line genetic organization of separate gene segments
(exons) encoding for Ig heavy-chain constant domains (not drawn to scale). (A) This diagram
depicts the four-chain structure of an Ig molecule, a dimeric protein composed of two identical
light (L) chains (IgL) and two identical heavy (H) chains (IgH), each consisting of a variable (V)
region and a constant (C) region. Individual IgL and IgH chains are folded into domains (also
known as Ig folds), which are discrete and compactly folded protein regions. Ig domains have
similar structures and, by themselves or through interactions with other domains, form functional
units of the Ig molecule. Each IgL comprises two domains, a variable (VL) and a constant (CL),
and each IgH comprises four (or five) domains, a V domain (VH) and three followed C domains
(CH1, CH2, and CH3). Each Ig domain, V or C, comprises about 110 amino acid residues and
an intra-chain disulfide bond (-S-S-) between two cysteine residues, forming a loop of about 60
amino acids. Individual IgL and IgH chains are held together by inter-chain disulfide bonds and
form a flexible Y shape of the molecule. The VH region, which is adjacent to the CH1 region, is
located at the amino terminus (NH2), and the CH3 (some have a CH4) region is positioned at the
carboxy terminus (COOH), which is at the 3’ end of the IgH [which can be either membranebound, mIg (or B-cell receptors, BCRs) or secreted, sIg]. The CH1 domain contributes to the
stability of V regions and to the diversity of Igs. In between the CH1 and CH2 domains is the
hinge portion, which contributes in the flexibility of the molecule. Based on the similarity level
of amino acid sequences, two major IgL types, namely κ and λ (encoded at different genetic loci
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and referred as Igκ and Igλ, respectively), and five major IgH classes isotypes), namely μ, γ, α, δ,
and ε (referred as Igμ, Igγ, Igα, Igδ, and Igε, respectively), are classified. IgHs in IgG, IgA, and
IgD classes contain four Ig domains and a hinge region, whereas those in the IgM and IgE
contain an additional Ig domain that replaces the hinge region. The five IgH isotypes also vary in
function, serum concentration, and serum stability. IgL type is not a determinant of the Ig class
(isotype) nor known to be associated with specific effector functions of the molecule. Each IgH
class Ig molecule has only one type of IgL. Ig chains can also be associated with carbohydrate
moieties (Ig CH2 has conserved glycosylation sites). Igs and BCRs are for antigen recognition
and destruction and also illustrated in this diagram are the regions that participate in antigen
recognition/binding (Fab; two identical sites constituted by the V regions and capable of binding
essentially any macromolecule, including proteins, carbohydrates, lipids, and nucleic acids, with
most binding proteins or carbohydrates), and the regions that mediate different effector functions
(Fc; constituted by the CH2 and CH3 domains of dimerized IgH chains and capable of recruiting
cells/molecules of effector functioning for destruction of antigens and pathogens), which include
interacting with complement (binding C1q), activating macrophage, polymorphonuclear
leukocytes (PMN), platelets, and binding Fc receptors, as indicated. Igs themselves are also
antigens. The hydrophobic leader sequence of both H and L chain is removed immediately after
synthesis and is not present in the mature Ig molecule. (B) This diagram depicts germ-line (nonrearranged) organization of human IgH chain gene segments (exons). Shown is for an Igγ3 (to be
used as an example), which consists of three exons (represented by red-filled, enlarged boxes;
numbered as indicated) encoding the corresponding C domains, and one exon (Hg; represented
by the purple-filled, enlarged box) encoding the hinge region. Due to sequence repetition, human
Igγ3 can have two to four hinge exons. Straight black lines indicate introns. Long and colorful
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arrows indicate the correspondence between the DNA exon segments and the different domains
of the IgH polypeptide that is encoded. Ig gene components are widely scattered through
different chromosomes (chromosomes 2 and 22 for Igκ and Igλ, respectively, and chromosome
14 for IgHs) and to assemble an intact Ig molecule, they are first rearranged/spliced at the DNA
level (i.e. not RNA splicing), as illustrated. Ig genetic organization, which contains individual
exons that encode for different functional domains of the protein products in which binding
specificity resides within V domains while subclass effector functions reside within C domains
makes it possible for generation of recombination Igs combining different binding specificity and
effector functions.
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polypeptide subunits – two identical heavy (H) and two identical light (L) chains. These four
polypeptide chains are held and stabilized together by covalent disulfide bonds between the H
and L chains and between the two H chains, as well as by non-covalent intra- and inter-chain
binding forces (such as salt linkages, hydrogen bonds, and hydrophobic bonds). Each of these
chains comprises of two distinct regions – a variable (V) region, which is found at the amino
terminal portion and has the greatest amino acid sequence variation among Ig molecules of
different specificity, and a constant (C) region, which is found at the carboxyl terminal portion
and, in contrast to the V region, is of relatively constant (i.e. more conserved) sequence. Fig. 1.1
shows the structure and arrangement of H and L chains and the relative positioning of inter-chain
disulfide bonds.
Being IgSF protein members, Igs utilize a globular, fairly constant motif structure known
as Ig domain (also called IgSF domain or Ig fold) as their basic building block (Fig. 1.1). Each Ig
domain is a specific tertiary homologous structural polypeptide unit consisting of from 110 to
130 amino acids and weighting approximately 12-13 kD. Regardless of amino acid differences
among Ig molecules of different classes, subclasses, or specificity, each Ig L and H chains
independently fold into homologous domains, where each contains of two sandwiched β-pleated
sheets linked together and stabilized by an intra-chain disulfide bond between the two conserved
cysteine residues and by hydrophobic interactions between the sheets (Schroeder and Cavacini,
2010; Williams and Barclay, 1988; Amzel and Poljak, 1979). Each L chain consists of one V
(VL) and one C (CL) domain, whereas each H chain contains one V (VH) and three to four C
(CH) domains (CH1-CH4), depending on the Ig class (as will be discussed below). In general, Ig
CH domains are defined as CH1-CH2-CH3 (IgG, IgA, and IgD), or with an additional domain
(CH4) (for IgM and IgE) (Schroeder and Cavacini, 2010). The two L chains and the two H
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chains weight ~25 kD and ~50-55 kD, respectively. The classical folding pattern of Ig molecules
remains intact in all of regions and fragments (Attanasio et al., 1994).
The entire L chains, VH, and CH1 domains together constitute two identical fragments
that recognize and bind antigens, known as Fab (Fragment – antigen binding), represented by the
arms of the symmetrical Y shape (Fig. 1.1). The rest of the Ig molecule [i.e. the remaining CH
domains (i.e. CH2 and CH3; also CH4 in IgM and IgE)] form a fragment that specify effector
functions, termed Fc (Fragment – crytallizable), represented by the tail (the stem) of the Y shape.
The V domains of both chains, which provide the structural basis of antigenic specificity,
unsurprisingly, localize to the Fab. As described previously, the CH1 domains localize to the
Fab, whereas the remaining CH domains (CH2-CH3 or CH2-CH3-CH4) constitute the Fc
(Schroeder and Cavacini, 2010). Fig. 1.1 also illustrates the paired domains and the classical Ab
fragments.
In addition to the relatively “constant”, or highly conserved, CH domains, the C region of
the IgH chains also contains between its CH1 and CH2 domains a nonglobular helical, extended
“spacer” region of 12-15 amino acids [an exception exists with human IgG3 hinge: it contains
up to 62 amino acids, dependent upon the number of repetitive sequences (Lefranc and Lefranc,
2001)] that has the highest Ig class/subclass sequence variability, both intra-species and interspecies. The region also varies in length between different Ig classes within a species. This
flexible region is called the hinge, and is characterized by evolutionary instability (Scinicariello
et al., 2004; Attanasio et al., 2002; Sumiyama et al., 2002; Scinicariello and Attanasio, 2001).
The hinge is rich in Cys and Pro residues and can be structurally split, based on crystallographic
data and the intermolecular interactions, into three discrete segments: the upper, the core (the
middle), and the lower hinges (Burton and Woof, 1992; Oi et al., 1984). The upper hinge is
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towards the amino terminal segment and exhibits the least homology of all sections, followed by
the core. The hinge can also be exposed to enzymatic or chemical cleavage, a characteristics that
has facilitated early studies of Ig structure/function relationships. For instance, papain cuts an
IgG molecule into two Fab and one single Fc, whereas pepsin digests it into one single dimeric
F(ab)2 and one single Fc (Schroeder and Cavacini, 2010).

1.2.3. Functional features and Ig V and C regions
Ig molecules serve many and varied functions through binding antigens and targeting
them to other components of the immune system (Fig. 1.2). On the basis of Ig forms of
existence, these functions can be separated into two purposes: those of circulating soluble
effector molecules, which recognize antigens at a distance and neutralize them, and those of
cellular receptors for antigen, which trigger cell activation and signaling (Schroeder and
Cavacini, 2010). On the structural basis, Igs can be subdivided into two distinct functional units:
the paired V domains (i.e. Fab, a combined property of VH and VL domains) that bind antigens
and confer antigenic specificity, and the Ig CH domains (i.e. Fc) that mediate effector functions
and define Ig isotypes (Schroeder and Cavacini, 2010). Igs, therefore, eliminate pathogens and
toxins by both cellular and non-cellular mechanisms through specific binding to them with their
V domains, followed by activating cell-killing effector mechanisms via their C domains. Because
of the domain structure of Ig molecules, for many purposes, the antigen-binding properties of the
whole Ab and the Fab are usually considered equal (Burton, 1991).
The key Ig Fab-mediated functional activity of Ig molecules is to neutralize, or directly
inactivate, toxins and infectious pathogens, particularly viruses (Fig. 1.2). For in vivo anti-virus
protection, directly neutralizing virion infectivity is considered the most important activity of Igs
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(Burton, 2002). Mechanistically, these functional activities are carried out by blocking of
pathogenic functional sites through enzymic or receptor binding activity: thank to their relatively
large molecular size (similar to the size of a typical virus envelope spike), Igs block virus entry
into host target cells through binding to free virus particles and occupying virion sites necessary
for attachment or fusion to the cells (cell receptors) (Parren and Burton, 2001). In this case, Igs,
or more specifically, neutralizing Abs, can act alone, without cellular effector immune
mechanisms, to protect vertebrates from viral pathogens. As described above, a single, intact Ig
molecule contains two identical Fab fragments (antigen binding sites), the so-called “bivalency”.
A single Ig molecule, therefore, although capable of recognizing only one type of antigen, can
bind and neutralize two antigens simultaneously. Furthermore, this bivalency characteristics
allows Igs to bind antigens possessing repeating antigenic determinants or aggregated antigens
with higher avidity (Clark 1997; Janeway et al., 1996). Due to the domain structure of Ab, the
antigen-binding properties of Fab are typically considered those of entire Ab.
The Ig Fc regions typically act through the interactions between their various Ig Fc
receptors (FcRs) and the Ab-antigen complexes (or immune complexes; ICs), which induce
diverse and potent immune responses that are critical for healthy immunity (Fig. 1.2). Following
the formation of ICs, the Fc regions can activate different cell-killing immune effector
mechanisms that effect the destruction and clearance of antigens and pathogens through their
binding to FcRs, which are expressed on various immune cells, or through recruiting other
immune mediators, such as complement (Schroeder and Cavacini, 2010). In normal immune
systems, three major mechanisms for the destruction and clearance of the antibody-coated (also
known as opsonized) antigens – all result in lysis of the pathogens by lytic enzymes – are known:
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Fig. 1.2. Functional features of Ig V and C regions and Ig domain structure/function properties.
See texts for details. Figure is modified from Weiner et al., 2010, Casadevall et al., 2004, and the
internet.
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1) Antibody-dependent cell cytotoxicity (ADCC), in which the ICs activate effector cells
[through the Fc-FcR (specifically, FcγRIIIa) binding], such as natural killer cells or monocytes;
2) Complement-dependent cytotoxicity (CDC; through C1q binding), in which the complement
pathway is recruited and the complement cascade is activated; and 3) Fc-mediated phagocytosis,
or Ab-dependent cellular phagocytosis (ADCP), in which phagocytic cells (i.e. macrophages
neutrophils, and dendritic cells) are activated [through the Fc-FcR (FcγRII/I) binding] (Fig. 1.2).
Other Ig functional activities and responses that assist in directing appropriate immune responses
include opsonizing, inducing respiratory burst, releasing inflammatory mediators (inflammation),
antigen presentation, degranulation of cytotoxic cells, mast cell degranulation, as well as other
antigen-independent functions, such as crossing the placenta [placental transport; through
binding to the neonatal FcR (FcRn)], maintaining half-life (through binding to FcRn),
multimerizing, regulating lymphocyte proliferation and differentiation, including B cell
activation, secreting cytokines and chemokines, and being secreted on mucosal surfaces
(Schroeder and Cavacini, 2010; Smith and Clatworthy, 2010; Weiner et al., 2010; Jefferis et al.,
1998; Burton and Woof, 1992). Therefore, through the binding of ICs to specific FcRs, the Ig Fc
regions can provide humoral immunity with a cell-based effector functional system (Smith and
Clatworthy, 2010).
In addition to being capable of inducing Ab-dependent killing of target cells, the Fc
regions can also affect V domain binding affinity and specificity (Torres and Casadevall, 2008)
and suppress humoral immunity (Smith and Clatworthy, 2010) (will be discussed in more details
later). Also, in abnormal immune circumstances, such as autoimmunity or allergies, the IC-FcR
interactions might cause adverse consequences, like development of tissue injury, or might even
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be involved in pathogenesis of immunological disorders and diseases, including rheumatoid
arthritis and systemic lupus erythematosus (SLE) (Takai 2005; Hogarth 2002).

1.2.4. Functional features and the role of the hinge and glycosylation
As discussed previously, the Ig hinge region contains several conserved Cys residues and
can be divided into three sections. The core hinge is rich in Cys (and Pro) residues that form the
IgH inter-chain disulfide bonds and is thus relatively inflexible (i.e. rigid). The upper and the
lower hinges can mediate Ig segmental (Fab-Fc) and rotational (Fab-Fab) flexibility by directly
allowing the two Fab portions of the Y-shaped molecule to “open” or “close” (for two Fab arms
as a whole), and rotate (for each individual Fab arm) – relative to the Fc position (Clark, 1997).
The ability of Fab arms to be differently positioned improves Ig access and accommodation, and
thus allows differently spaced and/or distinctly oriented antigens or antigen determinants to be
bivalently recognized by the two binding sites (Clark, 1997; Kim et al., 1994; Burton and Woof,
1992).
In addition to playing a role in intermolecular covalent assembly and flexibility (the core
hinge), the hinge also plays a crucial role in IC formation (the upper hinge), may be required for
FcR binding and complement activation (the lower hinge) (Coloma et al., 1997; Roux et al.,
1997), as well as may affect signal transduction (Clark, 1997; Rudich et al., 1988). The
flexibility of Fc portion, relative to Fab fragments, can influence interactions of Igs with
coresponding FcRs or other molecules. As a consequence, the extended human IgG3 hinge is
believed to have better flexibility, and thus be more effective in antigen binding and in triggering
effector mechanisms (Burton and Woof, 1992). The hinge of IgG subclasses will be described
further in the following sections. Distinct structures of the hinge in different species might,
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therefore, alter molecular flexibility, neutralizing ability, reactivity with and binding affinity to
FcRs, the capability to activate the complement cascade, susceptibility to proteolytic enzymes, or
other Ig functional properties of Igs (Torres and Casadevall, 2008; Thommesen et al., 2000;
Michealsen et al., 1990, Tan et al., 1990).
As mentioned above, Igs are glycoproteins in their nature. While IgL chains are
aglycosylated, IgH chains (in particular, Fc portions) are integrally attached covalently with
oligosaccharide groups (i.e. carbohydrate moieties), usually at CH2 domain (Sutton and Phillips,
1983). The extent of glycosylation varies, dependent upon Ig isotype (Arnold et al., 2007).
Carbohydrates are important for proper Ig folding and for stabilizing IgG-FcγR binding
(Schroeder and Cavacini, 2010; Lund et al., 1995). Fc-associated glycans are also capable of
affecting Ab functions, including mediating complement activation and influencing FcR binding
(Schroeder and Cavacini, 2010; Miletic and Frank, 1995). Changes in glycosylation of IgH
chains can, therefore, result in alteration of Ig functions, including effector functions
(particularly complement activation) (Schroeder and Cavacini, 2010). Indeed, more effective
therapies might be obtained from differential or modified glycosylation patterns engineered in
passive immunotherapy or in vivo treatment (Collin et al., 2008; Smith et al., 2004).
Collectively, Abs are extremely versatile molecules, structurally and functionally. The
globular domain structure of Ab molecules is facilitative of genetic engineering (as will be
discussed later). Changes in the Fc may influence the end result of Ab-antigen interactions,
including the affinity and/or kinetics of the Fab-mediated antigen recognition and binding
(Schroeder and Cavacini, 2010; Torres and Casadevall, 2008).
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1.2.5. Gene organization, DNA rearrangement, and production of Ig
Higher vertebrates feature with a humoral immune system that is uniquely characterized
by its ability to generate a vast diversity of Abs to respond to virtually unlimited array of
antigens or pathogens sharing little or no similarity. This unique characteristics relies largely on
the Ig gene organization and DNA rearrangement mechanisms. In humans, IgH and IgL chains
are encoded by separate multi-gene families located on three different chromosomes (Schroeder
and Cavacini, 2010; Tonegawa, 1983). Specifically, IgL κ and λ families are located on
chromosomes 2 and 22, respectively, whereas IgH family is located on chromosome 14 (Lefranc
and Lefranc, 2001). Each multi-gene family contains different, independent gene segments that
encode individual V and C domains of each Ig H or L chain. In particular, IgL

and

families

consist of V, J (for joining), and C gene segments, whereas IgH family contains V, D (for
diversity), J, and C gene segments. Each V gene segment generally contains its own promoter, a
leader exon, an intervening intron, an exon encoding V domain, and a recombination signal
sequence (RSS) (Schroeder and Cavacini, 2010). The IgH C gene (IGHC) segments consist of
nine functional and two pseudo (Ψ), non-functional, C genes. Each Ig isotype is encoded by a
separate CH gene region, namely

or

which correspond to the five IgH isotypes.

These CH region gene segments are aligned in the same transcriptional orientation on
chromosome 14, in the IgH locus, downstream of V region genes (IGHV) (Bengten et al., 2000).
Generally, each CH gene region consists of three main exons, each individually encoding CH1,
CH2, and CH3 IgH domains, and of one or more additional exons encoding the hinge (Schroeder
and Cavacini, 2010; Bengten et al., 2000).
Ig V and C domains are produced through two independent DNA rearrangement and
recombination events. VL and VH domains are expressed by the so-called rearranged VJ and
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rearranged VDJ gene segments, respectively. These VJ and VDJ rearranged gene segments result
from a number of gene rearrangement events that occur in B cells during their early development
in the bone marrow – in the absence of antigens. They are expressed in association with the Ig μ
chain (to produce IgM) and following antigen exposure, can undergo somatic hypermutation that
allow maturation and increase of affinity for the antigens. Ig CL and CH domains are expressed
by the C gene segments in the L and H multi-gene families, respectively. Different CH domains
(i.e.

or ) can be produced in response to antigenic stimulation (such as by immunization or

infection) and cytokine regulation by activated B cells in their late development – in the spleen
or lymph nodes. They can then be subjected to the so-called class switch recombination event
(i.e. from IgM to IgG, IgA, or IgE), a process in which effector functions may be altered but
antigen-binding specificity remains unchanged (Schroeder and Cavacini, 2010). Not only the
antigen and the signaling pathways, but also the local microenvironment may have influence on
which Ig isotype is to be chosen during class switch (Schroeder and Cavacini, 2010).
Therefore, a vast Ig repertoire with a great number (~1016) of structurally distinct
molecules (that is, against virtually any antigenic structure) can be generated through a number
of molecular mechanisms that alter the DNA of individual B cells. These mechanisms include
genetic organization by individual gene segments, somatic variation and random combinatorial
rearrangement of these segments, as well as combinatorial association between different L and H
chains – and all processes are without the presence of antigens (or further diversification by
hypermutation) (Schroeder and Cavacini, 2010). Thus, although an individual Ig molecule can
only bind a limited set of ligands, as discussed previously, Igs as a population can bind to an
almost unlimited array of antigens or chemical structures.
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1.2.6. Ig classification: Ig L and H chain classes (isotypes)
Humans Igs are categorized into five major classes (or isotypes), IgM, IgG, IgA, IgD, and
IgE, which are defined by and correspond to the five main classes of their low-variability CH
regions, designated , , , , and , respectively (Clark, 1997). IgL high-variability regions can
be grouped into two types, κ and λ. In a complete Ig molecule, each class (or isotype) of the five
H chains (i.e. , , , , or ) is associated to either – but not both – a κ or a λ chain. In some
species, these classes are further split into subclasses, which suggest their recent evolution (i.e.
recent gene duplication events) (Clark, 1997; Bruggemann, 1988). The ratio of Igs with κ or λ
chains represented in human serum is about 60:40, whereas it is 95:5 in mouse serum. The
numbers of Ig classes also vary among species.
It is the CH regions that distinguish the five different Ig classes and define their specific
effector mechanisms (Clark, 1997). In addition to exhibiting distinct characteristic patterns of
functional effector activities, classes also differ in some other properties, including size and
subclass response to antigen (Schroeder and Cavacini, 2010). Amino acid substitution or
polymorphism in Ig CH regions may also affect effector functions of Abs.

1.2.7. IgG: General functional activities and subclass classification
Human IgG represents the most abundant Ig class found in the body, including in serum
[constituting ~80% of the total serum Igs (Clark, 1997)], extracellular fluid, and lymph nodes
(Fig. 1.3). IgG exists as monomers and has the longest Ig serum half-life and is also most
extensively studied. This Ig class also represents the most frequently used Ig isotype in cancer
immunotherapy. IgG can be used as a model for considering many key Ig functional features,
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including binding antigen through V domains and, at the same time, interacting with conserved
effector systems through C domains.
IgG may contribute directly to an immune response, such as neutralizing toxins, viruses,
and other infectious pathogens. Patients diagnosed with low levels of IgG (hypogammaglobulinaemia) exhibit increased susceptibility to infections (Smith and Clatworthy, 2010). IgG
is capable of carrying out all the Ig cell-killing effector functions necessary for removal of
pathogens. Such functional activities include ADCC, CDC, ADCP, opsonization, as well as
sensitization and activation of other (than natural killer cells and macrophages) immune effector
cells, such as neutrophils, basophils, and mast cells, as discussed previously (Fig. 1.3). IgG that
coats antigens can bind FcRs through its Fc and trigger signaling through immunoreceptor
tyrosine-based activation motifs (ITAMs) or immunoreceptor tyrosine-based inhibitory motifs
(ITIMs). In addition to these antigen-dependent functions, this Ig class can also bind neonatal Fc
receptors (FcRn) on endothelial cells to maintain serum IgG levels or to define Ab half-life. The
binding to tumor cells of two or more IgG molecules can lead to subsequent recruitment and
binding of complement component 1q (C1q) to IgG Fc, which can then initiate the complement
cascade, resulting in tumor cell lysis by the membrane attack complex (MAC) (Weiner et al.,
2010). Regardless of subclasses (see below), IgG is also able to be transferred from the maternal
plasma to the fetus through the placenta to provide fetal immunity (trans-placental transport)
(Parham, 2000; Clark, 1997), as well as to participate in the secondary immune responses
(Schroeder and Cavacini, 2010).
Based on structural, antigenic, and functional differences in CH region, human IgG is
split into four subclasses, IgG1, IgG2, IgG3, and IgG4, designated 1, 2, 3, and 4, respectively
(Schroeder and Cavacini, 2010) (Fig. 1.3). This numbering of IgG subclasses is referred to the
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Fig. 1.3. Human IgG: most common in serum, classified into four subclasses, possessing slight
structural yet significant functional differences. See texts for details. Figure is modified from
Murphy et al., Immunobiology, 7th Edition, Garland Publishing, 2008, and Burmester and
Pezzutto, Color Atlas of Immunology, Georg Thieme Verlag, 2003.
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decreasing order (i.e. IgG1, IgG2, IgG3, and then IgG4) of their serum concentration level
(Schroeder and Cavacini, 2010). The production of IgG subclasses may be influenced by various
factors, including properties of antigens (i.e. structure and quantity, route of administration, and
duration of stimulation) and characteristics of individual host (such as age and the genetic
background) (Bachmann and Zinkernagel, 1996). Like with the class definition, the identity of
subclass of an individual IgG is determined by variations in its CH regions. Indeed, due to recent
gene duplication events (as described above), the four human IgG subclasses share high
homology in CH domain sequences (>90%; Clark, 1997). By contrast, the hinge, which is unique
to each subclass and most diverse among subclasses by amino acid composition and structure,
exhibits the greatest sequence variations among IgG subclasses within an individual species
(~56-60% identity among subclasses, compared to >90% homology shared by CH domains).
Therefore, the hinge can be used to rapidly differentiate the four subclasses (Papadea et al.,
1989) (the four subclasses, indeed, also differ in the number and arrangement of their interchain
disulfide bonds). Consequently, as will be described later, while the high identity within IgG
subclasses has facilitated studies of the key Ab functional residues, the heterogeneity of the
hinge can obscure investigating amino acids crucial for Ab intermolecular interactions (Clark,
1997; Roux et al., 1997).
As previously discussed, glycosylation pattern varies among Ig classes and subclasses.
Although glycosylation variation is also observed among IgG molecules (Schroeder and
Cavacini, 2010), the N-linked glycosylation site located at Asn297 on each CH2 domain is
highly conserved throughout IgG evolution. In addition, not only forming extensive contacts
with amino acid residues within CH2 domains and subjected to posttranslational modifications,
but also the N-glycan at Asn297 is involved in IgG-FcγR recognition and binding. These
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findings suggest that this N-linked carbohydrate moiety plays an important role in Ig domain
stabilization and may even be capable of optimizing IgG in vivo effector functions (Schroeder
and Cavacini, 2010; Burton and Woof, 1992).
The CH region genes of the four IgG subclasses (IGHG) are designated as IGHG1,
IGHG2, IGHG3, and IGHG4, according to the IMGT nomenclature (Lefranc and Lefranc, 2001).
Each of the four IGHG genes consists of four individual exons, namely CH1, the hinge, CH2,
and CH3, each individually encoding the corresponding CH domain (i.e. CH1, the hinge, CH2,
and CH3 domains, respectively). An exception exists in human IgG3, where its hinge, due to
sequence repeats, is encoded by two to five exons (Lefranc and Lefranc, 2001; Burton and Woof,
1992), as previously discussed. The IgG lower hinge, which is defined based on the
intermolecular interactions, is, nevertheless, encoded by partial CH1 (C-terminus) exon and
partial CH2 exon (Burton and Woof, 1992).

1.2.8. IgG subclasses: Distinct characteristic patterns of effector functions
While the four IgG subclasses exhibit light differences in sequence and structure, they
express significant differences in function. Each subclass is characteristic of its own patterns and
properties of functional activities, including in clearance mechanisms of opsonized antigens that
are carried out upon antigen exposure, and at level of expression in response to specific antigenic
stimulation (Schroeder and Cavacini, 2010). Generally, IgG1 and IgG3 are the most efficient
activators, followed by IgG2 which is moderately potent, whereas IgG4 is only marginally active
or inactive (Morrison et al., 1994). In particular, IgG1 and IgG3 are most effective with ADCC
and CDC, whereas IgG2 is only moderately efficient in and IgG4 is incapable of carrying out
CDC. Also, within the secondary immune response, while IgG1 and IgG3 are predominantly
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produced against protein antigens, IgG2 and IgG4 are generally induced by polysaccharide
antigens (Schroeder and Cavacini, 2010).
The four IgG subclasses also differ in their binding capability and affinity to the three
major IgG FcR (FcγR) classes: IgG1 and IgG3 are capable of binding and have the highest
affinity for all three FcγR classes, IgG2 fails to bind FcγRI and FcγRIII, whereas IgG4 can bind
FcγRII and FcγRIII but only with low affinity (Schroeder and Cavacini, 2010) (Fig. 1.3).
Binding of IgG subclasses can further be influenced by other factors, such as their hinge
structural diversity and flexibility, as well as the attached carbohydrates (glycans). Typically,
ligand IgG molecules bind coressponding FcγRs in the lower hinge through an extensive contact
surface. This area contains overlapping but not identical residues from the two IgH (Fc) chains,
thus the binding is asymmetrical. Also, the length and flexibility extent of IgG subclass hinge
regions are as from the greatest to the least as IgG3, IgG1, IgG4, and IgG2 (Clark, 1997;
Roux et al., 1997; Brekke et al., 1995). Early studies have recognized a correlation between
effector function efficiency (including complement activation) and flexibility patterns of IgG
subclasses (Clark, 1997; Burton and Woof, 1992). More recent data suggest that IgG subclasses
differ in their efficiency of neutralizing viruses and toxins, and that the hinge structure may
influence the in vitro neutralizing activity of Abs (Cavacini et al., 2003; Liu et al., 2003; Scharf
et al., 2001; Cavacini, 1995). In these studies, IgG3 appeared be more efficient than IgG1 at
neutralizing virus antigens (Schroeder and Cavacini, 2010). IgG3 is also highly susceptible to
proteolytic endonuclease cleavage (Clark, 1997). As previously discussed, the advantage of IgG3
in virus neutralizing capability may lie in its unique, extended hinge structure, which can
increase the segmental flexibility and improve the accessibility of the molecules onto the
antigens, thus enhance effector functions (Cavacini et al., 2003; Scharf et al., 2001). These
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findings imply the possibility of designing Ab molecules with improved functions through
manipulating their hinge region.
Taken as a whole, specific IgG subclass responses, amino acid residues involved in
specific FcγR binding and effector functions, and interactions with different antigenic
stimulations, can therefore all be associated with healthy immune responses (and, similarly,
individual disease processes). Understanding these specific responses and properties, particularly
different types of clearance mechanisms, will improve efficiency in the control and prevention of
diseases and infections, as well as in development of vaccines and therapeutic Abs (Schroeder
and Cavacini, 2010).

1.3. Ig and IgG Fc receptors: Overview, classification, structural and functional features,
and allelic polymorphism
1.3.1. Ig Fc receptors (FcRs) and IgG Fc receptors (FcγRs): Overview
To carry out their cell-killing effector functions, Igs, upon binding specific antigens with
their paired V domains and forming the Ab-antigen immune complexes (ICs), interact with
different innate immune effector cells through binding to their cell-surface receptors with their C
domains. Fc receptors (FcRs), as they are termed, are transmembrane glycoproteins that
specifically recognize and bind the multifunctional Fc portion of Igs. FcRs bind to Igs that are
attached to pathogens (antigens) or infected cells, or that are bound to tumor cells (i.e. Igopsonized particles, or ICs). This binding triggers the cell signal transduction events and initiates
various immune cell-killing effector functions (such as ADCC, CDC, and ADCP, as previously
described), resulting in cellular activation or inhibition of other immune-competent (phagocytic
or cytotoxic) cells (Ravetch and Bolland, 2001). Ultimately, activated phagocytic or cytotoxic
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Fig. 1.4. Mechanisms of action of FcRs: Binding of FcRs with Ig-opsonized particles triggers the
cell signal transduction events and initiates various cell-killing immune effector functions,
resulting in cellular activation or inhibition of other immune-competent cells. See texts for
details. Figure is reproduced from Sondermann and Oosthuizen, 2002.
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cells destroy and remove invading pathogens or infected cells, and promote tumor cell lysis
(Ravetch and Bolland, 2001) (Fig. 1.4). FcRs, therefore, form a bridge between the humoral and
cell-based immunity and couple the potency of cellular effector activities with the specificity of
Ig binding responses.
In addition to fulfilling such protective effector functions, FcR-mediated immunity also
plays an important role in the regulation of normal, healthy immune responses, including
modulation of Ig production by B cells (Fig. 1.5). It is also involved in a variety of diverse
disease groups, including autoimmune disorders (in particular, systemic lupus erythematosus),
allergies, infectious diseases, as well as in inflammatory diseases, hypersensitivity, and cancer.
Because of their involvement in diseases and capability to act as activators or inhibitors (i.e.
regulators) of the immune system, FcRs have been considered excellent targets for therapies.
Indeed, particular FcγR allelic variations that are associated with disease susceptibility and/or
severity, or that can influence the outcome of Ig-based treatments, have been documented (van
Sorge et al., 2003; Cartron et al., 2002). FcR-derived immunotherapies, particularly the
technology for enhancement of therapeutic monoclonal Ig potency through optimizing the IgFcR interactions, have risen as a promising approach for the treatment in numerous clinical
situations, including those named above (Sondermann and Oosthuizen, 2002).
FcRs, as a population, are expressed on the surface of many immune cells, virtually all
immunologically active and competent cells (called effector cells), or in other words, of almost
every cells of the immune system (Smith and Clatworthy, 2010; Sondermann and Oosthuizen,
2002) (Fig. 1.5). Due to several reasons, including encoding gene organization, multiple
transcripts (isoforms), and polymorphic forms, as discussed below, the cellular expression of
FcγR classes is complex. In humans, FcRs are classified based on the class of Igs that they
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Fig. 1.5. Activating and inhibitory FcRs and the regulatory functions of immune complexes.
See texts for details. Figure is reproduced from Nimmerjahn and Ravetch, 2008.
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recognize. FcRs for IgG, the most common serum and extracellular fluid Ig, are termed FcγRs.
FcγRs play an important role in promotion and regulation of the immune and inflammatory
responses to Ab-antigen immune complexes (Smith and Clatworthy, 2010). FcγRs have also
been most extensively studied among FcRs, and will be the only focus to be discussed hereafter.
The neonatal Fc receptor (FcRn), an IgG Fc receptor that mediates the transcytosis of maternal
IgG to the neonate and regulates serum IgG level (i.e. half-life) (Schroeder and Cavacini, 2010),
is neither included from consideration in this dissertation.

1.3.2. FcγRs: Classification, structural features, and effector cell distribution patterns
Human FcγRs are classified, based on sequence and molecular structure, into three
classes with eight members, FcγRI (CD64; consisting of three members a, b, and c), FcγRII
(CD32; consisting of three members a, b, and c), and FcγRIII (CD16; consisting of two members
a, and b) (Jefferis and Lund, 2002; Clark, 1997) (Fig. 1.6). Not only these classes exhibit
considerable genetic, structural, and functional diversity, but also they differ significantly in
binding affinity (due to ditinct molecular structure) and specificity for ligands (i.e. IgG
subclasses) (Smith and Clatworthy, 2010). These molecules also have unique cell type
distribution patterns (cell-specific distribution) and effector functions (Smith and Clatworthy,
2010; Jefferis and Lund, 2002; Ravetch and Kinet, 1991).
Structurally, all FcγRs represent typical type I transmembrane glycoproteins and are
members of the Ig superfamily (IgSF), which comprised of a unique ligand (IgG)-binding αchain consisting of Ig C-like extracellular domains (ectodomains) (D), followed by a short
cytoplasmic tail (CYT) that links the receptor to the cellular plasma membrane (transmembrane;
TM), and a signaling chain (Daeron, 1997) (Fig. 1.6). In general, FcγR classes either have CYT
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domains that are capable of delivering signal transduction or associate with signaling co-receptor
complexes (Ravetch, 1994). However, an exception exists in CD16b: it is attached by
glycophosphatidylinositol (GPI) tail instead of the TM/CYT (i.e. lacking a transmembrane
domain and being GPI-linked to the outer membrane) (Clark, 1997; Ravetch, 1994). CD32 and
CD16 contain two conserved ectodomains, N-terminal (membrane-distal) D1 and C-terminal
(membrane-proximal) D2, whereas CD64 has a third ectodomain, D3 (Ravetch and Bolland,
2001). These receptors are also composed of a signal/leader (L) peptide that allows their
transport to the cell surface.
All FcγR classes are encoded by a gene family located on chromosome 1. These genes
share common overall intron-exon genetic organization consisting of five or six exons: two
encoding leader (L) peptide, two or three encoding D ectodomains, and one encoding the
TM/CYT tail (van de Winkel and Capel, 1993). Individually, each of these three FcγR classes is
encoded by a cluster of closely related genes: the three human CD64 or CD32 isoforms are
encoded by three closely related genes, FcγRIa, FcγRIb, and FcγRIc, or FcγRIIa, FcγRIIb, and
FcγRIIc, respectively; similarly, the two human CD16 isoforms are encoded by two separate
highly homologous genes, FcγRIIIa and FcγRIIIb (Clark, 1997).
FcγRs also differ in their cellular expression profiles, as discussed above (Fig. 1.6). In
general, CD64 and CD32a are produced by both myeloid and granulocyte cells, whereas CD16a
or CD16b is expressed by myeloid cells or granulocyte cells, respectively (Smith and
Clatworthy, 2010). In particular, CD64 and CD32a are constitutively expressed, to varying
degrees, on innate immune cells capable of fulfilling multiple effector functions, including
phagocytosis and ADCC, which include macrophages, monocytes, neutrophils (granulocytes),
and dendritic cells (Schroeder and Cavacini, 2010; Nimmerjahn et al., 2008; Clark, 1997).
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Fig. 1.6. Activating and inhibitory IgG FcRs: Structure, function, binding affinity, and cellular
expression profiles. See texts for details. Figure is reproduced from Smith and Clatworthy, 2010.
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CD32b is mainly expressed on B-cells. Indeed, CD32b is the only FcγR expressed by B cells
(Smith and Clatworthy, 2010), and is also found on other immune effector cells, including
macrophages, dendritic cells, activated neutrophils, mast cells, and basophils (Smith and
Clatworthy, 2010; Nimmerjahn et al., 2008). CD16a is nearly exclusively expressed on natural
killer (NK) cells (which is also the only FcγR expressed on these cells), which are the principal
cell type carrying out ADCC. However, CD16a is also found on other effector cells such as
macrophages, monocytes, neutrophils, and dendritic cells, while CD16b, which has only been
described in humans, is exclusively present on neutrophils (Clark, 1997). Of immune effector
populations, NK cells, macrophages, neutrophils, and dendritic cells are most potent.

1.3.3. FcγRs: Functional activities, IgG isotype-binding affinity, and signal transduction of
activating and inhibitory FcγRs
Binding of ICs to FcγRs can induce potent and diverse immune responses. In healthy
immunity systems, the binding to activating FcγRs (see below for the concept) mediates
pathogen clearance – directly by various effector functional activities of Ab-dependent killing of
target cells, as well as indirectly through other antigen-dependent and antigen-independent
mechanisms, such as the release of cytokines and other inflammatory mediators (Smith and
Clatworthy, 2010; Nimmerjahn et al., 2008) (Fig. 1.5). The binding to inhibitory FcγRs, on the
other hand, can suppress humoral immunity (Smith and Clatworthy, 2010). FcγRs also mediate
neutralization of pathogen- or toxin-bound IgG complexes (Perez et al., 2009; Verma et al.,
2009). In abnormal immunity status, such as in autoimmunity, however, the binding to FcγRs
(especially FcγRIIa) might induce robust inflammatory responses with adverse consequences in
diseases or disorders like rheumatoid arthritis and SLE (Takai, 2005; Hogarth, 2002), as
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previously disccussed. Moreover, CD16-mediated ADCC responses are important for killing
tumor cells and thus, for the efficacy of therapeutic Abs in treating cancers (such as in follicular
lymphoma and Waldenstrom's macroglobulinemia patients).
As discussed previously, FcγRs differ in binding affinity to different IgG subclasses (Fig.
1.6). In general, they have the highest affinity for IgG1, then IgG3 and IgG4, whereas mostly
they do not bind IgG2 (Schroeder and Cavacini, 2010; Smith and Clatworthy, 2010).
Furthermore, upon ligand binding, they also exhibit differences in the signaling pathway (which
is associated with the initiation, amplification, and termination of both innate and adaptive
immune responses). In particular, an activating signal is transmitted upon IgG binding of CD64,
CD32a, or CD16a, an inhibitory signal is associated with binding of CD32b, whereas no signal is
delivered when IgG binds CD16b (Schroeder and Cavacini, 2010; Smith and Clatworthy, 2010;
Weiner et al., 2010). The five activating FcγRs, CD64, CD32a, CD32c, CD16a, and CD16b, are
thus referred as activating (or stimulatory) FcγRs, whereas CD32b is the only FcγR that has an
inhibitory function (referred as inhibitory FcγR) (Smith and Clatworthy, 2010). These opposite
FcγR functional activities must be appropriately coordinated to ensure healthy effector immune
responses. The exclusively B cell-expressed CD32b, thus, as the only inhibitory FcγR capable of
negatively modulating cell activation state previously initiated by an activating FcγR through ICs
formed upon antigen exposure, plays a unique role in these responses (Smith and Clatworthy,
2010).
Among the three FcγR classes, CD64 exhibits high IgG binding affinity, whereas the
other two are capable of only medium- to low-affinity binding (Fig. 1.6). Consequently, CD64 is
the only FcγR able to bind monomeric IgG with high affinity and functions during early immune
responses. In contrast, for efficient binding, CD32 and CD16 (CD16a) require the formation of
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ICs or IgG aggregates (i.e. IgG polymeric forms) surrounding multivalent antigens during late
immune responses (Schroeder and Cavacini, 2010; Nimmerjahn et al., 2008). Thus, CD64 is
referred as the high-affinity FcγR, whereas CD32 (i.e. CD32a and CD32c) and CD16 (i.e.
CD16a and CD16b) are referred as low-affinity FcγRs (Smith and Clatworthy, 2010).
Different FcγR classes may also differ in their N-glycosylation patterns, which play an
important role in the molecule folding, structure, degradation, and cell-cell adhesion (van Sorge
et al. 2003). N-glycosylation is also capable of influencing ligand binding and leukocyte
expression patterns of FcγRs (including the case of CD16 on ligand binding and cellular
expression) (Rogers et al., 2006; van Sorge et al. 2003).
FcγRs transduce activating or inhibitory signals through intrinsic immunoreceptor
tyrosine-based activation motifs (ITAMs) or inhibitory motifs (ITIMs), respectively (Smith and
Clatworthy, 2010) (Fig. 1.4 and 1.6). The ITAMs are present in either the CYT tail/domains (for
CD32a and CD32c) or the associated FcR common accessory γ-chain (for CD64 and CD16a),
whereas the ITIMs are present in CYT tail/domain (for CD32b) (Smith and Clatworthy, 2010)
(thus, each CD32 molecule possesses an ITAM or an ITIM of its own and has no additional
signaling chains). Mechanistically, cross-linking by Ab-antigen/pathogen ICs of activating or
inhibitory FcγRs results in the ITAM or ITIM phosphorylation, respectively (Smith and
Clatworthy, 2010). Such phosphorylation of ITAMs or ITIMs leads to signal transduction and
cell activation (i.e. the activating signaling cascade) or to inhibition of the activating signaling
cascade, respectively (Smith and Clatworthy, 2010). In addition, several FcRs expressed on a
single type of leukocytes may cooperate to modulate many cellular functional effects of IC
binding and cellular effector functions (Daëron, 1997). For instance, when on human neutrophils
CD16b is cross-linked to CD32a through a divalent antigen, the neutrophil cells can be
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synergistically activated (Green et al. 1997). Similarly, cross-linking on human B cells of CD32b
with B cell receptor (BCR) may result in an increase of the “threshold” (i.e. the ratio of binding
of an IgG subclass to activating FcγRs and inhibitory CD32b; also known as A/I ratio) for B cell
activation and a decrease of Ab production by these B cells (Smith and Clatworthy, 2010). Also,
CD16b, the GPI-linked receptor that has no CYT domain and does not contain the associated
FcR common γ-chain (Smith and Clatworthy, 2010), is also believed to modulate cellular
neutrophil responses to pathogens/antigens through interactions with other neutrophil FcRs.
The final outcome (end result) of IC-FcR interactions is, therefore, complex and hard to
predict – it is dependent upon the functional activities of the bound FcγR, the effector functions
of a particular IgG subclass, the FcγR-expressing effector cell type, and applicable contributory
(inhibitory or stimulatory) signals (Schroeder and Cavacini, 2010; Weiner et al., 2010).

1.3.4. Intra-species (inter-individual) allelic polymorphism (allotypic variation) of FcγRs
Adding to the complexity of distinct expression pattern, recognition, and activation
profiles of FcγRs, each class of these receptors contains multiple isoforms and furthermore, a
number of those isoforms exist as allelic dimorphisms (biallelic polymorphisms) (Takai, 2005;
Jefferis and Lund, 2002). Correlation between allelic polymorphism and function has been
demonstrated. Furthermore, a number of naturally-occurring single variations have established
their functional and even clinical significance. In particular, R131 (CD32a) ([D2] R80, IMGT
unique numbering), F158 (CD16a) ([D2] F108, IMGT unique numbering), and NA2 (CD16b)
have been shown to exhibit higher affinity and functional activity compared to their
corresponding alleles (H131, V158, and NA1, respectively) (Binstadt et al., 2003; van de Winkel
and Capel, 1993). As a result, these allelic FcγR variants have the ability to affect susceptibility
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and/or severity of certain autoimmune disorders, especially systemic lupus erythematosus, as
well as inflammatory and infectious diseases (Takai, 2005; Binstadt et al., 2003; van Sorge et al.,
2003). Moreover, these variations have been shown to influence the outcome of monoclonal
antibody treatment (Cartron et al., 2002). For instance, CD16 polymorphisms have been recently
shown to be associated with the therapeutic success in treatment of Waldenstrom’s
macroglobulinemia by the rituximab mAb. These polymorphisms, therefore, can serve as highrisk factors or genetic markers for certain diseases or IgG-based immunotherapies (van Sorge et
al., 2003). Characterization of these allelic polymorphisms and their relations with twodimensional and three dimensional structures are, thus, important for the understanding of their
physiological effects. In this context, the IMGT Collier de Perles graphical two-dimensional
representations may provide useful information for relating structure to potential function
(Bertrand et al., 2004).
Thus, even a single amino acid substitution in FcγRs could result in significant
differences in functional properties and ultimately, might establish clinical relevance.
Consequently, on one hand, it might in a distant future be possible for a particular FcγR allelic
isoform to be selectively regulated – and on specific cell types – for individualized
immunotherapies (Jefferis and Lund, 2002). On the other hand, the efficiency of future or
potential FcγR-directed immunotherapies might vary from individual patient to one another.

1.4. Monoclonal antibodies, molecularly-engineered (recombinant) IgG and FcγR
molecules, and recombinant DNA method
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1.4.1. Monoclonal antibodies (mAbs) as basic research and diagnostic tools as well as
prophylactic and therapeutic agents
The capability of Abs to bind with exquisite discrimination and high affinity to virtually
all possible arrays of diverse antigens and chemical structures has placed them to a special
position in both biological sciences and practical medicine (Clark, 1997). Nowadays,
recombinant mAbs represent important biomedical and pharmaceutical products. These
molecules are utilized not only as valuable tools in basic research and diagnostic areas, but also
as powerful agents in prophylaxis and therapeutics. More than two dozen therapeutic mAbs have
to date been approved for use in the clinic, and hundreds (~350) more mAbs are in development
or trials (Reichert, 2012; An, 2010).
MAbs, owning to their desirable safety profiles and high efficiency, have proved to
improve human health, fight diseases, and even save lives. MAbs have been widely used in basic
research and diagnostic tests such as Western blot, ELISA, immune dot blot, immunehistochemistry, immune-fluorescence, and flow cytometry, to name a few. Passive
immunotherapy with mAbs, which initially introduced mAbs into practical medicine, still retains
a powerful prophylactic and therapeutic strategy. It is routinely used for the control of hepatitis
B, rabies, and cytomegalovirus infections (Sawyer, 2000). It also has the potential use for
efficient control and treatment of other infectious diseases, such as the lethal influenza
H5N1virus infection (Simmons et al., 2007). MAb treatment of infections caused by bacteria
resistant to antibiotics may provide a lifesaving strategy (Keller and Stiehm, 2000). Not only
being utilized in infectious diseases and antiviral prophylaxis, but also mAb-based strategies for
treatment have been applied for a wide variety of other diseases and disorders, ranging from
cancer and malignancies to rheumatoid arthritis, inflammatory diseases, as well as from
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autoimmune disorders, to cardiovascular, asthma, poisoning, and organ transplantation
(transplant rejection) (Laffly and Sodoyer, 2005; Brekke and Thommesen, 2003; Park and
Smolen, 2001; Schulze- Koops and Lipsky, 2000; Zeitlin et al., 2000).
MAbs, including those produced from recombinant DNA molecules (i.e. recombinant
mAbs), are produced by a single cell clone and are all structurally and functionally identical (An,
2010). Due to the availability of the murine hybridoma technology in the early time (see below),
most therapeutic mAbs currently used in humans are of murine origin (An, 2010). Over the last
three decades, advances in recombinant Ab technology that promotes production of genetically
engineered mAbs has greatly driven the use of Abs, both as basic research and diagnostic tools
as well as prophylactic and therapeutic agents.

1.4.2. The hybridoma technique: The traditional method for production of mAbs
Traditionally, mAbs are produced in vitro by immortalizing antibody-producing cells
created through fusing myeloma (tumor) cells with the spleen cells from a mouse immunized
with the wanted antigen. This method, termed hybridoma technique, was developed nearly four
decades ago (Kohler and Milstein, 1975). It has been proven to be the most reproducible method
for generating murine mAbs.
The method, however, has a number of limitations. Not only murine mAbs produced by
this method consist of only ﬁxed (unchangeable) CH class and subclass regions, have short
serum half-life, and lack the capability to activate sufficient effector functions (including Abdependent killing of target cells, ADCC and CDC), but also the created hybridoma clones may
be genetically unstable (Nielsen et al., 2006). In addition, the technique itself is time-consuming
and laborious. More importantly, murine mAbs have poor pharmacokinetics in humans. When
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used as therapeutic agents, murine mAbs are recognized by the human immune system as
allogeneic proteins, resulting in a rapid removal of them from the blood, as well as in systemic
inflammatory effects and human anti-mouse antibody (HAMA) immune responses (Steinitz,
2009; Laffly and Sodoyer, 2005).
The problems associated with murine mAbs produced by the hybridoma method have
recently been overcome largely, owning to the advent of the recombinant DNA technology (i.e.
the genetic engineering technique). This advanced technology allows reducing HAMA
immunogenicity responses by making or modifying mAbs so as they are less “murine” or more
“human”, such as chimerizing murine/human mAbs, humanizing murine mAbs, or completely
human mAbs (An, 2010; Kipriyanov and Le Gall, 2004).

1.4.3. The recombinant DNA method for production of mAbs and molecularly-engineered
IgGs and FcγRs: Overview
Recombinant DNA method, or recombinant DNA technology, is a molecular technique
for engineering recombinant proteins. The technique is widely used in biological and biomedical
sciences, biopharmaceutical and biotechnology, as well as medicine. It takes advantage of the
fact that production of proteins can be accomplished using cloned DNA sequences or
recombinant DNA molecules to create plasmid constructs capable of growing and being
expressed by cell culture (i.e. expressing recombinant genes). Thus, in this method, a
recombinant DNA fragment (or gene segment) is first created by several molecular cloning steps,
and is subsequently inserted into a cloning vector, which is then transformed into and
multiplicated in competent cells (bacteria; such as E. coli competent cells). Prior to transfection,
the recombinant DNA constructs must be directionally inserted into an expression plasmid vector
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containing genetic sequences necessary for expression, including promoter, translational
initiation signal, and transcriptional terminator. Upon transfection into the host organism, the
recombinant foreign DNA molecule that is contained within the recombinant DNA plasmid
construct may be transcribed and translated by the host cell translational apparatus. Finally,
colonies producing the recombinant protein product were detected and isolated. These
procedures, thus, utilize a number of molecular techniques, including cloning vector, restriction
endonuclease digestion, DNA ligation (with DNA ligase), and selection of clones with desired
DNA inserts by appropriate antibiotics-supplemented culture medium.
The recombinant DNA technology for production of recombinant antibodies (rAbs) (also
called recombinant Ab technique) is a fully in vitro method for creating highly-specific and highaffinity mAbs. As discussed previously, it is the globular domain structure and genetic
organization of Abs, in which specificity-determined Fab is formed by V domains while different
effector functions Fc is constituted by C domains, that have greatly facilitated the manipulation
of Ig genes for Ab genetic engineering. In particular, the Ig domain structure enables exchange
and replacement of domains specializing in antigen-binding activities (Fab or partial Fab), or
those responsible for cell-killing effector functions (Fc) among Abs (Kipriyanov and Le Gall,
2004). In this method, recombinant Abs are created in a way that V region is made of a particular
species and C region is of another species. For instance, mouse V domains can be merged with
(or fused to) human C domains to yield partially-mouse, partially-human ("humanized") mAbs.
Among available mouse V gene segment sequences that have enabled rapid production of
recombinant Abs, murine V gene sequence specifically directed against the hapten 5-iodo-4hydroxy-3-nitrophenyl acetyl (NIP) has been established as a specificity system that has
facilitated studies of Ab effector functions. Traditionally used as a haptenic determinant, NIP
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may be further radiolabeled and used as salts or derivatives. Additionally, production of NIPspecific recombinant Abs is relativey straightforward. Various Ab variants possessing anti-NIP
specificity have been produced and used to assess the Fc-related structural basis of Ig effector
functions (Loset et al., 2004; Furebring et al., 2002; Redpath et al., 1998; Clark, 1997). A variety
of pre-designed expression vectors enabling rapid construction and driving expression of
complete and fragmental recombinant Ab molecules, such as pLNOH2 (Norderhaug et al.,
1997), have been also established.

1.4.4. The recombinant DNA method for production of mAbs and molecularly-engineered
IgGs and FcγRs: Advantages and limitations
Recombinant Ab technique offer many advantages over the conventional hybridoma Ab
production method. In the recombinant Ab method, mAbs can be produced in in vitro by cloning
entire Ig V region gene repertoire, and no immunization nor experimentation with animals are
needed (thus less time would be required). Indeed, the hybridoma cell lines are sometimes
genetically unstable and in such cases, immortalization of unique Abs by cloning corresponding
genes would be greatly useful. For many applications, only partial Ab molecules (i.e. Ab
fragments, instead of whole Ab molecules) are needed. Here the recombinant Ab method has
proved advantageous with its ability to genetically engineer Abs in bacterial expression systems,
which is rapid and straightforward.
More importantly, given the availability of enormous Ab gene sequences and a variety of
advanced molecular biology techniques, isolation and cloning of Ig genes can be rapidly carried
out. These sequences can be readily amenable to genetic manipulation and fusion. Genetic
manipulations, chemical modifications, or other intervening methods of the properties of
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expressed mAb – owing to V and/or C regions – can greatly enable the design of novel Abs with
predetermined effector functions or other desired functional activities (Fig. 1.7). Such
manipulations can be done through a variety of genetic engineering methods and using various
different strategies, such as "inserting" or "swapping-out" Ab portions, introducing mutations,
and adding markers, cytotoxic agents, cytokines, or other labeling or functional conjugates,
among other approaches (Carter, 2001; Clark, 1997). These modifications have enabled creation
or alteration of recombinant Abs with additional desired antigen binding specificity, enhanced
binding affinity, optimized or additional natural effector functions, or removal of unwanted
functional activities (such as placenta transfer or complement activation) for particular
applications (Carter, 2001; Clark, 1997). For instance, IgG Abs that are capable of binding FcRs
but not complement – or vice versus (i.e. those with only complement activation potential) – can
be designed. Engineering of recombinant Abs can also be further improved by manipulating
amino acid composition (sequences) within individual Ig domains to obtain particular Abs for
studying the structure basis and functional properties (such as binding, folding, stability,
catalysis, and effector functions) (Clark, 1997).
Advances in the recombinant Ab techniques have allowed production of Abs to virtually
any antigen, and facilitated generation of Abs never been made in vivo. Nevertheless, despite the
large diversity of potential applications ascribed to recombinant Abs, the method lacks of an
appropriate strategy for determining and selecting the desired high affinity Ab products that
would be effective in vivo.
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1.4.5. Creation of recombinant Ig gene constructs: Sequence overlap extension polymerase
chain reaction (SOE-PCR)
As discussed above, the recombinant Ab techniques rely on the rapid cloning of isolated
Ig gene segments before these genes can be cloned into cells that can grow and express
recombinant Ab products. Cloning of Ig Ab genes can be done by either isolating these
genesfrom the relevant genetic materials of a hybridoma cell line, or by synthesizing them using
polymerase chain reaction (PCR) amplification with degenerate primers on a pool of Abproducing cells obtained from an immunized animal or immunized human donor(s). The PCR
method has indeed allowed amplification of the entire Ig genes (or some of their components).
Subsequently, these genes can be introduced into a variety of cells for production of recombinant
Abs. At present, the PCR method is commonly used to amplify genes encoding Abs with desired
specificity. It can even be utilized to produce the entire Ab gene repertoire of immunized or nonimmunized animals for cloning purposes.
Recombinant Ig gene constructs can be created from individual Ig gene segments by a
method for splicing two pieces of DNA segments, known as sequence overlap extension PCR
(SOE-PCR) (Yolov and Shabarova, 1990; Yon and Fried, 1989; Ho et al., 1989). This technique
is a powerful tool for fusing two short DNA fragments whose total length is not greater than 3-4
kb at a time (Kuwayama 2002; Pont-Kingdon, 1997), which is ideal for creating Ig gene
constructs. Fig. 1.8 illustrates the principle of SOE-PCR to assemble a gene construct from two
DNA fragments. Two pairs of primers, the flanking and the internal pairs, are used. The overlap
(homologous or complementary) sequence is incorporated in the two internal primers, which
serve two functions: priming and overlapping, by their priming and overlap regions, respectively.
In particular, the 5’ end sequence of the internal reverse primer (to be used for amplifying the
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Fig. 1.7. Among the advantages of engineering Abs: Strategies for enhancing the potency and
activity of antitumor antibodies. See text for details. Figure is reproduced from Carter, 2001.
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first PCR fragment) is complementary to a short sequence of the second PCR fragment – and
thus, to the 5’ end sequence of the internal forward primer (to be used for amplifying the second
PCR fragment).
The theoretical stages of SOE-PCR amplification are also summaried in Fig. 1.8. Firstly,
two overlapping fragments are amplified in separate PCRs using the forward flanking and
reverse internal primer pair – as well as the forward internal and reverse flanking primer pair –
on the target sequence. In some cases, these two resultant PCR product fragments anneal to each
other through their complementary sequences. Since these two DNA template fragments were
introduced at their adjacent end an overlapping sequence, each of these overlap strands can act as
a giant “primer” on the other to extend its 3’ end by DNA polymerase. These reactions result in
the fused DNA species created in the mixture of early SOE-PCR products. The intact mixed
DNA strands are finally generated when the overlap is extended and co-ordinately amplified
with the outside forward and reverse flanking primer pair (i.e. hybridizing and amplifying the 3’
end of the upper strand of forward fragment and the 5’ end of the lower strand of the reverse
fragment). In all reactions, a PCR cycle comprises steps of denaturation, annealing, and
extension of the primed 3’ ends. Although SOE-PCR fusion offers greater speed and flexibility
for construction of recombinant DNA molecules than traditional RE and ligase cloning, it is,
however, expected to introduce errors, as any other PCR reactions.
Several sequential runs of SOE-PCR, with each run combining two DNA pieces at a
time, can assemble more than two short segments and generate a final constructs with the desired
length. Modifications of reaction parameters and/or conditions, such as designing longer
chimeric primers, optimizing molar ratios and DNA concentrations, adjusting annealing
temperature, and running with no primers for several first PCR cycles and using nested primers,
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Fig. 1.8. Diagrammatic overview of the sequence overlap extension polymerase chain reaction
(SOE-PCR) procedure to assemble a chimeric/mixed gene fragment. The procedure is also called
by various other names, such as overlap extension PCR, splice overlap extension PCR, overlap
PCR, overlapping PCR, two-step PCR, two-step overlap extension PCR, or three-part PCR. (A)
Individual strands of a DNA fragment displaying their 5’ and 3’ ends are illustrated as enlarged
boxes. Two pairs of primers are used: FW flanking primer/RV internal primer and FW internal
primer/RV flanking primer. The overlap (homologous or complementary) sequence is
incorporated in the FW and RV internal primer. Primer direction is indicated as arrows. The two
internal primers serve two functions, priming and overlapping, by their priming and overlap
regions, respectively. Complementary ends are shown by different colors boxes (i.e. small greenfilled and yellow-filled boxes). (B) Theoretical stages of formation of a SOE-PCR chimeric
product. See text for details. Overlapping ends of identical sequences of fragments are indicated
with the same color filled; complementary ends are shown by different colors boxes (i.e. small
green-filled and yellow-filled boxes). A PCR cycle comprises steps of denaturation, annealing,
and extension of primed 3’ ends.
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might be needed during the procedures in order to improve the success of reamplification and
generate the best products, as well as to minimize non-specific bands (as will be discussed in
more details later).

1.4.6. Mammalian expression systems for production of recombinant IgGs and FcγRs
Molecular engineering of Abs or Ab fragments enables manipulation and production of
Igs in various eukaryotic and prokaryotic cell types, including bacteria, yeast, plant cells, insect
cells, and mammalian cells (Kipriyanov and Le Gall, 2004). However, to be fully functional,
recombinant Ig products that are expressed must be correctly folded, wholly assembled, and
post-translationally modified. In particular, to form intact molecules, the two IgH chains must be
disulfide bound (and to be able to carry out effector functions), CH2 domains must be correctly
glycosylated, and CH3 domains must be paired (Kipriyanov and Le Gall, 2004; Brekke and
Thommesen, 2003). Glycosylation is also crucial for efficacy of Abs and protein drugs targeted
as human therapeutic agents. Expression systems possessing the mechanisms necessary for these
processes and events have been seen in various mammalian cell lines, including nonsecreting
myeloma, hybridoma, and nonlymphoid cells (Kipriyanov and Le Gall, 2004). Like with Igs, a
mammalian cell line system (rather than prokaryotic cell types) should also be considered for
expressing recombinant FcRs, as FcRs also contain conserved disulfide bridge (some FcR
members also consist of unpaired Cys residues) in each of their IgSF domain.
Dependent upon the quantity of the recombinant Ab products needed, transient or stable
expression of Abs in mammalian expression systems can be performed. In contrast to transient
production which is rapid, stable expression of Abs is time consuming. The reason is that stable
production is based on the stable integration of recombinant Ig genes into the host cell
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chromosomes, which is a largely random event. To facilitate successfully transfected cell clones
to be isolated from a heterogeneous population, the interested gene is integrated together with a
selection marker during engineering of the recombinant constructs. Among common types of
selection marker genes are those encoding resistance to antibiotics (such as neomycin gene,
which encodes resistance to G418) and enzyme analogs [such as dihydrofolate reductase
(DHFR) gene, which encodes methotrexate resistance].
Several mammalian expression cell lines capable of highly producing Ig molecules have
been developed. The murine IgL lambda (λ)-producing, IgH-defective, myeloma (i.e. cells that
produce Abs) J558L cell line is one of such cellular systems (details will be described later)
(Howard et al., 2002; Oi et al., 1983). Intact, glycosylated Abs that are fully functional and
capable of antigen-binding, have been successfully expressed and secreted by J558L cells
transfected with vectors expressing IgH chains and carrying the G418 selectable marker (Howard
et al., 2002; Fell et al., 1989; Oi et al., 1983).

1.5. Structural and functional features of rhesus macaque IgG and FcγRs: Current status
of knowledge
1.5.1. Presence of four IgG subclass genes, each with similar length and organization as that
of humans
Like humans, rhesus macaques express five Ig classes. Early studies had identified both
in serum and in genomic DNA in healthy rhesus macaques only three IgG subclasses, IgGl, IgG2,
and IgG3 (Calvas et al., 1999; Shearer et al., 1999). Later data obtained from genomic DNA
analysis, however, show that this primate species possess four IGHG genes, based on their
sequence similarity with the four corresponding human genes IGHG1, IGHG2, IGHG3, and
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IGHG4 (Scinicariello et al., 2004). These genes are expressed at least at the mRNA level,
including the lately-identified IGHG4, whose protein product (i.e. IgG4) may be present at
almost undetectable levels in rhesus macaque serum (Scinicariello et al., 2004). The early
serological failure of identifying the rhesus macaque IgG4 homologue of humans might also
indicate the possibility that differences between human and rhesus macaque IgG4 had
circumvented its detection and identification.
The intron-exon genomic organization of the four IGHG genes is similar between rhesus
macaques and humans. Each of the four rhesus macaques IGHG genes is composed of four
exons, individually encoding CH1, the hinge, CH2, and CH3 domains, and three introns, which
take place in-between the exons. Each rhesus macaque CH domains contains a similar number of
amino acids as that found in their human counterparts, which is 98, 109-110, and 107, in CH1,
CH2, and CH3 domains, respectively. The length of the introns is also similar to that of the
corresponding human introns (~390, ~120, and ~100 nucleotides for the intron located between
CH1-the hinge, the hinge-CH2, and CH2-CH3 exons, respectively) (Scinicariello et al., 2004).

1.5.2. A single exon encoding the IgG3 hinge region and key amino acid differences of IgGs
compared to human counterpart
IgG V region genes between rhesus macaques and humans are highly homologous and
their IgG C region genes are generally homologous. Indeed, rhesus macaque IgG1, IgG2, IgG3,
and IgG4 CH domains exhibit 89.9%, 88.0%, 92.9% and 91.4% amino acid identity to their
human counterpart (Scinicariello et al., 2004). The deduced amino acid sequence of each of four
rhesus macaque IgG subclasses differs from that of their human counterpart – generally for a few
amino acids (Scinicariello et al., 2004) – yet they share most amino acid residues known to be
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functionally conserved. Perhaps the most striking difference between rhesus macaque and human
IgG subclass genes is at the IgG3 hinge. Rhesus macaque IgG3 contains only one hinge exon
(Scinicariello et al., 2004), whereas, as previously described, the human IgG3 hinge most often
consists of four exons (can be two to five exons; with repetitive sequences and separated by short
introns) (Lefranc and Lefranc, 2001). In addition, it is deficient in Cys residues, which is
important for Ig stability through formation of disulfide bonds.
Some other key amino acid differences in IgGs of rhesus macaques and their human
counterparts have also been revealed. The upper hinge region of macaques contains several Pro
residues [known to be involved in stabilization or maintaince of the IgG tertiary structure and
might influence the hinge flexibility (Thommesen et al., 2000, Greenwood et al., 1993)] that are
not present in the human counterpart. Chinese rhesus macaque IgG4 also possesses Ala instead
of Pro at position 13 of the hinge. Also, rhesus macaque IgG4 has Pro at position 101 of CH2
domain, where in human IgG4 it is Ser. Moreover, in humans, unlike IgG4, other IgG subclasses
capable of activating complement contain Pro at position 101. The inefficiency in complement
activation of human IgG4 is thought to be associated with lack of Pro at the position 101 (Xu et
al., 1994). The presence of Cys-to-Ser substitution at position 10 in rhesus macaque IgG4 CH1
domain as compared to humans might affect the formation of interchain disulfide bridges
involved in this Cys residue (Scinicariello et al., 2004). Interestingly, a Ser exists at this position
in IgG1 in both species.
Although characterized by evolutionary instability, as discussed previously, the structural
distinctions of the IgG hinges in rhesus macaques as compared to human counterparts might lead
to alterations in the formation of disulfide bridges and functional properties of IgG molecules,
including molecular flexibility (Thommesen et al., 2000; Roux et al., 1997), neutralizing ability,
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binding affinity to FcRs, capability of complement activation (Burton and Woof, 1992;
Michealsen et al., 1990, Tan et al., 1990), and susceptibility to proteolytic enzymes. The singlehinge IgG3 in rhesus macaques (and other macaque species) might exhibit unique properties
and/or carry out different effector functions when compared to human IgG3.

1.5.3. Intra-species IgG H chain genes: Relatively high level of heterogeneity (polymorphism)
and variability of disease susceptibility
As previously mentioned, rhesus macaques are characterized by a high level of
polymorphism of MHC genes (Shedlock et al., 2009). Like several other NHP species, rhesus
macaques also feature a relatively high degree of intraspecies CH gene heterogeneity (allelic
polymorphism) for IgGs, particularly IgG2 and IgG4, as compared to humans (Scinicariello et
al., 2004; Scinicariello et al., 2001). Although IgG (i.e. IGHG) polymorphism level is less
extensive than that of IgA in this animal species (Sumiyama et al., 2002; Scinicariello et al.,
2001), many IgG substitutions are located in CH2 domains, the place that is responsible for most
IgG effector functions and properties (Radaev and Sun, 2002).
In addition to species-specific differences from humans, individual rhesus macaque
animals originated from different geographical areas also show considerable variation in immune
conding genes and disease susceptibility. Examples of such variations include those observed
with IGHG2 and IGHG4 genes of Chinese- versus Indian-originated macaques (Scinicariello et
al., 2001). These geographically different rhesus macaque animals also vary in their
susceptibility to infectious diseases, especially SIV infection: when inoculated with the same
infectious challenge virua stock, some animals progressed disease – and at different extents –
while others remained relatively unaffected (Reimann et al., 2005; Ling et al., 2002; Marthas et
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al., 2001; Joag et al., 1994). Some rhesus macaque individual animals may thus be better than
others to be used as a research model.
The extensive polymorphism in IgG CH genes might be involved in the presence of
structurally, and thereby functionally, variable IgG molecules in different rhesus macaque
animals. This relatively high level of allelic polymorphism might also reflect an alternative
strategy developed by rhesus macaques to clear invading pathogens, however. Also,
polymorphisms might explain the poor (cross)reactivity or inactivity of anti-human reagents to
different rhesus macaque IgG subclasses. Moreover, these Ig allelic forms, with different
functional properties, might contribute to different susceptibility, progression, or severity to
infections. These differences should be taken into account when designing experimental
strategies and protocols with various model systems – as well as to select appropriate animals for
studying pathogenesis of human infectious diseases, immunization, and vaccine strategies.
Theoretically, substitutions in rhesus macaques of individual amino acid residues known
in humans to be functionally important may lead to changes in Ig effector functions (such as
ADCC, CDC, ADCP, or IgG half-life), as well as in Ig structure-function relationships.
However, polymorphisms that occur co-locally in both IgG Fc ligand and their native FcγR
molecules within their binding areas would, under natural evolutionary selection, have the
potential to optimize functional activity and increase the binding fitness of both interacting
players (Kim et al., 2001). Furthermore, because of the extensive contact surface and multiple
residues interacting with receptors, the interactions between IgG (ligand) subclasses and different
FcγRs and are complex. In addition, interaction of the homodimeric Fc fragment with its
receptors is asymmetrical (i.e. overlapping but not identical residues in both Fc fragments may
take part in binding). Therefore, in order to adequately assess the binding properties and the
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ability to mediate effector functions of IgG molecules in rhesus macaques or other NHP animals,
not only heterogeneity (polymorphism) of ligand IgGs themselves need to be considered, but
also structure of corresponding FcγRs in those species must also be taken into account.

1.5.4. Rhesus macaque FcγR biology system and related pathogen-clearance mechanisms are
largely uncharacterized
Although the information available on rhesus macaque Ab molecules and corresponding
receptors is steadily increasing (Rogers et al., 2008, 2006a, and 2004; Scinicariello et al., 2004;
Scinicariello and Attanasio, 2001; Calvas et al., 1999), basic characterization is still lacking for
the majority of Fc receptors. Indeed, research on NHP FcR biology is still in its nascent stage.
Rhesus macaque FcRs have only been described recently and are limited to few classes (Rogers
et al., 2008, 2006b, and 2004). Within FcγRs in this species, only gene sequences for FcγRIII
(CD16) have to date been identified (Rogers et al., 2008; Miller et al., 2007; Rogers et al., 2006b
and 2004), whereas the genes encoding CD32 and CD64-“like” sequences have been only
computationally predicted. Rhesus macaque CD16 gene shows 91.7% identity to human CD16a
(Rogers et al., 2006b). Although CD16 molecules in NHP species (including rhesus macaques)
and humans share an extensive similarity in sequence and genetic organization – with nearly
complete conservation of residues known to be critical for IgG binding – they have been found to
be different in some key aspects. In particular, while human CD16 consists of two isoforms
encoded by two separate genes, only a single CD16 gene homologue, which encodes a protein
with over 90% homology to human CD16, was identified in rhesus macaques and other NHP
animals (Rogers et al., 2006b). CD16 cell-type expression patterns on the leukocyte population
differ not only between humans and NHP scpecies, but also among different NHP species

65
(Warncke et al., 2012; Rogers et al., 2006). Also, in contrast to corresponding human FcγR,
recombinant NHP CD16 exhibits different binding specificity to different NHP and human IgG
subclasses (Rogers et al., 2006). Difference in functional properties of different cynomolgus IgG
subclasses has also been recently characterized (Warncke et al., 2012; Jacobsen et al., 2011).
The findings about a high degree of inter-individual genetic heterogeneity of NHP IgSF
molecules such as IgG and CD16 [as well as IgA and IgD (Rogers et al., 2006a)] characterized to
date raise the question whether such diversity might also be reflected in other IgSF members,
including other classes of FcγR, in these species. Although CD16 is known to be polymorphic in
humans and its inter-individual allelic variants have recently been reported in rhesus macaques
(Miller et al., 2007), we do not know at what extent these molecules are heterogeneous. More
importantly, CD16 allelic variants appear to influence the host responses to mAb treatment
(Miller et al., 2007). As discussed previously, CD16 also plays an important role in destruction
of HIV-infected NK cells and malignancies via ADCC mechanism. The fact that the neutrophil
expression profile of CD16 differs among several macaque species usually used in evaluation of
therapeutic Abs based on IgG-FcγR interactions (Rogers et al., 2006), should be considered in
experimental design and data interpretation.
As mentioned previously, even a single amino acid change in FcγR amino acid sequences
might result in the possibility of significantly altering ligand binding affinity of a particular FcγR
(Rogers et al., 2006a; Scinicariello et al., 2004; Scinicariello et al., 2001). Particular FcγR allelic
variations might also be associated with disease susceptibility and/or severity, or can even
influence the outcome of Ig-based treatments (van Sorge et al., 2003; Cartron et al., 2002). Thus,
specific sequence alleles or variations indentified in individual animals might be assessed for
their potentially altered binding affinity or specificity – or even clinical relevance as needed. In
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addition, discrepancy should be considered when using NHP models in the evaluation of Igbased or, in the near future, FcγR-derived, immunotherapies. These observations highlight the
need to further characterize FcγRs in rhesus macaques.
Taken together, on one hand, rhesus macaque IgGs and associated FcγR systems
characterized to date are conserved and extensively homologous compared to those in humans.
This similarity suggests that immune responses and mechanisms of protection modeled from this
species can be translated into humans. On the other hand, rhesus macaque IgGs are highly
polymorphic and have several key differences from their human counterparts. This distinction
suggests that efffector functional activities of IgG subclasses, including their interactions with
corresponding FcγRs, between these two species may not be directly equal or simply similar.
The presence of allelic forms of rhesus macaque IgG CH region and FcγR genes might result in
production of IgGs and FcγR molecules exhibiting different functional properties, thus
potentially contributing to individual immune responsiveness profiles. These differences should
be clarified in order to correctly interpret and evaluate experimental results generated using the
rhesus macaque model. Additionally, as discussed previously, amino acid changes in FcγRs
might have the potential to influence the possible effects caused by IgG substitutions (due to
relatively high polymorphism of IGHG genes), leading to the unique properties and functions of
their IgGs in rhesus macaques. Comprehensive characterization of FcγR structures is, thus,
necessary in order to adequately assess the binding properties and the ability to mediate effector
functions of their IgG ligands. The first steps towards definition of all such functional activities
and properties in rhesus macaques would, therefore, be the creation of their genetically
engineered IgG subclasses.
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1.6. Study objectives and specific aims
Taken together, rhesus macaques are used widely in immune-related research and vaccine
studies, yet their immune system components and mechanisms are largely uncharacterized.
Although extensively similar as compared to humans, IgGs and corresponding FcγRs in this
species possess several key structural and functional differences that must be considered when
interpreting experimental data and evaluating therapeutic strategies. To validate and improve the
use of a rhesus macaque model for human diseases, comprehensive characterization of the
elements responsible for the humoral immune responses and the mechanisms for elimination of
invading pathogens is imperative. Previous work in our laboratory has successfully identified the
IgG CH region genes in rhesus macaques. The presence of several allelic forms of IgG CH genes
(and some other IgSF members identified to date) might result in production of Ab molecules
exhibiting different functional properties. However, the effector functions and clearance
mechanisms associated with rhesus macaque IgG CH regions are presently undefined.
Information on IgG responses, including the preferential usage of certain IgG subclasses during
various immune responses to pathogens or vaccination, is also currently unavailable. In addition,
the structure-function relationship of molecules encoded by recently identified IgG CH region
genes are uncharacterized.
These gaps of knowledge are mainly due to lack of specific reference reagents (Abs)
capable of specifically recognizing and unequivocally differentiating rhesus macaque IgG
subclass molecules. Such Abs represent a valuable tool to further characterize IgG immune
responses and vaccine efficacy in this species. Also, although rhesus macaque CD16 genes have
recently been described, other important FcγR classes, including CD64 and CD32, have not been
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defined. The needs for complete characterization of various IgG and FcγR genes and for
generation of their recombinant molecules are, therefore, widely recognized.
The present study was designed to fill some of these gaps. Specifically, the goal of this
study is to define and further characterize the two major components of the humoral immune
system, IgG and FcγR molecules, in rhesus macaques, focusing on the following aims:

1. To generate recombinant Abs for each of the four rhesus macaque IgG1, IgG2, IgG3,
and IgG4 subclasses – to be utilized for defining IgG functional properties and
immune response patterns in this species as well as for generation of reference Abs.
2. To identify and characterize FcγR genes and protein products existing within rhesus
macaques, including identifying CD64 and CD32 genes, defining intraspecies
variations of CD64, CD32, and CD16 genes, as well as determining their genetic
polymorphisms and similarity with their human counterpart.
3. To generation of recombinant cDNA cloning and expression vectors for rhesus
macaques CD64 and CD32 – to be utilized for expression of protein products for
studying IgG/FcγR interactions and functional activities.

Accomplishment of these specific aims will add into the long-term goals of providing a
well-defined rhesus macaque model for understanding IgG-mediated protective and pathogenetic
mechanisms, as well as for evaluating efficacy of novel immune intervention strategies.
Apart from the findings about IgGs and FcγRs in rhesus macaques, we also reported in
this study our data demonstrating that the main female hormone substance, 17β-estradiol, is
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capable of restoring Ab responses to an influenza vaccine in a postmenopausal mouse model.
These findings suggest that immunogenicity and efficacy of influenza vaccines should be
evaluated in postmenopausal women, which belong to an age group that is highly susceptible to
influenza infection and its most serious complications.
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CHAPTER 2
ENGINEERING OF CHIMERIC MOUSE-RHESUS MACAQUE
IGG1, IGG2, IGG3, AND IGG4 SUBCLASS RECOMBINANT ANTIBODIES
RECOGNIZING THE HAPTEN 5-IODO-4-HYDROXY-3-NITROPHENACETYL

2.1. Summary
Four IgG subclass homologues, corresponding to the four human IgG subclass genes,
were discovered and characterized in rhesus macaques, an important non-human primate
research model for human diseases. The functional properties that distinguish these IgG
subclasses, however, is largely unexplored. The obvious reason for such unavailability of
information is lack of specific reagents. To fill this gap, we engineered all four chimeric mouserhesus macaque IgG1, IgG2, IgG3, and IgG4 subclass recombinant antibodies (Ab) specifically
recognizing the hapten 5-iodo-4-hydroxy-3-nitrophenacetyl (NIP), an established specificity
system for studying IgG effector functional properties. We first created recombinant IgG heavy
chain (IgH) cDNA gene fragments encoding each rhesus macaque IgG class using sequence
overlap extension (SOE)-PCRs, where murine VH anti-NIP and Chinese rhesus macaque CH
region genes were PCR-amplified and joined together as single fragments. The resultant
fragments were then cloned into specialized expression vectors. The IgH expression vectors were
subsequently transfected into the murine IgH-loss-variant myeloma cell line, J558L, which
synthesizes and secrets an IgL λ but does not produce murine intact Ig molecules. G418-selected
cells were tested for IgG production and binding by ELISA with NIP coupled to BSA-coated
microtiter plates and goat anti-monkey purified IgGs. Horseradish peroxidase (HRP)-conjugated
anti-mouse IgL λ or HRP-conjugated goat anti-monkey IgG-specific was used as the detection
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Ab. We successfully produced recombinant rhesus macaque IgG chimeras of the four subclasses,
which would represent both the foundations and the tools for further studies on IgG effector
functions and Ab structure-function relationship in the rhesus macaque model.

2.2. Materials and Methods
Fig. 2.1. represents the steps involved in the construction, production, and detection of
the NIP-rhIGHG chimeras/chimeric molecules using recombinant DNA technology, which
include the following precedures.

2.2.1. Construction of NIP-specific murine VH–rhesus macaque IgG CH (rhIGHG) cDNA
hybrids (NIP-rhIGHG): DNA sources, SOE-PCR, and primer design
NIP-rhIGHG cDNA hybrids, including NIP-rhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3,
and NIP-rhIGHG4 IgG subclass gene cassettes, were constructed by sequential sequence overlap
extension PCRs (SOE-PCRs). Firstly, separate PCRs were used to amplify cDNAs encoding
NIP-specific mouse variable heavy (VH) and rhesus macaque (rh) constant heavy (CH) IgG gene
segments (exons) of each of the four subclasses (referred to as rhIGHG1, rhIGHG2, rhIGHGH3,
and rhIGHG4, according to the IMGT nomenclature). cDNA encoding VH, which has
specificity for 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP; a hapten that can be used for
studying specific effector immune responses), was cloned from pLNOH2 “RNA-Chinese” vector
(see below), which was available in our laboratory plasmid repository (Rogers et al., 2008),
using primer set FVH5FW and FVH3G4R (Table 2.1). The resultant VH PCR product contains a
BsmI restriction endonuclease (RE) recognition site at the 5’ end, and a 42-bp sequence at the 3’
end that is homologous to the 5’ end of rhCH1 IgG gene segment.
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Fig. 2.1. Flowchart representation summarizing the major steps involved in construction,
production, and detection of NIP-rhIGHG chimeras using recombinant DNA technology (genetic
engineering). Individual DNA gene fragments were first isolated and amplified from the rhesus
macaque Ab-producing cells by PCR/RT-PCR using primers that were designed based on known
conserved regions of the publicly available rhesus macaque and corresponding human IgG
sequences. These fragments were then used as DNA templates in SOE-PCRs to generate in in
vitro the complete cDNAs, which contain a mouse VH in combination with rhesus macaque CH
sequences. The resulting chimeric cDNA gene constructs were cloned into pCR2.1 TOPO TA
cloning vector containing a selectable marker sequence. Selection for transformed clones that
picked up the constructs and replicated in competent bacterium cells was made by culturing the
cells in medium containing X-gals and ampicillin. The constructs were then amplified from the
cloning vector by PCR using the primers that incorporated appropriate restriction sites which
were used to transfer the desired constructs into an expression vector, where it fit exactly
between the two defined restriction sites. To make a large quantity of the constructs, the resulting
recombinant expression vector was transformed back into competent bacterium cells so that they
were multiplicated by these cells following their division and replication. An appropriate amount
of recombinant DNAs were then transfected into the appropriate recipient cell lines (murine
myeloma J558L cells), where the cellular machinery directed the cells to synthesize, assemble,
and secret protein products. Stable transfectants synthesizing the genes of interest are
subsequently identified. The resulting chimeric IgGs now contained NIP-specific V domains
derived from mice that was fused to rhesus macaque C domains. The secreted recombinant IgGs
were detected from supernatants of cell cultures by ELISAs. Mammalian cell lines (not bacteria
or yeast) must be used as the four chains of the molecules have to assemble correctly, as well as
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the glycosylation and the large number of disulfide bonds have to be made correctly. Some
figure pieces are reproduced from the internet.
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Next, cDNAs encoding each of IGHG gene segments, rhCH1, rhCH2, and rhCH3, of
each of the four subclass molecules of rhesus macaques were isolated and PCR-amplified from
the appropriate plasmid vectors that contain IGHG genes identified in the genomic DNAs
isolated from a Chinese rhesus macaque [available in our laboratory plasmid repository
(Scinicariello et al., 2004)]. The primer sets used in these PCRs were designed so that short
homologous or complementary nucleotide sequences were introduced at the joint of any two
adjacent gene segments (Fig. 2.2). For example, for IgG2 molecule, the resultant rhCH1 PCR
product contains a 30-bp sequence on the 3’ end that is homologous to the 5’ end of the resultant
rhCH2 PCR product. Similarly, the resultant rhCH2 PCR product has a 43-bp and 30-bp
sequence on the 5’ end that is homologous to the 3’ end of the resultant rhCH3 PCR product in
IgG2 and IgG3 molecules, respectively (Table 2.1). The resultant rhCH3 PCR product further
contains a BamHI or a XhoI RE recognition site at the 3’ end.
Unlike in humans where IgG3 has three hinge segments due to sequence repetition (Roux
et al., 1997), one hinge segment is identified in this IgG subclass of rhesus macaques
(Scinicariello et al., 2004). To ascertain this feature in generation of rhesus macaque IgG3, a
primer pair specific for the hinge, namely G3CHF (forward direction) and G3CHR (reverse
direction), was designed. These IgG3 hinge primers, G3CHF and G3CHR, shares a 33-bp and
36-bp identical sequence with the forward primer for the IgG3 gene segment rhCH2 (i.e. G3C2F)
and the reverse primer for the IgG3 gene segment rhCH1 (i.e. G3C1R), respectively (Table 2.1).
For other IgG subclasses, primer sets specific for the hinge were embedded in the reverse primer
for the rhCH1 gene segment and the forward primer for the rhCH2 gene segment.
All primers were designed to flank known conserved regions of human and NHP IgG
gene sequences, and were subsequently optimized (such as increasing the length of overlaps in
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Fig. 2.2. Schematic representation illustrating the separate exons that encode for individual
heavy-chain constant domains of an Ig molecule, as well as diagrammatic representation
depicting organization of a complete IgG3 heavy chain gene fragment with name and location of
a pair of primers at the CH2-CH3 boundary, shown as an example for overlap primer sequences.
(A) Separate exons encoding individual heavy-chain constant domains of an Ig protein molecule
(not drawn to scale). Shown is the organization of IgG3 H chain genes with CH1, hinge (Hg),
CH2, and CH3 exons, represented in the 5’ to 3’ orientation. Purple and red boxes indicate exons
and straight black lines indicate introns. Lightly purple shaded areas indicate the correspondence
between the DNA segments and the different domains of the Ig polypeptide chain that they
encode. The intron-exon organization of the IGHG genes was inferred from the human and
rhesus macaque sequences publicly available. (B) Organization of a complete IgG3 heavy chain
gene fragment and name and location of a pair of primers at the CH2-CH3 boundary, shown as
an example for overlap primer sequences. The Ig intron-exon genetic segmental organization
facilitates the design of primers for amplification of mRNA without interfering the DNA.
Primers should flank the spliced regions where two exons are fused and contain the homologous
annealing sequences that are seen in mRNA but not in the DNA. Individual IgG exons encoding
corresponding CH domains is demonstrated by enlarged boxes. The necessary splice sites found
at intron boundaries and the sequences of the introns were removed. Name and relative location
(indicated by vertical bars) of primers used to amplify the appropriate fragments are illustrated.
The red arrow indicates the direction of the forward primer and the green arrows indicates that of
the reverse primer. The primer sequences shown in the dot-line box are the overlap sequence of
these two middle (internal) primers. Alignment of these primer sequences were performed using
BioEdit sofware. Code: rc, reverse complementary.
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internal primers to reduce the background of non-specific products) following analysis of PCR
and sequencing reactions. All primers were synthesized by Sigma–Aldrich Co. (St. Louis, MO).
All primers have specificity to the corresponding 5’ and 3’ ends of all rhesus macaque domain
coding regions and, as indicated above, were incorporated with RE recognition sites located
outside V and C gene coding regions to allow subsequent cloning (see below). To all primers,
ambiguous bases were introduced to make them compatible with the primer sets previously
published. The final sequences of the primers are shown in Table 2.1.

2.2.2. Construction of the NIP-rhIGHG cDNA hybrids: Optimization of SOE-PCRs and
amplification strategies
cDNA encoding the heavy chain rhCH fragment of each of the four rhesus macaque IgG
subclasses was PCR-annealed together by SOE-PCRs using the resultant rhCH1, rhCH2, and
rhCH3 cDNA gene segments as DNA templates, and by different strategies that were optimized
and dependent upon each subclass (Fig. 2.3). By separate SOE-PCRs using appropriate primer
pairs on the four gene segment PCR products, VH, rhCH1, rhCH2, and rhCH3, as DNA
templates, immediate ligation fragments, including [VH+rhCH1], [rhCH1+rhCH2], and
[rhCD2+rhCH3], were generated. These immediate fragments, together with the rhCH1, rhCH2,
and rhCH3 segments, were subsequently used as DNA templates in additional SOE-PCRs to
create rhIGHG fragments ([rhCH1+rhCH2+rhCH3]) using primers 3FCG4F and FCG4R. The
final whole chimeric IgG fusion fragments, [VH+rhCH1+rhCH2+rhCH3] (NIP-rhIGHG), were
constructed by annealing the VH gene segment with the rhIGHG fragment – or the [VH+rhCH1]
fragment with the [rhCH2+rhCH3] fragment – by SOE-PCRs using primers FVH5FW and
FCG4R. The size in base pairs (bp) of the whole chimeric recombinant constructs NIP-rhIGHG1,
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Table 2.1. Primers used for generation of rhesus macaque IgG gene fragments and recombinant constructs by PCR and SOE-PCR
amplifications.
Primer
namea

Sequence (5’-3’ direction)b

Specificity
(region of genes; species)c

FVH5FW

GGTGTGCATTCCCAGGTCCAATTGCAGCAGCCT

5’; murine anti-NIP VH

FCG4R

AGTGGATCCATTACTAGTAGCAGGTGCCGTCCACCTCCGCCATGATCTGCGTGTAGTGGTTGTGCAGA

3’; rhesus macaque IgG CH3

IGC2

TCTGCGTGTAGTGGTTGTGCAG

3’; rhesus macaque IgG CH3

FVH3G4R

GACCGATGGGCCCTTGGTGGAGGCTGAAGAGACTGTGAGAGTGG

3’; murine anti-NIP VH

3FCG4F

ACTCTCACAGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTC

5’; rhesus macaque IgG CH1

IGF

TCCTCAGCCTCCACCAAGGGCCCA

5’; rhesus macaque IgG CH1

IgG1R

Sequence
characteristics
Containing BsmI site (5’-TGCATTC-3’)
Contained in full (33-bp sequence) in IgNotI
Containing BamHI site (5’-GGATCC-3’)
22-bp homologous to IGC2
Contained in part (65-bp sequence) in IgXhoI
22-bp homologous to FCG4R
Contained in full (22-bp) in IgXhoI
42-bp homologous to 3FCG4F
21-bp homologous to IGF
42-bp homologous to FVH3G4R
21-bp homologous to IGF
21-bp homologous to FVH3G4R
21-bp homologous to 3FCG4F

GACGGTCCCCCCAGGAG

3’; rhesus macaque IgG1 CH1

14-bp homologous to G2C1RN

G2C1RN

GATGGTCCCCCCAGGAGTTCAGCTGGGCACGGTGGGCACGTGGAACGACATGGGAGCCCAACTGTCTTGTCCACCTTGG

3’; rhesus macaque IgG2 CH1

79-bp homologous to G2C2FN
14-bp homologous to IgG1R

G2C2FN

CCAAGGTGGACAAGACAGTTGGGCTCCCATGTCGTTCCACGTGCCCACCGTGCCCAGCTGAACTCCTGGGGGGACCATC

5’; rhesus macaque IgG2 CH2

79-bp homologous to G2C1RN

G2C2R

CACCTGTGGCTCTCGGGGCTGCCCTTTGGTTTTGGAGACAGTTTTCT

3’; rhesus macaque IgG2 CH2

43-bp homologous to G2C3F

G2C3F

AACTGTCTCCAAAACCAAAGGGCAGCCCCGAGAGCCACAGGTG

5’; rhesus macaque IgG2 CH3

43-bp homologous to G2C2R

G3C1R

ATGGGGGTGTGAACTCAACTCTCTTGTCCACCTTGG

3’; rhesus macaque IgG3 CH1

G3CHR

CTGGGCATGGTGGGCATGGGGGAGTTGTGTCACCACATGGGGGTGTGAACTCAACTCTCTTGTCCACCTTGG

3’; rhesus macaque IgG3 hinge

G3CHF

AGTTCACACCCCCATGTGGTGACACAACTCCCCCATGCCCACCATGCCCAGCACCTGAACTCCTGGGGGGAC

5’; rhesus macaque IgG3 hinge

G3C2F

CACCATGCCCAGCACCTGAACTCCTGGGGGGAC

5’; rhesus macaque IgG3 CH2

36-bp homologous to G3CHR
15-bp homologous to G3CHF
36-bp homologous to G3C1R
51-bp homologous to G3CHF
12-bp homologous to G3C2F
33-bp homologous to G3C2F
51-bp homologous to G3CHF
15-bp homologous to G3C1R
33-bp homologous to G3CHF
12-bp homologous to G3CHR

G3C2R

GCTCTCGGGGCTGCCCTTTGGCTTTGGAGATGGTTT

3’; rhesus macaque IgG3 CH2

30-bp homologous to G3C3F

G3C3F

TCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCGCAGG

5’; rhesus macaque IgG3 CH3

30-bp homologous to G3C2R

IG4CR1

ATGCTGGGCATGGGGGTGTGAACTCAACTCTCTTGT

3’; rhesus macaque IgG4 CH1

12-bp homologous to IG4CF2

IG4CF2

CATGCCCAGCATGCCCAGCACCTGAACTCCTGG

5’; rhesus macaque IgG4 CH2

12-bp homologous to IG4CR1

IG4R2

GCTCTCGGGGCTGCCCTTTGGCTTTGGAGATGG

3’; rhesus macaque IgG4 CH2

33-bp homologous to IG4F3

IG4F3

CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC

5’; rhesus macaque IgG4 CH3

33-bp homologous to IG4R2

IgNotI

ATTAGCGGCCGCATAATGGGTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTGCATTCCCAGGTCCAATTGCAGCAGCCT

5’; murine anti-NIP VHb

IgXhoI

ACTCACTCGAGGGATCCATTACTAGTAGCAGGTGCCGTCCACCTCCGCCATGATCTGCGTGTAGTGGTTGTGCAGA

3’; rhesus macaque IgG CH3c

Containing NotI site (5’-GCGGCCGC-3’)
Containing full 33-bp sequence of FVH5FW
Containing XhoI site (5’-CTCGAG-3’)
Containing partial 65-bp sequence of FCG4R
Containing full 22-bp sequence of IGC2
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a

Ending with or before the last single digit/letter with -FW or -F, or ending with NotI, forward direction; ending with –R or XhoI,

reverse direction; IgC2, reverse direction.
b

Bold and underline, restriction endonuclease sequences; bold and italic, with or without underline, overlapping (“homologous”)

region (with underline, identical; without underline, complementary in reverse direction) with the relevant primer(s) indicated in
“Sequence characteristics” column.
c

For non-flanking (“internal”) primers, the 5’ or the 3’ end represents that at the 5’or 3’ intron-exon junction, respectively.
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NIP-rhIGHG2, NIP-rhIGHG3, and NIP-rhIGHG4 are 1,390, 1,369, 1,423, and 1,366,
respectively. These constructs encode four corresponding rhesus macaque IgH subclasses. As
mentioned above, the final fragment contains two unique BsmI (or NotI) and BamHI (or XhoI)
RE sites whose sequences were embedded in the two far end flanking primers (i.e. the outermost
5’ and 3’ primers) and were introduced into the constructs by PCRs.
SOE-PCRs were carried out by Expand High Fidelity polymerase (Roche Diagnostics
North America, Indianapolis, IN) or Ex Taq DNA polymerase (Clontech Laboratories Inc.,
Mountain View, CA) in a total of 50 or 100 μl final reaction volume containing 10-200 ng
plasmid DNA, 10-50 pmol (each) primers, 200-250 µM (each) dNTPs, 1.5-2.5 mM MgCl2, and
2-2.5 U of DNA Taq polymerase. DNA concentration of samples was calculated using the
formula C (pmol/μL) = (75 x A260 x d)/(bp x l), in which A260 is the absorbance at 260 nm, d is
the dilution factor, bp is the length of DNA in basepair, and l is cuvette width in cm. PCR
conditions were as follows: after initial denaturation at 95°C for 5-10 min to melt strands into
single strands, cDNAs were amplified for 25-40 cycles, with each cycle consisting of 94°C for
30 sec-1 min to melt strands, 56°C for 30 sec-1 min to anneal primers, and 72°C for 30 sec-2 min
and 30 sec to extend strands. To ensure complete extension, a final step at 72°C for 5-10 min
was applied. The negative controls consisted of the reaction mixture with no template DNAs.
Adjustment of PCR conditions and parameters, including optimization of time in each
step and of the annealing temperature (from 52-600C, with 0.50C or 10C increment, to promote
annealing), as well as additional cloning steps in pCR2.1-TOPO TA vector (see below for
procedures) for some of the gene segments and fragments, were needed to minimize non-specific
products and to improve the success of SOE-PCR ligation and amplification. The concentrations
of the two primers in each primer pair were close to each other and ranged from 20-200 nM per
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reaction (in each reaction, specific primers were used dependent on which PCR was being
performed, as described above). To allow for better annealing and extension of overlaps in some
reactions – such as those for generation of IgG3, which were with additional hinge primers –
PCRs that used equimolar concentrations of DNA fragments were run without primers and low
annealing temperature during early cycles (i.e. the first 5-10 cycles), followed by a higher
annealing temperature with fresh PCR mixtures in the remaining 20-30 cycles. Whenever
possible, fragments and sub-fragments (intermediate fragments) were put into cloning plasmid
vectors to serve as a source of DNA templates. Flanking primers were sometimes added after
two to three cycles to reduce competition for the available reagents in the reactions. To
determine the optimal SOE-PCR reaction conditions and parameters, varying magnesium
concentrations were also applied in a series of SOE-PCR reactions. The molar ratios of the two
DNA segment or fragment templates used in annealing SOE-PCRs were generally equal (1:1,
with total DNA amount was at least 0.7 μg/50 ml PCR); but in some cases, variable ratios such
as 1:2, 1:3, or 1:5, dependent upon their sizes, were applied in order for the desired fragments to
be better annealed.

2.2.3. Cloning and sequence analysis of the NIP-rhIGHG cDNA constructs
To assess the fidelity of PCR reactions and to improve the purity of the fused fragments
(i.e. to minimize the appearance of non-specific side products), SOE-PCR products were cloned
into pCR2.1-TOPO cloning vector (Fig. 2.4). As described above, the resultant cDNA hybrids
were introduced at the 5’ end of V coding gene and the 3’ end of C coding gene region with
BsmI and BamHI (B-B) restriction sites, respectively, in one subset of the molecules, or with
NotI and XhoI (N-X) restriction sites, respectively, in another subset. These restriction sites were
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intentionally incorporated (embedded) in the appropriate primers and were unique, as they were
not present in any of the examined IgH cDNA genes. These sites will allow for cloning of the
cDNA into specialized expression vectors (see below). After SOE-PCR annealing and
amplification, an appropriate volume of SOE-PCR reactions containing the final chimeric IgG
fusion genes were subjected to electrophoresis on a 1-2% agarose gel (dependent upon the
fragment sizes) diluted in TBE buffer (Sigma–Aldrich Co., St. Louis, MO) and containing 0.10.2 mg/ml ethidium bromide (Sigma–Aldrich Co., St. Louis, MO). The DNAs were subsequently
visualized using an ultraviolet transilluminator, and the bands of interest (showing expected size)
were individually excised and purified using QIAquick Gel Extraction kit (Qiagen Inc.,
Valencia, CA) using a microcentrifuge. Purified NIP-rhIGHG PCR products were then cloned
within EcoRI sites into pCR 2.1-TOPO TA cloning vector (Invitrogen, Carlsbad, CA), which
contains an ampicillin resistance gene. For optimal incorporation, different molar ratios
(vector:insert) were applied, including 1:1, 1:3, 1:5, 1:10, 2:1, 3:1, and 5:1 (higher ratios were for
difficult cloning). The amount of vector to start with ranged between 10-20 ng and was
calculated as [(ng vector x kb insert)/kb vector] x (moles insert/moles vector) = ng insert
(http://www.promega.com/biomath/Default.htm). Resultant plasmids were subsequently
transformed into Top10 Escherichia coli (E. coli) chemically competent cells using One Shot
Chemical Transformation kit (Invitrogen, Carlsbad, CA), following the manufacturer's protocols.
The competent cells were then spread onto LB agar plates containing 50 μg/ml of ampicillin and
1 μg of X-Gal for screening for suitable colonies. Insert-positive clones were then picked and
further cultured (expanded) by incubation overnight in LB culture tubes containing 50 μg/ml of
ampicillin at 37°C in a shaking rotary incubator (200-230 rpm).
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Fig. 2.3. Flowchart diagrams outlining different experimental strategies for generation of
recombinant NIP-rhIGHG cDNA constructs by SOE-PCRs (not drawn to scale). (A) PCR
amplification of individual mouse VH (represented as the yellow-line, enlarged box) and rhesus
macaque IgG CH (represented as red-line, enlarged boxes) fragments (i.e. CH1, CH2, and CH3)
encoding corresponding domains of recombinant IgGs to be generated. These fragments are
represented in the 5’ to 3’ orientation. cDNAs coding for these VH and CH domains were
amplified from the appropriate plasmid vectors (shown are not the real names of the plasmids),
retrieved from our plasmid repository. The direction of the primers used to amplify these
fragments are illustrated as short black horizontal arrows (shown are not the real names of the
primers). Straight short black lines represent flanking sequences. (B) A representative strategy of
SOE-PCR joining (see Fig. 1.8 for the principle) of DNA fragments. The fragments were jointed
by SOE-PCRs using the appropriate primer sets, as indicated. Arrows indicate the direction of
the primers used to amplify the fragments. (C) An alternative strategy. (D) Additional strategies.
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Fig. 2.4. Ligation of PCR products into pCR2.1 TOPO TA cloning vector. (A) These fragments
are used as an example to show the procedure of TOPO cloning for ligation of PCR products (as
to assess the fidelity of PCRs). The recognition sites for a number of restriction endonucleases
(the unique multiple cloning site, which is used to clone in DNA fragments of interest) are
embedded within the lacZ coding sequence. Because the lacZ peptide will be functionally
disrupted or inactivated by the presence of the DNA insert, the lacZ coding gene sequence is
used as a selectable marker. (B) Schematic representation of ligation of PCR product ligates into
TOPO vector in the presence of Topoisomerase (hence the name of the vector). Some figure
pieces are reproduced from the internet.
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NIP-rhIGHG insertion, proper orientation, and accuracy of sequences were confirmed by
RE digestion and DNA sequencing (Fig. 2.5). Briefly, the minipreps DNA Purification System
kit (Promega Corporation, Madison, WI) was used to purify plasmid DNAs extracted from
grown clones in LB medium, and the obtained plasmid DNAs were digested with EcoRI (New
England Biolabs, Beverly, MA). EcoRI-digested plasmids were then electrophoresed on a 1%
agarose gel to verify the presence of the desired insert based on the size of the inserted
fragments. Bands containing NIP-rhIGHG constructs with the correct size were extracted using a
QIAquick gel extraction kit (Qiagen Inc., Valencia, CA) and the recombinant plasmids were
sequenced to confirm cloning correctness. All DNA sequences were determined using the ABI
Prism Dye Termination Cycle Sequencing kit and on an ABI model 3100 automated sequencing
apparatus (PerkinElmer, Wellesley, MA). Sequencing primers were those used for PCR
amplifications and the forward and reverse M13 primers.
Further sequencing analysis was also applied to sequences of the resultant constructs.
MacVector software (Accelrys Inc., San Diego, CA) and the free BioEdit program
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) were used to identify overlapping regions and
to edit sequences. Sequences were aligned using the CLUSTAL function of the MEGALIGN,
part of the LASERGENE software package (DNASTAR Inc., Madison, WI). The prediction of
potential N-glcosylation sites was conducted by analyzing the full length sequence of the
obtained molecules using the online tool NetNGlyc 1.0 Server
(http://www.cbs.dtu.dk/services/NetNGlyc/), which is based on identifying Asn-Xaa-Ser/Thr
consensus sequences (Julenius et al., 2005). Drawing plasmids was performed using the free
Plasm plasmid drawing software (http://biofreesoftware.com/plasm). Standardized nomenclature,
labels, and numbering of IMGT®, the international ImMunoGeneTics information system®
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(http://www.imgt.org or http://imgt.cines.fr) (Lefranc et al., 2009) were used to identify IgSF
gene segments, as well as to display and discuss sequencing data based on human reference
sequences. Two-dimensional representation, or IMGT Colliers de Perles on one layer was
obtained with the IMGT Collier-de-Perles tool in the IMGT/DomainGapAlign
(http://www.imgt.org/3Dstructure-DB/cgi/Collier-de-Perles.cgi) (Ehrenmann et al., 2010).
Allelic polymorphisms and characteristic positions of the C-like domains were described using
the IMGT unique numbering for C domain [C-DOMAIN of IG and T cell receptors (TR)]
(Lefranc et al., 2005).

2.2.4. pLNOH2 and P2561/2/3 expression vector systems and the murine IgH-defective
myeloma J558L cell line
For expression vectors, we used the pLNOH2 (or pLNOH2γ3) (Norderhaug et al., 1997)
plasmid vector (kindly provided by Drs. Lars Norderhaug and Inger Sandlie, University of Oslo
and Ab Design AS, Nesoddtangen, Norway) (Fig. 2.6). This vector is derived from the
expression vector pcDNA3 (Invitrogen, Carlsbad, CA) and contains essential elements for
transcription and translational regulation. Specifically, it consists of a CMV promoter (P)
situated at the 5’ end of a gene cassette containing an Ig leader (L) (signal peptide) region
sequence of murine Ig genes (to permit secretion of the fusion protein), a murine VH gene
encoding an Igλ domain with specificity for the hapten NIP inserted between RE sites BsmI and
BsiWI, followed by an intron. The intron comprises splice acceptor (GU) and splice donor (AG)
signals for correct processing of mRNA. The vector also harbors a gene restriction cassette,
located downstream of the murine V gene and inserted between RE sites HindIII and BamHI,
encoding the CH fragment of human IgG3 sequence (IGHG3), followed by a strong
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polyadenylation signal and transcription termination sequence in the 3’ end (pA). These C and V
region genes together encode complete IgG H chains. The vector further contains unique
restriction sites for easy subcloning of V and C region genes as cassettes, and can be used to
express an anti-NIP VH gene segment in combination with any CH region genes of different IgG
subclasses exchanged as HindIII-BamHI fragments (Norderhaug et al., 1997). For selection and
stable expression of transformant cells, the vector also carries a neomycin resistance gene, which
is under the control of CMV promoter. The vector also possesses an ampicillin resistance marker
gene (Amp) (for selection in E. coli), f1 origin of replication (f1), and SV40 origin of replication
(to allow for transient expression). The use of the vector allows both transient and stable
expression in mammalian cells.
To improve stability of expression vectors in transfected cells, we also used a modified
version of the vector pLSXN (BD Biosciences, San Jose, CA), which contains long terminal
repeats (LTR) that allow for the gene of interest to integrate into the host cell chromosomes for
stable expression (Fig. 2.8). Constitutive transcription of cloned genes inserted into this plasmid
vector is driven by CMV promoter. Promoter and enhancer sequences controlling expression of
the gene of interest in the multiple cloning site are also inserted in the 5’ viral LTR of this vector.
pLSXN also contains a neomycin resistance gene, controlled by SV40 early promoter (PSV40e),
that allows antibiotic transfectant selection in eukaryotic cells. Additionally, pLXSN consists of
Col E1 origin of replication and E. coli Amp resistance gene for propagation and antibiotic
selection in bacteria. We amplified by PCR using primers that incorporated desirable RE sites a
portion of the pcDNA3.1 constructs that contains cDNA of NHP FcγIIIRa (or another gene of
interest), a CMV promoter, L signal peptide, a bovine growth hormone polyadenylation signal,
and an f1 origin. This PCR portion was then sequentially transferred to the multiple cloning site
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Fig. 2.5. Schematic representation of the PCR- and SOE-PCR-amplified IGHG fragments that
make up of the four recombinant NIP-rhIGHG (Igγ) cDNA constructs. CH1, the hinge (for
Igγ3), CH2, and CH3 amplified fragments of each Igγ cDNA construct, as well as the VH
amplified fragment to be connected to all of these constructs, are shown. Each amplified
fragment is represented as an enlarged box, as indicated. The VH fragment, which was derived
from murine myeloma and specific to NIP (5-iodo-4-hydroxy-3-nitrophenyl acetyl), was joined
by SOE-PCRs to a complete rhesus macaque IgH fragment, which were constructed also by
SOE-PCRs. Name and relative location (indicated by vertical black bars) of primers used to
amplify different fragments in these SOE-PCRs are depicted. The final recombinant constructs
were amplified in SOE-PCRs using the primers flanking the VH 5’ end (FVH5FW) and the CH3
3’ end (FCG4R, or IGC2 in the case of NIP-rhIGHG4), as indicated. Each primer was designed
to flank the appropriate gene fragments; the sequences of the primers used are given in Table 2.1.
The trans-membrane exons at the 3’ end of the mRNA of the Igγ chains are not depicted. The
Igγ3 hinge is not drawn to scale. Illustrated below the scheme is a bar representing relative
length distance scale (in bp) in the 5’ to 3’ orientation for the fragments. The intron-exon
organization of the IGHG genes was inferred from the human and rhesus macaque sequences
publicly available. The necessary splice sites found at intron boundaries and the sequences of the
introns were removed.
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Fig. 2.6. Schematic representation of the structure of a representative recombinant NIP-rhIGHG
cDNA construct (shown is the NIP-rhIGH3 cDNA construct) and simplification of the
architecture of the expression plasmid vector pLNOH2, highlighting regions of functional
significance and relevant features (not drawn to scale). (A) Schematic representation of structure
of recombinant NIP-rhIGHG3 cDNA construct. A mouse VH fragment with NIP specificity that
contained a BsmI restriction site at the 5’ end was joined by SOE-PCRs to rhesus macaque Igγ3
CH fragment constructed also by SOE-PCRs and contained a BamHI restriction site at the 3’
end. Only restriction sites at the ends of the constructs are depicted. The trans-membrane exons
at the 3’ end of mRNA of IgH chains are not illustrated. The hybrid chain was subcloned into the
expression plasmid vector pLNOH2 onto BsmI and BamHI sites. The hinge is not drawn to scale.
(B) Simplification of the map of specialized pLNOH2 expression vector, highlighting regions of
relevant features (not drawn to scale). This double-stranded closed-circular DNA molecule
vector is derived from vector pcDNA3 (Invitrogen, Carlsbad, CA) (Norderhaug et al., 1997).
Expression is driven by a cytomegalovirus promoter (CMV) and leader (L) (signal peptide)
sequence (L permits secretion of the expressed protein). The vector contains, adjacent to L
sequence, an anti-NIP murine VH gene cloned in BsmI and BsiWI restriction sites, followed by a
human genomic Igγ3 CH gene cassette, which can be replaced by those of different subclasses of
rhesus macaques onto the HindIII and BamHI sites, as indicated. CH1, CH2, and CH3 refer to
the corresponding domains in Igγ3 CH genes. Polyadenylation signal (pA; recognition sequence
for polyadenylation) of the vector is inserted downstream of the Igγ CH coding sequence to
ensure proper and efficient processing of mRNA transcript in eukaryotic cells. The vector
backbone also contains an f1 ori (f1) for single-stranded DNA production (plasmid origin of
replication), as well as an SV40 promoter (SV40ori) for plasmid replication in mammalian cells.
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Plasmid DNA replication occurs in one direction, as illustrated by the f1 ori arrow. Located
downstream of SV40ori region in the vector is a gene cassette for neomycin resistance (Neo),
which is controlled by SV40 promoter and allows for G418 antibiotic selection of stable
expression by transfected eukaryotic cells. Structurally similar to gentamycin and generally toxic
to eukaryotic and prokaryotic cells, the aminoglycoside antibiotic G418 is useful for selection of
cells stably transfected with Neo gene (presence of insert DNA will disrupt functional activities
and allow for selection). The pLNOH2 vector also comprises an ampicillin resistance gene
(Amp) for propagation and antibiotic selection in bacteria (E. coli). The curve arrows on the
genes illustrate the direction of transcription. VH gene is oriented so that its direction of
transcription is opposite to that of the Amp gene. BsmI and BamHI sites, located downstream of
CMV promoter/L sequence and Igγ CH cassette, respectively, are unique and can be used for
directional insertion of constructs of interest as BsmI-BamHI restriction fragments. The BsmIBamHI restriction fragments of NIP-rhIGHG inserts are ~1.37 kb-1.42 kb in size, varying
dependent on IgH subclasses. The vector sequence totals ~8.6kb in length and all sites illustrated
are unique (occur only once in within the plasmid sequence). The orientation and sequence of
DNA inserts in the recombinant plasmids were confirmed by RE digestions and/or nucleotide
sequencing. This map was constructed using the plasmid drawing software Plasm
(http://biofreesoftware.com/plasm) and based on information described in Brekke and
Thommesen, 2003, and Norderhaug et al., 1997.
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of pLXSN (BD Biosciences, San Jose, CA) (Rogers et al., 2006), generating the P2561/2/3
expression vectors. These recombinant plasmid vectors facilitate selection of transformants on
culture media containing ampicillin, and enable stable integration into nuclear chromosomal
cellular DNA.
For production of intact recombinant IgGs, we employed a well-characterized and
genetically stable mammalian host cell line, the BALB/c murine IgH-loss-variant myeloma (i.e.
Ab-producing cells) J558L cells (Oi et al., 1983; kindly provided by Dr. Sherie L. Morrison,
University of California, Los Angeles, Los Angeles, CA). Although being a murine
plasmacytoma, these cells do not produce intact mouse Ig Abs as they express no endogenous
IgH chain [due to a spontaneous loss of IgH chain from their parental myeloma cell line J558
(Morrison, 1985)]. However, these cells continue to constitutively synthesize and secret an IgL
λ1 chain specific for NIP (Oi et a., 1983), which can form complete Ig molecules with NIP
affinity when combined with anti-NIP (i.e. containing anti-NIP VH) IgH chains. The cells can
also recombine two transfected DNA molecules in an appropriate manner (in about 30% of cells
that received and integrated intact copies of both DNA molecules) (Fell et al., 1989). Thus, once
transfected with an IgH chain expression vector, such as that encoded in pLNOH2 plasmid, the
cell machinery will synthesize and assemble IgL and IgH chains (chain-assembly), ultimately
secreting endogenously intact Ig molecules. Additionally, murine IgH-chain defective myeloma
cells are capable of producing greater amounts (and with higher protein concentration) of ectopic
fusion protein compared to other cell lines, including CHO or HEK293 cells (Howard et al.,
2002). The cells were maintained in Iscove’s modified Dulbecco’s medium (IMDM)
supplemented with 10% fetal bovine serum (FBS), penicillin G sodium 100 IU/ml, and
streptomycin sulfate 100 μg/ml under standard conditions in 25-ml or 75-ml sterile filter screw-
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Fig. 2.7. Schematic representation of generation of recombinant expression plasmid vector
pLNOH2-IgH (not drawn to scale). NIP-rhIGHG constructs were PCR-amplified from
appropriate TOPO vectors using forward primer FVH5FW (containing BsmI restriction site in its
5’ end) and reverse primer FCG4R (containing BamHI restriction site in its 5’ end), as indicated.
The resultant PCR products were then ligated into pLNOH2 vector previously digested with both
BsmI and BamHI REs. The recombinant constructs are therefore encoded within BsmI-BamHI
sites of the resulting recombinant expression vector.
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Fig. 2.8. Simplification of the architecture of the expression plasmid vector P2561/2/3,
highlighting regions of functional and relevant features (not drawn to scale). The vector contains
a unique multiple cloning site for cDNA insertion and a variety of promoters, including strong
retroviral promoters, to facilitate expression of inserted cDNA constructs. This double-stranded
closed-circular DNA molecule vector was made up by ligating NIP-rhIGHG-containing HpaISalI restriction fragment (~1.1 kb in size) of recombinant expression pcDNA3.1(+) vector into
retroviral vector pLXSN to HpaI and XhoI restriction sites (~5.9 kb in size, after digestion). RE
HpaI, which cuts between nucleotide location 163-164 or 1,477-1,478 in pcDNA3.1(+) or
pLXSN vector, respectively, is a blunt-end ligation. RE SalI, which cuts between nucleotide
location 1,272-1,273 in pcDNA3.1(+) vector, and RE XhoI, which cuts between nucleotide
location 1,484-1,485 in pLXSN vector, have their overhangs matched (ligation would destroy
these cut sites). Expression is driven by a cytomegalovirus promoter (CMV)/leader (L) sequence,
which are derived from pcDNA3.1(+) vector (L signal peptide allows secretion of protein). In
addition to recombinant NIP-rhIGHG constructs, the HpaI-SalI-digested restriction fragments
that were cut out from the recombinant pcDNA3.1(+) vectors also comprise of the
pcDNA3.1(+)-derived polyadenylation signal (pA; recognition sequence for polyadenylation),
located downstream of Igγ CH coding sequence to direct proper and efficient processing of
mRNA transcript in eukaryotic cells, as well as of f1 ori (f1; plasmid origin of replication),which
is for single-stranded DNA replication. Plasmid DNA replication occurs in one direction, as
illustrated by the f1 ori arrow. The P2561/2/3 vector maintains from pLXSN retroviral vector
SV40 early promoter (SV40ori) for plasmid replication in mammalian cells, the gene cassette for
neomycin resistance (Neo), located downstream of and controlled by SV40ori promoter, which
allows for G418 antibiotic selection of stable expression by transfected eukaryotic cells, as well
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as ampicillin resistance gene (Amp) for propagation and antibiotic selection in bacteria (E. coli).
Therefore, only bacteria containing the vector are capable of growing in the presence of
ampicillin, and cell clones selected by Neo resistance indicate those cells in which an
endogenous gene was disrupted due to the proviral insertion. pLXSN vector also contains, in the
5’ viral long terminal repeat (LTR) sequence, a viral promoter and enhancer sequences that
direct expression of the genes of interest inserted in its multiple cloning site. Thus, P2561/2/3
vector permits expression of DNA constructs inserted into the multiple cloning site, which is
sandwiched between the 5′ and 3′ LTR sequences, under the controls of a variety of promoters
(i.e. retroviral LTR, CMV, or SV40ori). The curve arrows on the genes illustrate the direction of
transcription. VH gene is oriented so that its direction of transcription is opposite to that of Amp
gene. As with expression vector pLNOH2 regarding BsmI and BamHI sites, NotI and XhoI sites
in P2561/2/3 vector, which are located downstream of CMV promoter and Igγ CH cassette,
respectively, are unique; these sites separate CMV promoter from Neo gene sequence and can be
used for directional insertion of recombinant constructs of interest as NotI-XhoI restriction
fragments (none of these constructs has NotI or XhoI site). NotI-XhoI restriction fragments of
NIP-rhIGHG inserts are ~1.37 kb-1.42 kb in size, varying dependent on IgH subclasses.
P2561/2/3 vector sequence totals ~8.4 kb (~7.0 kb if without insertion of a recombinant
construct) in length and all sites indicated are unique (occur only once in within plasmid
sequence). pLXSN vector (~5.9 kb in size), through its retroviral 5’ LTR and 3’ LTR sequences,
between which the gene of interest are cloned, facilitates integration of the insert into
chromosomes for stable expression and, therefore, making it easy for isolation and providing
higher yield than if using expression vectors pLNOH2 or pcDNA3.1(+) alone (both of which
have almost the same yield). The orientation and sequence of DNA inserts in recombinant
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plasmids were confirmed by RE digestions and DNA sequencing. This map was constructed
using the plasmid drawing software Plasm (http://biofreesoftware.com/plasm) and based on
information described in Rogers et al., 2006, and on Clontech website
(http://www.synthesisgene.com/vector/pLXSN.pdf). Some figure pieces are reproduced from the
internet.
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caps flasks, and grown at 37°C with 5% CO2 atmosphere.

2.2.5. Generation of expression vectors for NIP-rhIGHG chimeric constructs
To construct NIP-rhIGHG IgH expression vectors, we excised and replaced VH and
human IgG3 CH genes in pLNOH2γ3 plasmid with cDNA containing anti-NIP VH of
pLNOH2γ3 fused to the entire Chinese rhesus macaque IGHGs (IgG CH) as a single fragment.
pLNOH2 was sequentially digested with BsmI and BamHI or NotI and XhoI RE pair (New
England BioLabs, Ipswich, MA) to remove murine VH and human IGHG3 genes from the parent
vector (Fig. 2.7 and 2.9). A verified TOPO clone containing cDNA constructs encoding
sequence of recombinant NIP-rhIGHG was similarly excised (i.e. under sequential digestion with
the same two REs) to release the constructs. Resultant ~1.5-kb BsmI-BamHI-digested gene
fragments obtained from TOPO clones were purified and subcloned into pLNOH2 to the unique
BsmI and BamHI RE sites, downstream of CMV promoter and in proper orientation, to create
constructs pLNOH2-rhIGHG1, pLNOH2-rhIGHG2, pLNOH2-rhIGHG3, and pLNOH2rhIGHG4. Only pLNOH2 plasmids with correct DNA sequences, which are the original anti-NIP
VH fused with each of the four rhesus macaque IGHG subclasses, were used for transferring of
expression vector and mammalian cell transfection.
To improve the stability of expression vectors in transfected cells, the above mentioned
P2561/2/3 expression vectors were used. Firstly, the original NIP-rhIGHG constructs were PCRamplified from verified pCR2.1-TOPO vector clones (that carry the original engineered NIPrhIgG constructs) using forward IgNotI and reverse IgXhoI primers (Table 2.1). These
amplifications added NotI and XhoI RE sites into the 5’ end and the 3’ end, respectively, of
original NIP-rhIGHG cDNA constructs. Next, the modified NotI-XhoI-containing NIP-rhIGHG
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Fig. 2.9. Schematic representation of generation of recombinant expression plasmid vectors
pcDNA3.1-IgH and P2561/2/3-IgH (not drawn to scale). The NIP-rhIGHG constructs were
PCR-amplified from appropriate TOPO vectors using forward primer IgNotI (containing NotI
restriction site in its 5’ end; Table 2.1) and the reverse primer IgXhoI (containing XhoI restriction
site in its 5’ end; Table 2.1), as indicated. Resultant PCR products were then ligated into
pcDNA3.1(+) or P2561/2/3 vectors previously digested with both NotI and XhoI REs.
Recombinant constructs are therefore encoded within NotI-XhoI sites of resulting recombinant
expression vectors.
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cDNA constructs were ligated into ampicillin-resistant pCR2.1 TOPO TA cloning vector
(Invitrogen, Carlsbad, CA), within EcoRI sites, following the procedure as described previously.
Then the ~1.5 kb fragments (with confirmed correct sequence) were released from pCR 2.1
TOPO clones (that carry the modified engineered NIP-rhIGHGs) by sequential digestion with
NotI and XhoI REs (New England BioLabs, Ipswich, MA), and cleaned up on a 1% agarose gel.
These NotI-XhoI-containing fragments were subsequently subcloned into expression vectors
P2561/2/3 using the unique NotI and XhoI RE sites, downstream CMV promoter and in proper
orientation, to yield plasmid constructs P2561/2/3-rhIGHG1, P2561/2/3-rhIGHG2, P2561/2/3rhIGHG3, and P2561/2/3-rhIGHG4. Thus, the final IgG gene cassettes contained at their 5’ end a
NotI site (between CMV promoter and Ig leader) and at their 3’ end a XhoI site (between Ig CH
region stop codon and poly(A) signal sequence).
In addition to using P2561/2/3 vectors, the ~1.5-kb NotI-XhoI-digested fragments were
also subcloned – to the unique NotI and XhoI RE sites – onto pcDNA3.1 expression vector by
similar procedures, yielding constructs pcDNA3-rhIGHG1, pcDNA3-rhIGHG2, pcDNA3rhIGHG3, and pcDNA3-rhIGHG4.
Thus, two subsets of recombinant pCR2.1-TOPO cloning vectors were digested with a
pair of REs – BsmI and BamHI or NotI and XhoI – as appropriately (Fig. 2.7 and 2.9). Excised
restriction cDNA hybrid constructs were accordingly engineered into plasmids pLNOH2,
pcDNA3.1, and P2561/2/3 digested with corresponding pair of REs to make final recombinant
expression vectors. Insertion and orientation were analyzed by PCR and RE digestion, and
subsequently confirmed by DNA sequencing in both forward and reverse directions.
All ligation reactions were performed overnight at 14°C in the presence of T4 DNA
ligase (Roche Diagnostics North America, Indianapolis, IN). Resultant NIP-rhIGHG-containing
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plasmid DNAs were then transformed into and amplified in Top10 E. coli competent cells
selected on ampicillin (Invitrogen, Carlsbad, CA) by heat shock, as previously described (except
that no X-Gal was included in LB plates). Colonies were first screened for the presence of
insertion by PCR directly on raw extracts from clones. Subsequently, miniprep DNAs derived
from the PCR-screened positive colonies, which were purified by plasmid mini-preparations
(Qiagen Inc., Valencia, CA), were verified for insertion and proper orientation by RE digestion
using BsmI and BamHI REs, and by DNA sequencing. After verification, good clones were
expanded and prepared with an EndoFree plasmid maxi kit (Qiagen Inc., Valencia, CA). The
maxiprep yields from these expression vectors varied among 1.5-2.5 μg/ml (with the use of an
initial culture volume of 5 ml).

2.2.6. Production of transient and stable J558L transfectoma cell lines expressing
recombinant NIP-rhIGHG chimeras
To determine whether pLNOH2, pcDNA3.1, and P2561/2/3 vectors that contained cDNA
constructs encoding NIP-rhIGHG IgH subclass chimeras and containing CMV promoter, murine
Ig leader, and poly-A signal sequences could express complete IgGs, we transfected each of
them into J558L cells. Transfection was performed by electroporation using closed-circle DNA
plasmids and G418-resistant clones would grow out. Transfectoma cell lines were produced on
small-scale expression for specificity analysis purpose. Only plasmids with correct DNA
sequences were used for transfection. Before transfection, production of murine IgL λ chain by
J558L cells was confirmed by ELISA.
Briefly, after antibiotic-resistant bacterium cells retaining the constructs were selected,
NIP-rhIGHG-containing plasmid vectors were purified and prepared in large quantities using
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using EndoFree Plasmid Maxi kits (Qiagen Inc., Valencia, CA). The quantity and quality of
DNA were assessed by DNA gel electrophoresis and by optical density at 260/280 nm. Twenty
micrograms of each supercoiled plasmid expression vector DNAs, including those of pLNOH2,
which served as positive controls (known to react with rhesus macaque IgGs), were pulsed into 5
x 106 to 1 x 107 J558L cells resuspended in 200-300 μl ice-cold PBS (without Ca2++ and Mg2++)
placed in 1 cm x 0.4 cm x 4.5 cm plastic microcuvettes that had been equipped with aluminum
electrodes. Two to three pulses at 1 second intervals with 300 V were applied using the gene
pulser Electroporator II (Invitrogen, Carlsbad, CA), setting at 1000 μF (at a capacitance setting
of 25 μF) and infinite resistance (giving a ~30-40 msec pulse). Following 10 min of incubation
on ice, the cells were suspended in pre-warmed 10-20 ml of complete IMDM [i.e. Iscove’s
modified Dulbecco’s medium containing 2 mM L-glutamine, 100 IU/ml penicillin G sodium,
100 g/ml streptomycin sulfate, 5 mM HEPES (Sigma–Aldrich Co., St. Louis, MO), and 5-10%
fetal bovine serum (FBS)]. The cells were allowed to recover by incubation for 24-48 hrs at 370C
in a 5% CO2 atmosphere.
At 72 h post-transfection, stable transfectants were selected by resistance under the final
concentration of 0.8-1.0 mg/ml (400-2,000 μg/ml) geneticin (antibiotic G418; Invitrogen,
Carlsbad, CA) in complete IMDM medium and were allowed to grow to saturation for four
weeks or until a concentration of 3-4 x 106 cells/ml was achieved. During incubation, cell
supernatants were harvested and replaced at 5, 10, 14, 21, and 28 days post-transfection.
Supernatants were also obtained from the cells that were allowed to grow to saturation for up to
six weeks. Cell supernatants were centrifuged (20,000 g for 30 min) to remove cellular debris
before using in subsequent assays. Because usually production of Abs gradually decline due to
transient nature of transfection, cell cultures were terminated after six weeks.
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2.2.7. Detection of Igλ and complete (assembled) recombinant NIP-rhIGHG chimeric
antibodies
Ab production and binding activity to specific antigen of anti-NIP murine Igλ chain and
complete recombinant IgG (NIP-rhIgGs) in transfected J558L cell supernatants were determined
by capture enzyme linked immunosorbent assay (ELISA). Secreted IgGs were detected by either
immobilized affinity purified goat anti-monkey IgG(H+L)-specific Abs (KPL, Baltimore, MD;
Cat. #071-11-021; for detection of IgH γ), or an immobilized goat anti-mouse Ig λ Abs (Southern
Biotech, Birmingham, AL; Cat. #1060-01; IgL-specific Ab, for detection of IgL λ), or
immobilized NIP-BSA (KPL, Baltimore, MD; NIP-specific IgGs, containing both anti-NIP VL
and VH regions; for detection of whole IgG Ab). For goat anti-mouse Igλ ELISAs, bound Igλ
was detected by HRP-conjugated secondary Ab goat anti-mouse λ (Invitrogen, Carlsbad, CA).
For anti-IgH γ-specific or anti-whole chimeric IgG Abs, bound Abs were detected by horse
radish peroxidase (HRP)-conjugated anti-monkey IgGs (KPL, Baltimore, MD; Cat. #074-11021). All Ab reagents were diluted in blocking buffer.
Briefly, 96-well high-binding polyvinyl microtiter ELISA plates were coated with 50 μl
goat anti-mouse Ig λ Ab (Invitrogen, Carlsbad, CA) at 4 or 8 μg/ml or with NIP-BSA (KPL,
Baltimore, MD) at 8 or 15 μg/ml in coating buffer (KPL, Baltimore, MD). Following incubation
at 4°C overnight, plates were washed with PBS containing 0.05% Tween-20 and unoccupied
wells were blocked with 5% FCS (or BSA) diluted in PBS at 37°C for 30 min. After washing the
plates, undiluted cell culture supernatants of G418 resistant transfectants and the appropriate
controls [positive control: purified murine myeloma IgG3 λ (Sigma–Aldrich Co., St. Louis, MO;
Cat. # M9019; negative controls: culture media plus 5% FCS] were added to pre-coated plates
(100 μl/well) for triplicate wells. For Igλ assays, culture supernatant from untransfected J558L
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cells (test samples), purified mouse myeloma IgG1 with a λ-chain (Sigma–Aldrich Co., St.
Louis, MO) (positive control), or 5% FCS in either culture media or PBS [or 0.05% (vol/vol) of
PBS-Tween 20] (negative control), was added (100 μl/well), and incubated at 37°C for 1 h. For
IgH/IgG assays, supernatants from transfected J558L cells (test samples), from unstranfected
cells (negative controls), or from cells transfected with pLNOH2 (positive controls), were added
(100 μl/well), and incubated overnight at 4°C. Following washing four times with PBS
containing 0.05% Tween 20 to remove unbound Ab, the bound Abs were detected by adding
(100 μl/well) 1/1,000-1/10,000 diluted, appropriate HRP-labeled secondary Abs [HRPconjugated goat anti-mouse Igλ (Invitrogen, Carlsbad, CA) for detection of IgL λ and IgG, and
HRP-conjugated anti-monkey IgH γ (KPL, Baltimore, MD) for detection of IgH and IgG]. Plates
were incubated for 1 h at 37°C, washed four times, and the bound peroxidase was revealed by
adding OPD and ABTS/H2O2 (Sigma–Aldrich Co., St. Louis, MO) for color development,
followed by addition of stop solution. Absorbance was measured at 405 or 492 nm after 15-30
min using an automated Benchmark microplate reader (Bio-Rad, Hercules, CA). Tests were done
in triplicate wells and triplicates were averaged.

2.3. Results
2.3.1. Four NIP-rhIGHG cDNA hybrid constructs were successfully generated by SOE-PCRs
and were properly incorporated into pCR2.1-TOPO cloning vector
cDNA segments encoding anti-NIP murine VH and rhesus macaque individual CH
domains CH1, CH2, and CH3 (the hinge is embedded in CH1 and CH2 domains, as previously
described) of each of four rhesus macaque IgG subclasses were successfully amplified by PCRs
from the appropriate plasmid vectors (data not shown). Complete IgH cDNA hybrid encoding
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Fig. 2.10. Gel electrophoresis separation of DNA products resulting from SOE-PCR annealing
and amplification or digestion of clones of recombinant gene constructs of NIP-rhIGHG1 (A),
NIP-rhIGHG2 (B), NIP-rhIGHG3 (C), and NIP-rhIGHG4 (D) that were ligated into cloning and
expression vectors. RE digestions were used to confirm that the recombinant constructs had each
been inserted into the correct region of vectors and in the correct orientation (which were
subsequently confirmed by DNA sequencing). SOE-PCR-generated products or fragments
obtained from RE-digested DNA plasmids were separated on 1-2% agarose gels, adjacent to
DNA molecular weight standards. The gels were stained with ethidium bromide and were
visualized and photographed under UV light. Each quadrant in this figure contains a
representative gel for, from left to right, annealing and amplification of subclass recombinant
gene construct using the two flanking primers at the 5’ end of VH and the 3’ end of CH3 by a
single SOE-PCR, RE with single enzyme EcoRI of pCR2.1 TOPO TA transformed clones, and
restriction digestion with double enzymes BsmI and BamHI of pLNOH2 transformed clones.
Arrows indicate where DNA fragments are expected to be shown (correct-sized bands). In each
gel, both lanes shown correspond to the same DNA product, except for the middle gels in (A)
and (B), which have only one lane shown. For lanes with two bands, the above released band
corresponds to the digested vector and the below released band corresponds to the inserted DNA
fragment. The DNA molecular weight standards are represented by lanes with multiple bands.
As being shown, in each quadrant, the size (in kilobase-pairs, kb) of DNA fragments after RE
digestions are the same as those of the SOE-PCR products, which are 1.39 (A), 1.37 (B), 1.42
(C), and 1.37 (D). The size (kb) of plasmid vectors after digestions are 3.9 (pCR2.1 TOPO
cloning vector) and 7.2 (pLNOH2 expression vector). Only representative clones containing
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bands of expected sizes are shown. Lanes showing no bands correspond to undetectable DNA
products.
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each IgG subclass was created by several sequential SOE-PCRs. Agarose gel analysis of these
SOE-PCR products (Fig. 2.10) showed DNA bands of approximately 1.39, 1.37, 1.42, and 1.37
kb, representing the four corresponding recombinant IgH hybrids, IgHγ1, IgHγ2, IgHγ3, and
IgHγ4, respectively. When performed with the annealing temperature of 560C or 580C and a
magnesium concentration of 2.5 mM, SOE-PCRs using the two outermost flanking primers were
generally found to yield minimal non-specific (due to sequence differences) products while
producing desired amplification fragments.
For cloning and sequencing, resultant hybrid cDNA genes were subsequently ligated into
pCR2.1-TOPO TA cloning vector. These ligations resulted in two subsets of recombinant
cloning vectors: one containing cDNAs carrying BsmI-BamHI restriction sites and the another
carrying NotI-XhoI restriction sites. Insertion and orientation were checked by PCR and RE
digestion. Digestion of resultant recombinant cloning vectors with EcoRI (Fig. 2.10) or BsmI and
BamHI pair (data not shown) for the BsmI-BamHI subset, as well as with EcoRI or NotI and XhoI
pair (Fig. 2.11) for the NotI-XhoI subset, yielded bands of similar sizes as those of SOE-PCR
products of corresponding cDNA hybrids. These results verified the correct size and proper
orientation of the hybrids incorporated in pCR2.1 TOPO TA clones.
Correct sequence and orientation of the hybrids were also confirmed by DNA sequencing
in both forward and reverse directions across the inserted points. Alignment of deduced amino
acid sequences of IgH γ CH1, CH2, and CH3 domains belonging to four IgG isotypes (IgG1,
IgG2, IgG3, and IgG4) gene fragments from human (Homsap) and rhesus macaque (Macmul) is
shown in Fig. 2.12. Each rhesus macaque CH domains contains a similar number of amino acids
as that found in human counterparts, which is 98, 109-110, and 107, in CH1, CH2, and CH3
domains, respectively. Majority of differences were located in the hinge region for all compared
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Fig. 2.11. Gel electrophoresis separation of DNA fragments resulting from digestions of clones
of recombinant gene constructs of NIP-rhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3, and NIPrhIGHG4 that were ligated into cloning and expression vectors. RE digestions were used to
confirm that recombinant gene constructs had each been inserted into the correct region of
vectors and in the correct orientation (which were subsequently confirmed by sequencing).
Fragments obtained from RE-digested DNA plasmids were separated on 1-2% agarose gels,
adjacent to DNA molecular weight standards. The gels were stained with ethidium bromide and
were visualized and photographed under UV light. Shown in this figure are a representative gel
for restriction digestion with double enzymes BsmI and BamHI of pLNOH2 transformed clones
(A), with single enzyme EcoRI of pCR2.1 TOPO TA transformed clones (B), with double
enzymes NotI and XhoI of pCR2.1 TOPO TA transformed clones (C), and with double enzymes
NotI and XhoI of P2561/2/3 transformed clones (D). As being shown, each lane displays two
bands, of which the above released band corresponds to the digested vector and the below
released band corresponds to inserted DNA fragment. Number of lanes corresponding to each
construct varies, as indicated by the horizontal lines. The vertical arrows with short notations
show lanes corresponding to the indicated constructs. The DNA molecular weight standards are
represented by lanes with multiple bands. In each quadrant, the size (in kilobase-pairs, kb) of the
DNA fragments after RE digestions are 1.39, 1.37, 1.42, and 1.37 for NIP-rhIGHG1, NIPrhIGHG2, NIP-rhIGHG3, and NIP-rhIGHG4 construct, respectively. The size (kb) of the
plasmid vectors after digestions are 3.9 (pCR2.1-TOPO), 7.2 (pLNOH2), and 7.0 (P2561/2/3).
Only representative clones containing bands of the expected sizes are shown. Lanes showing
only one band (with size similar to that of the relevant vector) correspond to clones without
successful DNA ligation.
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sequences (Table. 2.2). Two-dimensional structure and secondary structure according to IMGT
were also displayed (Fig. 2.13). As discussed previously, these IMGT Collier de Perles graphical
two-dimensional representations provide useful information for relating structure to potential
function (Bertrand et al., 2004). The sequence of anti-NIP V regions of the resultant rhesus
macaque IgHs was identical to each other and to the original sequence (data not shown).
Taken together, these data indicate that all four chimeric NIP-rhIGHG cDNA gene
constructs were accurately and successfully created by SOE-PCRs and were properly
incorporated into pCR2.1 TOPO TA cloning vectors.

2.3.2. Four NIP-rhIGHG cDNA hybrid constructs were successfully engineered into
pLNOH2, pcDNA3.1(+), and P2561/2/3 expression vectors
As shown in Fig. 2.11, pLNOH2 plasmids digested by BsmI and BamHI gave rise to
individual bands of approximately 1.39, 1.37, 1.42, and 1.37 kb, which were the same size as that
of corresponding SOE-PCR products. Analysis of the restriction digests with NotI and XhoI (Fig.
2.11) confirmed that the cDNA hybrids were successfully engineered into pLNOH2. Similar
restriction digests with BsmI and BamHI pair or with NotI and XhoI RE pair indicated that the
hybrids were recombined into P2561/2/3 (Fig. 2.11) and pcDNA3.1 (data not shown) vectors.
The correct insertion and proper orientation were also confirmed by sequencing cDNA hybrids
(data not shown). DNA sequencing data of NIP-rhIGHG hybrid genes were consistent with DNA
sequences of VH (data not shown) and rhIGHGs genes listed in Genbank (Fig. 2.12).
Taken together, these data demonstrate that all four chimeric NIP-rhIGHG cDNA gene
constructs were accurately and successfully engineered into pLNOH2, pcDNA3.1, and
P2561/2/3 expression vectors.
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Fig. 2.12. Alignment of deduced amino acid sequences of IgH CH1, CH2, and CH3 domains of
four IgG isotypes (IgG1, IgG2, IgG3, and IgG4) from human (Homsap) and rhesus macaques
(Macmul). The top upper line illustrates the domain beta strands, as indicated by the letters and
numbering positions, with a horizontal arrow; the double letters represent the turns (AB, DE, and
EF) and the loops (BC and FG) between the sandwich fold beta strands, or the transversal strand
(CD) (Lefranc et al., 2005). The second and third upper lines indicate the C-DOMAIN IMGT
unique numbering. Conserved Cys residues (i.e. positions 23 and 104) are colored in magenta;
conserved Trp (position 41) and hydrophobic residues (positions 89 and 121) are illustrated in
blue. Residues of the beta strand loops (BC and FG) are shown in dark red. Two sequences for
each individual domain of rhesus macaques were included for each IgH domain and are bordered
in single-line enlarged boxes, as indicated. In each box, the above sequence (black “Macmul”
text) indicates the published sequences and the below sequence (colorful “Macmul” text)
indicates the sequences generated in the present study. The GenBank access codes for the
published sequences included are AAQ57550.1 (IGHG1), AAQ57562.1 (IGHG2), AAQ57556.1
(IGHG3), and AAQ57568.1 (IGHG4) (Scinicariello et al., 2004). Between parentheses is the first
amino acid that results from the splicing of each preceding exon. Underlined Cs indicate Cys
residues that have the potential to form intra-chain disulfide bonds. Potential N-linked
glycosylation sites (N-x-S/T; x denotes any amino acid) are underlined. Dot-line small-sized
boxes represent residual differences between rhesus macaques and humans with regard to amino
acids that are known to be functionally important, including those of potential N-linked
glycosylation sites (n=2), or with regard to Cys (which is known to have the potential to form
intra-chain disulfide bonds) (n=1). The last nine amino acids in the non-human primate species
are not present in the figure, and slashes indicate the positions where our sequences are ended.
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Dots illustrate the IMGT gaps (missing amino acids, according to the IMGT unique numbering)
inserted to maximize alignment. This display is according to the IMGT unique numbering for CDOMAIN and C-LIKE DOMAIN and is based on the IMGT protein display (Lefranc et al.,
2005).
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Table 2.2. Deduced amino acid sequences of the hinge of IgH CH1, CH2, and CH3 domains of four IgG isotypes (IgG1, IgG2, IgG3,
and IgG4) from human (Homsap) and rhesus macaque (Macmul)a.
IGHG1
Homsap

(E)PKSCDKTHTCPPCP(A)PELLGGP

IGHG2
e

(E)RKCCVECPPCP(A)PPVAGP

IGHG3
[H1] (E)LKTPLGDTTHTCPRCP(A)PELLGGP

IGHG4
(E)SKYGPPCPSCP(A)PEFLGGP

[H2] (E)PSKCDTPPPCPRCP
[H3] (E)PSKCDTPPPCPRCP
[H4] (E)PSKCDTPPPCPRCP
Macmul

(E)IKTCGGGSKPPTCPPCP(A)PELLGGP

(G)LPCRSTCPPCP(A)ELLGGP

(E)FTPPCGDTTPPCPPCP(A)PELLGGP

(E)FTPPCPPCP(A)PELLGGP

Macmul

(E)IKTCGGGSKPPTCPPCP(A)PELLGGP

(G)LPCRSTCPPCP(A)ELLGGP

(E)FTPPCGDTTPPCPPCP(A)PELLGGP

(E)FTPPCPPCP(A)PELLGGP

a

Two sequences for each hinge of rhesus macaques were included for each IgH isotype: the above sequence (black “Macmul” text)

indicates the published sequences (Scinicariello et al., 2004) and the below sequence (colorful “Macmul” text) indicates the sequences
generated in the present study. The hinge is composed of three distinct regions: the upper hinge (the fragment in front of the italic,
underlined text), the core hinge (the italic, underlined text fragment), followed by the lower hinge/CH2 terminus [although the “lower
hinge” is encoded by the C-terminus of the CH2 exon, it is considered to be part of the hinge due to the intermolecular interactions
(Burton and Woof, 1992)]. Human IgG3 hinge has four sequence repetitions, with three times the [(E)PSKCDTPPPCPRCP] sequence
is repeated. Between parentheses is the first amino acid that results from the splicing of each preceding exon. Underlined C, Cys
involved in the formation of intrachain disulfide bridges. The GenBank access codes for the published sequences included are
AAQ57550.1 (IGHG1), AAQ57562.1 (IGHG2), AAQ57556.1 (IGHG3), and AAQ57568.1 (IGHG4) (Scinicariello et al., 2004).
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2.3.3. Four chimeric NIP-rhIGHG IgH chains with NIP-specificity of the original murine VH
were successfully expressed by J558L cells
ELISA plates were coated with purified anti-monkey IgG, which recognizes different Ab
epitopes of the whole IgG(H+L) or IgH. Therefore, affinity purified anti-monkey IgG(H+L)
recognized recombinant IgH or IgG subclasses, which were bound to and were detectable by
HRP-conjugated anti-monkey IgG [due to the bivalent nature of IgGs (two IgH chains in a single
IgG)]. As shown in Fig. 2.16, the average OD reading at 405 nm in supernatants collected from
cells transfected with chimeric IgH fusions was much higher than that of negative controls using
the whole IgG- or IgH-specific conjugate, indicating that chimeric IgGs are bound by antimonkey IgG Abs. These OD values were similar to or in several cases even higher than those of
positive controls (Fig. 2.16). We found no expressed IgH nor IgG in IMDM medium
transfectoma supernatants, which served as negative controls as well. Supernatants of pLNOH2
(served as a positive control) reacted with immobilized purified anti-monkey IgG, while the
medium control (IMDM) or supernatant of untransfected J558L cells was non-reactive with the
purified Ab (Fig. 2.16). These results confirm the chimeric IgH identity through its anti-monkey
IgH-specific reactivity upon transfection and selection in J558L cells.

2.3.4. Four NIP-rhIGHG intact IgG subclass Abs that retained binding specificity of the
original V regions were successfully produced by J558L cells
To verify that secreted recombinant rhesus macaque IgH chains were assembled with
NIP-specific murine IgL λ chains, we carried out another set of sandwich ELISAs where NIPBSA was immobilized on plates and bound IgGs were detected by HRP-conjugated anti-monkey
IgG Abs. Before transfection, production of murine IgL λ from J558L cells was confirmed by
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Fig. 2.13. Two-dimentional representation, or IMGT Colliers de Perles, of rhesus macaque
(Macmul) CH domain sequences of each of the four IGHG subclass molecules. Shown are
Colliers de Perles representation on one layer obtained with the IMGT/Collier-de-Perles tool in
the IMGT/DomainGapAlign (http://www.imgt.org/3Dstructure-DB/cgi/Collier-de-Perles.cgi)
(Ehrenmann et al., 2010). Colliers de Perles is the two-dimentional graphical representations of
IG and TR V, C domains, highlighting conserved amino acids. The C-DOMAIN IMGT Colliers
de Perles is based on the IMGT unique numbering for C- and C-LIKE DOMAIN and allows
sequence comparison of Ig superfamily (IgSF) domains in different species (one layer Colliers
de Perles), as well as localization of amino acids involved in FcR binding, in C1q binding, and in
N-glycosylation sites (two layer Colliers de Perles) (Lefranc et al., 2005). The conserved Cys
(position 23), and Cys (position 104), are indicated. Blue circles or squares represent core
positions at which hydrophobic amino acids (I, V, L, F, C, M, A) and W are found in more than
50% of analyzed IgSF sequences. All Pro residues are shown in yellow. Squares illustrate
homology with the corresponding positions in the V-DOMAINs (positions 26, 39, 104, and 118)
or delimitation of the characteristic transversal CD strand of the C-LIKE-DOMAINs (positions
45 and 77). The BC loop, CD transversal strand, and FG loop are limited by amino acids
displayed in squares. Hatched circles indicate missing positions according to the IMGT unique
numbering for C-DOMAIN and C-LIKE-DOMAIN (Lefranc et al., 2005). Arrows indicate the
beta strand direction.
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Fig. 2.14. Prediction of potential N-glcosylation sites for CH3 domains of human (above) and
rhesus macaque (below) IgG4 sequences, conducted by the use of the online tool NetNGlyc 1.0
Server (http://www.cbs.dtu.dk/services/NetNGlyc/), which is based on identifying Asn-XaaSer/Thr consensus sequences (Julenius et al., 2005). Unlike in humans (above), in rhesus
macaques (below), IgG4 has one additional computationally-predicted N-glycolsylation site at
CH3.
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Fig. 2.15. Expression by J558L cells of NIP-specific mouse Igλ associated with secreted
recombinant IgHs as detected by sandwich ELISA for its binding to purified anti-mouse IgL λ
Abs produced in goat (NIP anti-λ ELISA). For detecting an antigen or Ab, sandwich ELISA is a
sensitive and specific technique that uses two Abs, both of which are specific to the antigen or
the Ab of interest and bind it at non-overlapping epitopes. Undiluted supernatants collected at
different time points from J558L cells transfected with recombinant pLNOH2 expression vector
containing NIP-rhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3, or NIP-rhIGHG4 chimeric construct,
from unstransfected cells (represents a negative control), or from cells transfected with the
original pLNOH2 vector, which encodes human IgH and is specific for NIP, were incubated on
ELISA plates coated with goat anti-mouse λ (Southern Biotech, Birmingham, AL; Cat. #106001). IgL λ was detected by HRP-conjugated secondary Ab goat anti-mouse λ (Southern Biotech,
Birmingham, AL; Cat. #1060-05). Absorbance was measured at 405 nm using an automated
microplate reader. Purified mouse IgG3 λ (Sigma–Aldrich Co., St. Louis, MO; Cat. # M9019)
was added as a positive control. IMDM, the cell culture medium, and PBS, were also included to
serve as additional negative and blank controls. Day numbers indicate numbers of days after
transfection when supernatants were harvested for testing. Values are means of duplicate wells.
The assays were performed twice and yielded similar results. *Data shown for IMDM/PBS,
Untransfected, and pLNOH2 were from the NIP-rhIGHG3 experiments, which were used as
representative; IMDM/PBS, Untransfected, and pLNOH2 values obtained from the NIPrhIGHG1, NIP-rhIGHG2, and NIP-rhIGHG4 experiments were similar. PosCTRL**, purified
mouse IgG3 λ (Sigma–Aldrich Co., St. Louis, MO; Cat. # M9019).

136

ELISA (data not shown).
As shown in Fig. 2.17, supernatants collected from cells transfected with recombinant
IgH hybrids that were captured with NIP-BSA were readily detectable with HRP-conjugated
anti-monkey IgGs. Supernatant from cells transfected with pLNO2 vector (human IgG3), which
represented a positive control, also bound NIP-BSA. No binding was observed for supernatants
from untransfected cells. These data indicate that intact IgG subclass Abs were assembled, as
secreted recombinant Ab molecules featured both the VL/VH IgL NIP-specificity and the antimonkey IgH-specific reactivity.
For all gene hybrids, Ab secretion level was with a peak on day 10 after transfection (Fig.
2.16, 2.17, and 2.18). Furthermore, protein production proceeded as early as at day 5 (Fig. 2.16
and 2.17). Six weeks after transfection, ELISA assays showed that the transfectomas producing
good quantities of IgGs were still active (i.e. secreting Abs) (data not shown). Expression levels
varied dependent on subclasses and the yield was generally highest for IgG2, followed by IgG3
then IgG4, and lowest for IgG1 (Fig. 2.18). During the examining period of time (up to six
weeks post-transfection), production of murine λ IgL by J558L cells was confirmed by ELISA
(Fig. 2.15). In these assays, ELISA plates were coated with goat anti-mouse λ [purified antimouse λ Abs produced in goat (NIP-specific anti-VL/VH λ Abs)] and bound IgL λ was detected
by HRP-conjugated secondary Ab goat anti-mouse λ.
Taken together, production of recombinant IgGs recognized by both anti-NIP (i.e. Fab)
and anti-monkey (i.e. Fc/IgH) Abs suggest that upon transfection with chimeric NIP-rhIGHG
vectors, the IgH-deficient myeloma J558L cells produce complete H2L2 complete IgG molecules,
resulting from pairing of transfected recombinant IgH with IgL λ endogenously expressed by the
cells. Secreted Abs were with the pre-defined specificity (intact binding capability) against NIP.
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Fig. 2.16. Production of recombinant NIP-rhIGHG IgH chains of different IgG subclasses as
determined by sandwich ELISA for their binding to an affinity purified anti-monkey IgG
produced in goat (monkey-specific anti-gamma ELISA). For detecting an antigen or Ab,
sandwich ELISA is a sensitive and specific technique that uses two Abs, both of which are
specific to the antigen or the Ab of interest and bind it at non-overlapping epitopes. Undiluted
supernatants collected at different time points from J558L cells transfected with a recombinant
pLNOH2 expression vector containing the NIP-rhIGHG1 (A), NIP-rhIGHG2 (B), NIP-rhIGHG3
(C), or NIP-rhIGHG4 (D) chimeric construct, from unstransfected cells (represents a negative
control), or from cells transfected with the original pLNOH2 vector, which encodes human IgH
chain and is specific for NIP [represents a positive control (known to react with rhesus macaque
IgG)], were incubated on ELISA plates coated with affinity purified goat anti-monkey IgG(H+L)
(KPL, Baltimore, MD; Cat. #071-11-021) as the capture Ab. Bound Abs were detected by HRPconjugated secondary Abs goat anti-monkey IgG (whole IgG- or IgH-specific) (KPL, Baltimore,
MD; Cat. #074-11-021) for rhesus macaques. Due to rhesus macaque IgG bivalency, if they bind
to immobilized purified goat anti-monkey IgG, they will also bind to HRP-conjugated goat antimonkey secondary Abs. Absorbance was measured at 405 nm using an automated microplate
reader. IMDM, the cell culture medium, was also included to serve as an additional negative
control. Day numbers indicate numbers of days after transfection when supernatants were
harvested for testing. Values are means of duplicate wells. The assays were performed twice and
yielded similar results.
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Fig. 2.17. Production of complete recombinant NIP-rhIGHG Abs of different IgG subclasses as
determined by capture (indirect) ELISA for their binding to NIP-BSA (NIP coupled to BSA)
antigen (NIP-specific anti-gamma ELISA). Expression of rhesus macaque IgH and its ability to
pair with NIP-specific mouse IgL λ were tested using capture ELISAs. Undiluted supernatants
collected at different time points from J558L cells transfected with a recombinant pLNOH2
expression vector containing NIP-rhIGHG1 (A), NIP-rhIGHG2 (B), NIP-rhIGHG3 (C), or NIPrhIGHG4 (D) chimeric construct, from unstransfected cells (represents a negative control), or
from cells transfected with the original pLNOH2 vector, which encodes human IgH chain and is
specific for NIP (known to react with rhesus macaque IgG and represents a positive control),
were incubated on ELISA plates coated with NIP-BSA (Biosearch Technologies, Birmingham,
AL; Cat. #N-5040-10; 8-15 μg/ml). Bound Abs were detected by HRP-conjugated secondary
Abs goat anti-monkey IgG (whole IgG- or IgH-specific) (KPL, Baltimore, MD; Cat. #074-11021) for rhesus macaques. Absorbance was measured at 405 nm using an automated microplate
reader. IMDM, the cell culture medium, was also included to serve as an additional negative
control. Day numbers indicate numbers of days after transfection when supernatants were
harvested for testing. Values are means of duplicate wells. The assays were performed twice and
yielded similar results.
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Thus, four chimeric NIP-rhIGHG intact IgGs that retained binding specificity of the original
anti-NIP V regions were successfully produced.

2.4. Discussion
One of the major reasons for lack of IgG functional in vitro studies for the rhesus
macaque model is the unavailability of specific serological reagents, whereas human Abs poorly
or rarely interact with rhesus macaque effector leukocytes. To circumvent this pitfall, we have
engineered recombinant Abs representing each of the four IgG subclasses of rhesus macaques.
Previously, our laboratory has utilized molecular cloning techniques to identify and characterize
IgG genes in rhesus macaques. From these studies, four IgG subclasses are discovered and are
found to be variable most in the hinge region, although isotypic variation in amino acid
sequences is also identified in CH1, CH2, and CH3 domains (Scinicariello et al., 2004). In
addition to isotypic variation, intra-species allelic polymorphism also appears among individual
animals. Of particular note from these findings is the addition in rhesus macaque IgG4 CH3
domain of a potential N-glycosylation site, from which possible related structural and/or
functional changes remain to be elucidated. These characterized IGHG genes in rhesus macaques
have provided the knowledge to generate their recombinant Abs.
In this study, we describe the procedures for engineering four chimeric recombinant
murine-rhesus macaque IgGs. Here the ~1.4-1.5 kb BsmI-BamHI- and NotI-XhoI-containing IgH
chain cDNA cassettes (which contained a murine VH region specific for the hapten NIP) of each
of the four rhesus macaque IgG CH subclasses, were constructed by SOE-PCRs and
subsequently cloned into pLNOH2 and P2561/2/3 expression vectors, respectively. Resultant
IgH expression vectors were then transfected by electroporation into a murine myeloma cell line,
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Fig. 2.18. Different yields in production of recombinant NIP-rhIGHG Abs of different IgG
subclasses as determined by ELISA for their binding to NIP-BSA antigen [(A); NIP-specific
anti-gamma ELISA] or to an affinity purified anti-monkey IgG produced in goat [(B); monkeyspecific anti-gamma ELISA]. Undiluted supernatants collected at day 10 post-transfection from
J558L cells transfected with recombinant pLNOH2 expression vector containing the NIPrhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3, or NIP-rhIGHG4 chimeric construct, from
unstransfected cells (represents a negative control), or from cells transfected with the original
pLNOH2 vector, which encodes human IgH chain and is specific for NIP (known to react with
rhesus macaque IgG and represents a positive control), were incubated on ELISA plates coated
with NIP-BSA (Biosearch Technologies, Birmingham, AL; Cat. #N-5040-10; 8-15 μg/ml) (A) or
with with purified goat anti-monkey IgG (KPL, Baltimore, MD; Cat. #071-11-021) (B). Bound
Abs were detected by HRP-conjugated secondary Abs goat anti-monkey IgG (whole IgG- or
IgH-specific) (KPL, Baltimore, MD; Cat. #074-11-021) for rhesus macaque. Absorbance was
measured at 405 nm (the X-axis) using an automated microplate reader. IMDM, the cell culture
medium, was also included to serve as an additional negative control. Values are means of
duplicate wells. The assays were performed twice and yielded similar results. *Data shown for
IMDM and Untransfected were from the NIP-rhIGHG3 experiments, which were used as
representative; IMDM and Untransfected values obtained from the NIP-rhIGHG1, NIPrhIGHG2, and NIP-rhIGHG4 experiments were similar).
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J558L, which express the NIP-specific IgL chain. Surviving cells were selected by G418
antibiotics and IgG production was determined by ELISA. Successful production and identity of
intact recombinant IgGs were confirmed by their capability of binding the hapten NIP and being
bound by purified goat anti-monkey Abs. All resultant recombinant molecules were confirmed
for sequence accuracy.
The recombinant DNA method is a powerful tool for construction of Ab genes and
production of genetically engineered Abs with novel or modified structural and/or functional
properties for applications in both basic and applied research. With more and more Ig gene
sequences and specifically constructed vectors for subsequent cloning and expression become
available, the process of producing recombinant Igs can nowadays be faster and more flexible.
cDNA-based vector systems have been also used to express chimeric murine (V)-human (C) Abs
under CMV promoter direction (McLean et al., 2000; Preston et al., 1998; Norderhaug et al.,
1997). Also, in vitro Ab expression requires cloning of Ig (V and C) gene fragments into
eukaryotic cell expression plasmids containing specifically constructed functional sequences,
including those encoding an Ig promoter (for transcription control), an Ig intron leader (allowing
for secretion of fusion protein), a poly(A) signal (for transcription termination), an origin of
replication, and antibiotic resistance markers (for clone selection) (Tiller et al., 2008; Wrammert
et al., 2008). Several such Ig expression vectors have been developed (Tiller et al., 2008;
McLean et al., 2000; Persic et al., 1997). However, Ig expression vectors lacking intron
sequences have generally yielded a low level of secreted Abs (Gillies et al., 1989; Neuberger and
Williams, 1988). In this study, we took advantages of these techniques to successfully create and
produce four complete recombinant chimeric cDNA gene constructs consisting of rhesus
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macaque IgG CH region genes in combination with the murine VH region genes whose protein
product direct against the NIP hapten.
Amplification of rhesus macaques IgG CH gene segments was carried out with
degenerate primers designed from known conserved regions of IgG CH sequences in humans
and optimized for sufficient (re)amplification SOE-PCRs. Also, these primers were designed so
that they would not only amplify Ig gene fragments, but also appropriately add unique, desirable
RE sites that overlapped with adjunct fragments or with the cloning and expression vectors – yet
absent in IgG gene constructs (Persic et al., 1997) – for easy exchange of Ig gene cassettes and
allowing for straightforward subsequent cloning of DNA constructs. These primers have allowed
murine V region genes to be fused in frame to rhesus macaque C regions genes to create a single,
complete IgH chain fragment for cloning and ligation. Additionally, the primers employed were
also appropriately provided with sequence extensions for overlap reactions or were embedded
with necessary Ig functional element sequences for transcription, transport, and translation.
The creation of recombinant IgH gene fragment in this study relied on the method for
splicing two pieces of DNA, SOE-PCR (Yolov and Shabarova, 1990; Yon and Fried, 1989). As
previously described, this technique is a powerful tool for fusing two short DNA fragments
whose total length is not greater than 3-4 kb (Kuwayama 2002; Pont-Kingdon, 1997), which is
ideal for creating IgH gene region. Using sequential SOE-PCRs, we have successfully assembled
individual DNA fragments with overlapping sequences to generate four recombinant cDNA
fusion constructs, each encoding a rhesus macaque IgG CH subclass. Constructed plasmids were
examined by restriction analysis and confirmed by DNA sequence analysis for their sequence
accuracy and insert orientation. As described in the Materials and Methods section, since the two
DNA template fragments were introduced at their adjacent end an overlapping sequence, each of
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them can act as a giant “primer” on the other one. These reactions resulted in the fused DNA
species to be created in the mixture of early SOE-PCR products. Due to the low concentration of
the complementary DNA fragments and their shorter sequence (thus, lower melting
temperature), appearance of the fused DNA species at this stage of SOE-PCR reactions (i.e.
amplification, not reamplification) would be most successful at a relatively low annealing
temperature. Indeed, when performed with the annealing temperature of 560C or 580C and a
magnesium concentration of 2.5 mM, SOE-PCRs that used the two outermost flanking primers
were generally found to yield minimal nonspecific products while producing desired
amplification fragments. This melting temperature range should be considered when designing
degenerate primers.
In some particular instances, however, such as with IgG3 with which additional primers
were used, creating a complete recombinant cDNA fragments using these approaches was not
straightforward: many non-specific DNA species were yielded while little or no desired DNA
product was produced. In such cases, redesigning internal primers by increasing their overlap
length (of up to 47-99 nt long; Shevchuk et al., 2004) could improve the (re)amplification
success rate. This observation is consistent with previous findings (Shevchuk et al., 2004).
Alternatively, modification of SOE-PCR strategy by adding the flanking primer pairs after
running of several reactions (i.e. these early runs are with no primers to allow for fusion DNA
species to pair) could be applied (Shevchuk et al., 2004). Also, in general, we observed that the
use of equimolar concentrations of DNA template fragments tended to reduce the presence of
non-specific products. We also note that use of Clontech DNA polymerase generally improves
the success of amplification compared to using the Taq-based polymerases. Cloning of amplified

147

SOE-PCR products of IgG CH cDNA fragments into plasmid vectors was also necessary, given
the slight sequence differences between the IgG subclasses.
In this study, we used an established pLNOH2 expression plasmid vector that not only
contains all the essential elements necessary for transcription – including the appropriate intronic
sequences and the needed splicing signals at the intron boundaries – but also consists of unique
restriction sites for easy subcloning or straightforward substitution of IgG CH region genes
(Norderhaug et al., 1997). We have also demonstrated the expression and assembly of full-length
IgH and IgL to form complete rIgs by a specialized mammalian cell line. The IgH was cloned
and expressed using a eukaryotic plasmid expression vector. Successful recognition of rIgs by
whole IgG-specific or IgH-specific conjugate indicate that IgH chains were correctly assembled
with the IgL chains that were endogenously secreted by J558L cells (these cells express no
endogenous IgH, hence no intact Abs are secreted). These data proved that IgL and IgH chains
were produced and were able to covalently associate to make intact (H2L2) IgG molecules. These
results also indicate that all expressed proteins, throughout the incubation period, were correctly
folded. Additional experiments, however, are needed to examine if the Abs were glycosylated
correctly.
Previous work in our laboratory has used cDNA-based expression systems to produce
functional recombinant Abs and FcRs (Rogers et al., 2008 and 2006). An early Ig expression
system was applied to express recombinant Abs composing of NIP-binding V regions and
macaque IgA CH region genes; the resultant recombinant Abs were able to bind NIP (Rogers et
al., 2008). In this study, we improved the use of this early Ig expression system by employing
unique RE sites and made the P2561/2/3 Ig expression system. This system can be used to create
recombinant Abs possessing rhesus macaque or other NHP polymorphic Ig CH genes for
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functional characterization of recently recognized high levels of intraspecies variability. Also,
because our functional Ig gene constructs were transfected into a murine myeloma (i.e. Abproducing cells) that endogenously express IgL λ chains, the steps involved in cloning of IgL
chains could be bypassed, thus avoiding some SOE-PCR and subsequent cloning procedures,
which are often obstacles in recombinant Ab production. Furthermore, successful production of
complete chimeric IgG subclasses reactive with purified anti-monkey IgG directed whole IgG or
IgH and capable of specifically binding to the NIP-BSA hapten, as described in this study,
confirms that murine IgL λ chain (V and C regions) was successfully engineered into rhesus
macaque IgH chains while still retained specificity of the original V regions. Since the hapten
NIP is directed by murine IgL λ chain but not by rhesus macaque IgH regions, the use of this
specificity would avoid potential detection problems associated with intra- and/or inter-species
sequence variability within IgH CH domains. Thus, this system would be a useful tool for
engineering complete recombinant IgG Abs with pre-defined specificity and desired CH regions.
In conclusions, the Ig cloning and expression systems, and the genetically engineered
recombinant IgG chimeras created in this study, represent both the foundations and the tools for
further studies of IgG effector functions, such as activating pathogen-clearance cell-killing
effector mechanisms through binding corresponding FcγRs, and IgG preferential serum usage
during various immune responses in the rhesus macaque model. These materials can also be
utilized for basic studies of Ab structure-function relationship. These potential studies will be
discussed in more details later in this dissertation.
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CHAPTER 3
RHESUS MACAQUE IGG FC RECEPTORS:
CHARACTERIZATION AND ALLELIC POLYMORPHISMS OF ENCODING GENES
AND GENERATION OF RECOMBINANT cDNA EXPRESSION VECTORS

(PARTIAL CONTENT OF THIS CHAPTER WAS PUBLISHED AS:
NGUYEN ET AL., IMMUNOGENETICS 2011;63:351–62)

3.1. Summary
Macaque models are invaluable for AIDS research. Initial development of HIV-1
vaccines relies heavily on SIV-infected rhesus macaques. Neutralizing Abs, a major component
of anti-HIV protective responses, ultimately interact with FcRs on phagocytic and NK cells to
eliminate the pathogen. Despite the major role that FcRs play in protective responses, limited
information is available on these molecules in rhesus macaques. In this study, rhesus macaque
CD64 (FcγRI) and CD32 (FcγRII) homologues were genetically characterized. Presence of
CD64, CD32, and CD16 (FcγRIII) allelic polymorphisms were also determined in a group of
nine animals. Results from this study show that the predicted structures of rhesus macaque CD64
and CD32 are highly similar to their human counterparts. Rhesus macaque and human CD64 and
CD32 extracellular domains are 94–95% and 88–90% homologous, respectively. Although all
Cys residues are conserved between the two species, rhesus macaque CD32 exhibits two
additional N-linked glycosylation sites, whereas CD64 lacks three of them, when compared to
humans. Three CD64, five CD32, and three CD16 distinct allelic sequences were indentified in
the nine animals examined, indicating a relatively high level of polymorphism in rhesus macaque
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FcγRs. Recombinant FcγR gene cDNA constructs were successfully generated and engineered
into cloning and expression vectors using novel refined plasmid systems. These constructs can be
cloned into HeLa cells for production of recombinant FcγRs, which will be a useful tool for
functional studies, including those related to IgG/FcγR interactions and initiation of cellular
immune responses. Collectively, these results validate rhesus macaques as models for vaccine
development and Ab responses, while at the same time, underscoring the need to take into
account the high degree of genetic heterogeneity present in this species when designing
experimental protocols.

3.2. Materials and methods
3.2.1. Blood samples, total RNA isolation, reverse transcription, and cDNA synthesis of FcγR
genes
Fig. 3.1. shows the major steps involved in identifying and cloning rhesus macaque FcγR
genes, and in generation of their recombinant cloning and expression plasmid vectors.
Heparinized blood samples were collected from nine healthy rhesus macaque (Macaca mulatta)
of different ages housed at the Language Research Center of Georgia State University, Atlanta,
GA. Animal blood collection was done according to local and federal guidelines. Total RNA was
extracted from whole blood using QiaAmp RNA Blood Mini kit (Qiagen Inc., Valencia, CA).
Total RNA (~1–3 μg) was then reverse transcribed into single-stranded cDNA using either oligo
(dT)15 or random primers, followed by primer extension with the AMV reverse transcriptase
(Roche Diagnostics North America, Indianapolis, IN), in a total reaction volume of 15–30 μl.
Next, the resulting first-strand cDNA products were serially diluted and PCR-amplified with
Expand High Fidelity polymerase (Roche Diagnostics North America, Indianapolis, IN) using
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Fig. 3.1. Flowchart representation illustrating major steps involved in identifying and cloning
rhesus macaque FcγR genes, as well as in generation of recombinant FcγR cloning and
expression plasmid vectors. Individual cDNA gene fragments were first isolated and amplified
from total RNA extracted from whole blood cells by RT-PCR and PCR using primers that were
designed based on known conserved regions of corresponding human FcγR gene sequences.
Resulting cDNA genes were cloned into pCR2.1 TOPO TA cloning vector containing a
selectable marker sequence, which was used for selection of transformed clones that picked up
constructs and replicated in competent bacterium cells cultured in medium containing X-gals and
ampicillin antibiotic. All constructs were verified by DNA sequencing before further steps. For
generating recombinant molecules, cDNA constructs were firstly amplified from cloning vectors
by PCR using primers that incorporated appropriate restriction sites (that were used to ligate a
desired contruct into an expression vector, where it fits exactly between the two restriction sites).
To make a large quantity of the constructs, resulting recombinant expression vector was then
transformed back into competent bacterium cells so that they were multiplicated by these cells
following their division and replication. An appropriate amount of recombinant DNAs were
made available and ready for mammalian cellular transfection. Some figure pieces are
reproduced from Smith and Clatworthy, 2010, and from the internet.
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Fig. 3.2. Schematic representation of FcγRIIIa genomic and cDNA structure and of gene
fragments encoding the extra cellular domains of FcγRI and FcγRII molecules, as well as
strategy for creating recombinant cDNA fragments. (A) Schematic representation of FcγRIIIa
genomic and cDNA structure (not drawn to scale). S, signal sequence (encoded in 2 exons); EC,
extracellular Ig-like domains; TM/CYT, transmembrane/cytoplasmic domains. The intron-exon
organization of the FcγR genes was inferred from the human and rhesus macaque sequences
publicly available. The necessary splice sites found at intron boundaries and the sequences of the
introns were removed. (B) Diagrammatic representation of gene fragments encoding the extra
cellular domains of FcγRI and FcγRII molecules and strategy for creating recombinant cDNA
fragments. Name, direction (horizontal black arrows), and relative positioning/location (colorful
numbers) of primers as well as corresponding amplified PCR products are depicted. The final
recombinant constructs were amplified in SOE-PCRs using the outermost flanking primers. The
sequences of primers used are given in Table 3.1.
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appropriate oligonucleotide primer pairs (see below) in a total of 50 or 100 μl reaction volume.
PCR conditions were as follows: after initial denaturation at 95°C for 10 min, the cDNAs were
amplified for 40 cycles, with each cycle consisting of 94°C for 1 min, 56°C for 1 min, and 72°C
for 2 min and 30 s. To ensure complete extension, a final step at 72°C for 10 min was applied. At
least two independent RT-PCR reactions using the same total RNA were performed, and from 10
to 15 independent cDNA clones per individual macaque and from each of two separate PCR
reactions were analyzed. These steps were performed to rule out that the putative allelic
polymorphisms were due to a PCR amplification artifact.

3.2.2. Design of primers
Primers for amplification of macaque FcγRI (CD64) and FcγRII (CD32) genes were
designed from the corresponding human sequences (assuming conserved homology between
primates) (Fig.3.2). The terminal sense and antisense FcγRII/FcγRI primers are located within
the start of the leader region (exon 1) and within the end of the cytoplamic region (FcγRII exon 5
and FcγRI exon 6), respectively, of the cDNAs shared by multiple human FcγRIIa/FcγRIa
sequences (Table 3.1). Internal primers for each of these two receptors were situated within exon
4, which encodes the [D2] domain of CD32, or exon 5, which encodes the [D3] domain of
CD64. Using these primer sets, the PCR amplification product should span most of the FcγRII or
FcγRI-targeted cDNAs (covering from exon 1 to the most 3′ exon). Specifically, the CD32.1 and
CD32.2 primer pair was used to generate a 566-bp product spanning the first part of FcγRII,
beginning from the leader region. CD32.3 and CD32.8 primer pair would amplify a 502-bp
fragment that had a 191-bp overlapping sequence with the fragment produced by CD32.1 and
CD32.2, and that spanned the second part of FcγRII, including the CO-TM-CYT region.
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Similarly, two FcγRI fragments that had a 194-bp overlapping sequence were amplified by the
use of CD64.1 and CD64.4 (yielding an 800-bp fragment) and CD64.9 and CD64.10 (generating
a 424-bp fragment) primer pairs. For FcγRIII, primers included FCG3aF (located within the start
of the leader region) and FCG3aR (located within the end of the cytoplamic region). All primers
were designed to generate FcγRIIa, FcγRIa, and FcγRIIIa homologue products, and were used
for each individual animal of the nine macaques examined.

3.2.3. Cloning and sequencing of amplified FcγR cDNAs
Appropriate volume of PCR reactions were run on a 2% agarose gel and the bands of
interest (showing expected size) were excised and purified using QIAquick Gel Extraction kit
(Qiagen Inc., Valencia, CA) using a microcentrifuge. The purified PCR products were then
cloned into the pCR2.1 TOPO TA cloning vector (Invitrogen, Carlsbad, CA) for sequencing
analysis purpose. The plasmids were transformed into Top10 E. Coli chemically competent cells
using TOPO TA Cloning and One Shot Chemical Transformation following the manufacturer's
protocols (Invitrogen, Carlsbad, CA). Subsequently, 10–15 inserted, positive colonies from each
sample were picked and incubated overnight in LB culture tubes at 37°C in a shaking rotary
incubator (200–230 rpm). The minipreps DNA Purification System kit (Promega Corporation,
Madison, WI) was used to purify plasmid DNA, and the plasmid DNA was then screened on a
1% agarose gel after digestion with EcoRI to confirm the inserted fragment size. All DNA
sequences were determined using the ABI Prism Dye Termination Cycle Sequencing kit and on
an ABI model 3100 automated sequencing apparatus (PerkinElmer, Wellesley, MA). Sequencing
primers were those used for PCR amplifications and the forward and reverse M13 primers.
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Table 3.1. Primers used for amplification of rhesus macaque FcγRa cDNAs.
Primer Name
FCG3aF (fw)b
FCG3aR (rv)
CD32.1 (fw)
CD32.2 (rv)
CD32.3 (fw)
CD32.8 (rv)
CD64.1 (fw)
CD64.4 (rv)
CD64.9 (fw)
CD64.10 (rv)

Sequence (5’-3’)
Product size (bp)
ATGTGGCAGCTGCTCCTCCCA
765
TCATTTGTCTTGAGGGTCCTT
TTTTGCTGCTGCTGGCTTCTGC
556
ATGCTGGGCACTTGGACAGTGATG
AAGGACAAGCCTCTGATCAAGGTC 502
TGACATGGTCGTTGGGAGGAAG
GACAGCTCTGCTCCTTTGGGTTC
800
AGGACATTTCCGTCTTCTGTGG
AATCTGGTCACCCTGAGCTGTG
424
AATGTCTGTCTTCTTGAAGGCTGG

Position
(-51)-(-31)
(714)-(694)
(-32)-(-11)
(527)-(504)
(337)-(360)
(838)-(817)
(-40)-(-18)
(758)-(737)
(565)-(586)
(988)-(965)

a

Location
Accession numberc
L-encoded region
DQ423379.1
CYT-encoded region
DQ423379.1
L-encoded region
BC020823.1
[D2]-encoded exon 4
BC020823.1
[D2]-encoded exon 4 XM_001118066.2
CYT-encoded region
BC020823.1
L-encoded region
NM_000566.3
[D3]-encoded exon 5
NM_000566.3
[D3]-encoded exon 5
NM_000566.3
CYT-encoded region
NM_000566.3

Abbreviation and full gene designations are the following: FcγRI: IgG Fc high affinity I receptor (CD64); FcγRII: IgG Fc low affinity

II receptor (CD32); FcγRIII (or FCG3a): IgG Fc low affinity III receptor (CD16).
b

c

fw, forward direction; rv, reverse direction.

GenBank accession number for the reference sequences used for designing primers.
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3.2.4. Construction of rhesus macaque FcγR cloning vector
The complete CD64 and CD32 extracellular domain cDNA gene fragments were
generated by SOE-PCR ligating two separate fragments containing overlapping short sequences,
which were produced by PCRs using the appropriate primer pairs (CD64.1 and CD64.10, and
CD32.1 and CD32.8; Fig. 3.2 and Table 3.1). The CD16 cDNA fragment was directly amplified
from relevant sequencing-verified plasmids. To facilitate transfer of these FcγR cDNA fragments
from TOPO TA cloning vector into expression vectors, HindIII and BamHI restriction sites were
introduced to their 5' and 3' ends, respectively, by PCRs using forward FCG3FHind and reverse
FCG3RBam primers (Table 3.2 and Fig. 3.3) on the appropriate cloning vector previously
generated. Also, additional FcγR cDNA fragments were incorporated with NotI and XhoI
restriction sites to their 5' and 3' ends, respectively, following a similar strategy with the use of
FcγR.NotI and FcγR.XhoI primers (Table 3.2 and Fig. 3.4). Resultant FcγR cDNAs (i.e.
consisting of the two added restriction sites: HindIII and BamHI, or NotI and XhoI) were then
run on a 1% gel, extracted, and put into pCR2.1 TOPO TA cloning vectors, and were
subsequently transformed into Top10 E. Coli chemical competent cells for cloning again,
following previously described procedures.

3.2.5. Construction of rhesus macaque FcγR expression plasmid systems using pcDNA3.1(+)
(HindIII/BamHI), as well as pcDNA3.1(+) (Not/Xho) and P2561/2/3 (Not/Xho) vectors
To create expression vectors, the newly RE-added FcγR cDNA gene fragments were
excised from the pCR2.1-TOPO TA cloning vector clones with correct sequences by sequential
digestion with HindIII and BamHI and cleaned up on a 1% agarose gel (Fig. 3.3). Plasmids were
purified using the QIAprep spin miniprep kit (Qiagen Inc., Valencia, CA) and bands containing
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Table 3.2. Primers used for generation of rhesus macaque FcγR recombinant DNA constructs by SOE-PCR amplifications.
Primer
namea

Sequence (5’-3’ direction)b

FcγR.FHind
(fw)

AGATAAGCTTGATATGTGGCAGCTGCTCCTCCCA

5’;
FcγRIIIa

FcγR.RBam
(rv)

TCTAGGATCCTCATTTGTCTTGAGGGTCCTT

3’;
FcγRIIIa

CD32.NotI
(fw)

ATTAGCGGCCGCATAATGACTATGGAGACCCAAATGTCTCA
GAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGAC
AGTTTTGCTGCTGCTGGCTTCTGC

5’;
FcγRII

CD32.XhoI
(rv)

ACTCGACTCGAGTTATTAGTTATTACTGTTGACATGGTCGTT
GGGAGGAAG

3’;
FcγRII

CD64.NotI
(fw)

ATTAGCGGCCGCATAATGTGGTTCTTGACAGCTCTGCTCCTT
TGGGTTC

5’;
FcγRI

CD64.XhoI
(rv)

ACTCGACTCGAGTTATTACTACGTGGCCCCCTGGGGCTCCTT
CCGGTGCACCCCTTCCTGCAGCTGTTCTTCTTTTTGTTCCTGA
CATTTCAGCTCTTCTTCTAAATGTCTGTCTTCTTGAAGGCTGG

3’;
FcγRI

Specificity

Sequence characteristicsc
Containing HindIII site (5’-AAGCTT-3’)
Containing full 21-bp sequence of FCG3aF
Containing an ATG start codon
Containing XhoI site (5’-GGATCC-3’)
Containing full 21-bp sequence of FCG3aR
Containing a TGA stop codon
Containing NotI site (5’-GCGGCCGC-3’)
Containing full 22-bp sequence of CD32.1
Containing an ATG start codon
Containing XhoI site (5’-CTCGAG-3’)
Containing full 22-bp sequence of CD32.8
Containing a TGA stop codon
Containing NotI site (5’-GCGGCCGC-3’)
Containing full 23-bp sequence of CD64.1
Containing an ATG start codon
Containing XhoI site (5’-CTCGAG-3’)
Containing full 24-bp sequence of CD64.10
Containing a TGA stop codon

a

fw, forward direction; rv, reverse direction.

b

Bold and underline, restriction endonuclease sequences; bold and italic, with or without underline, overlapping (“homologous”)

region with the relevant primer indicated in “Sequence characteristics” column.
c

An (ATG) start codon needed for proper initiation of translation and a stop (TGA) codon necessary for proper termination.
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Fig. 3.3. Schematic representation of major steps in generation of recombinant expression
plasmid vector pcDNA3.1-FcγR-Hind/Bam (not drawn to scale). The FcγR constructs were
PCR-amplified from the appropriate TOPO vectors using forward primer FcγR.FHind
(containing HindIII restriction site in its 5’ end) and reverse primer FcγR.RBam (containing
BamHI restriction site in its 5’ end), as indicated. Resultant PCR products were then incorporated
into pcDNA3.1 vector previously digested with both HindIII and BamHI REs. Recombinant
constructs are therefore encoded within the HindIII-BamHI sites of resulting recombinant
expression vector.
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FcγR DNAs of the correct size were extracted using a QIAquick gel extraction kit (Qiagen Inc.,
Valencia, CA). The extracted cDNAs were then cloned into the HindIII- and BamHI-digested
(i.e. within the multiple cloning site) expression vector pcDNA3.1(+), which contain SV40 ori
and CMV promoter (Invitrogen, Carlsbad, CA). Similar procedures were applied on expression
vectors pcDNA3.1(+) and P2561/2/3 using NotI and XhoI instead of HindIII and BamHI REs, as
appropriately (Fig. 3.4). Ligations were performed using T4 DNA ligase (Roche Diagnostics
North America, Indianapolis, IN) overnight at 140C. Resultant FcγR expression vectors were
then transformed into Top10 E. Coli chemical competent cells (Invitrogen, Carlsbad, CA) by
heat shock, as previously described in production of recombinant IgGs. Miniprep DNAs derived
from the colonies were screened for successful insertion and correct orientation by PCR and RE
digestions of plasmids using appropriate enzymes, followed by confirmation by DNA
sequencing in both forward and reverse directions across fusion points with selected FcγR
primers (and/or pcDNA3.1 T7 and T7 reverse primers). All constructs verified by sequence
analysis were produced in large quantities of expression vectors using EndoFree Plasmid Maxi
kits (Qiagen Inc., Valencia, CA), to be used for transfection into HeLa cells by electroporation
method.

3.2.6. Sequence analysis
MacVector software (Accelrys Inc., San Diego, CA) and BioEdit program
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) were used to identify overlapping regions and
edit sequences. Sequences were aligned with each other within the same receptor group and with
other known counterparts using the CLUSTAL function of the MEGALIGN, part of the
LASERGENE software package (DNASTAR Inc., Madison, WI). Construction of the
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Fig. 3.4. Schematic representation of major steps involved in generation of the recombinant
expression plasmid vectors pcDNA3.1-FcγR-NotI/XhoI and P2561/2/3-FcγR (not drawn to
scale). The FcγR constructs were PCR-amplified from the appropriate TOPO vectors using
forward primer FcγR.NotI (containing NotI restriction site in its 5’ end) and reverse primer
FcγR.XhoI (containing XhoI restriction site in its 5’ end), as indicated. Resultant PCR products
were then ligated into pcDNA3.1(+) or P2561/2/3 vectors previously digested with both NotI and
XhoI REs. The recombinant constructs are therefore encoded within the NotI-XhoI sites of
resulting recombinant expression vectors.
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phylogenetic tree was also based on the use of the LASERGENE's MEGALIGN part. Prediction
of potential glycosylation site was performed online using EnsembleGly website
(http://turing.cs.iastate.edu/EnsembleGly/; Caragea et al., 2007). Standardized nomenclature,
labels, and numbering of IMGT®, the international ImMunoGeneTics information system®
(http://www.imgt.org) (Lefranc et al., 2009) were used to display and discuss sequencing data
based on human reference sequences. Allelic polymorphisms and characteristic positions of the
C-like domains were described using the IMGT unique numbering for C domain (C-DOMAIN
of IG and T cell receptors (TR) and C-LIKE-DOMAIN of IgSF other than IG and TR) (Lefranc
et al., 2005).

3.3. Results
We identified macaque FcγR at the cDNA level and examined whether allelic
polymorphisms were present by analyzing PCR-amplified cDNA sequences. These sequences
were obtained from reverse transcription of whole blood total RNA extracts, followed by PCR
amplification using primers complementary to human sequences located within the beginning L
and the ending CO-TM-CYT exons. All PCR amplifications were successful in each of the nine
animals examined. The introduction of PCR artifacts was minimized by the use of a high-fidelity
polymerase with proofreading ability, and by carrying out separate PCRs and multiple clone
selections for each individual animal. The cDNA sequences determined in the present study are
available as GenBank accession numbers HQ423386- HQ423388 (FcγRIII), HQ423389HQ423393 (FcγRII), and HQ423394-HQ423396 (FcγRI).
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Fig. 3.5. Nucleotide and deduced amino acid sequences of rhesus macaque Fcγ receptor I
(FcγRI, CD64) (GenBank accession number: HQ423396). Nucleotides are numbered at right and
amino acids are numbered throughout. The amino acid numbering is in accordance with the
IMGT unique numbering system for Ig C-like domains (Lefranc et al., 2005). Following the Nterminal signal sequence (a 13 amino acid part is shown doubly underlined) is the extracellular
portion of ~270 amino acids in length. The predicted start site of the mature protein is indicated
by the number “1” below the amino acid A. +1, above the nucleotide sequence, indicates the start
of the extracellular chain. Underlined Cs indicates cysteines (n=6) that have potential to form
intra-chain disulfide bonds. Potential N-linked glycosylation sites (n=4; Caragea et al., 2007) (Nx-S/T) are represented by single-line broken boxes. Boxes with broken double line (n=3) denote
potential N-linked glycosylation sites recognized in humans only. The underlined sequence
represents the CO-TM region. The two over-line arrows at the beginning and the end of the
nucleotide sequence represent the binding regions and directions for the designed CD64.1
(forward) and CD64.10 (reverse) primers, respectively. The other two over-line arrows in the
middle of the sequence denote internal primers [CD64.9 (forward) and CD64.4 (reverse), in that
order]. Arrowheads indicate the allelic positions at which the polymorphic residues (represented
by amino acids displayed below and in parentheses) identified in this work are present.
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3.3.1. Rhesus macaque FcγRI (CD64) and FcγRII (CD32) cDNA clones exhibit the typical
mRNA primary structure of their human counterpart
Using the primer sets which were designed based on human FcγRII gene sequences, we
identified an almost full-length macaque FcγRII homologue cDNA. The molecule contains 865
bp, encoding a 288-amino acid protein (Fig. 3.6; shown is a representative sequence). The
structure of the deduced amino acid sequence was inferred by analogy to published human
sequences. It was found extensively similar to that described for human FcγRIIa mRNA
structure, typical of type I membrane IgSF C-like domain proteins. The first 12-amino acid
stretch, which formed the partial putative N terminal leader (L) region, is followed by a predicted
mature protein. The mature protein is composed of an extracellular portion of 176 amino acids,
which, as previously described for the human counterpart receptor, contains two extracellular
domains, namely [D1] and [D2].
As expected, four cysteines (C26, C68, C107, and C151), that have potential to form the
characteristic C-like intradomain disulfide bonds, are conserved in the extracellular portion (1stCYS 23 and 2nd-CYS 104 in the IMGT unique numbering; Lefranc et al., 2005). The conserved
C-like domain structure suggests that disulfide bonds are formed between C26 and C68 and
between C107 and C151 in [D1] and [D2], respectively. The conserved C-like extracellular
portion is followed by a relatively short segment of 32 amino acids (AA) that, by analogy to
human CD32a, represents the connecting region (CO) of 10 AA and the transmembrane region
(TM) of 22 AA. The remaining amino acids of the deduced sequence form the partial C-terminal
cytoplasmic (CYT) region. Three potential N-linked glycosylation sites are conserved between
humans and macaques, two of which, [D1] N97 and [D2] N95 (IMGT unique numbering;
Lefranc et al., 2005) are present in the extracellular portion, whereas the third one, [CYT] N10,
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located in the CYT region, has probably no functional significance (Table 3.3). Macaques carry
two additional N linked glycosylation sites [D2] N77 and N88 (resulting from amino acid
changes) compared to humans (Table 3.3 and Fig. 3.6). However, these two positions are
polymorphic: the first one, [D2] 77, in rhesus macaques, the N glycosylation site being or not
present, whereas the second one, [D2] 88, is polymorphic in humans, and may have an Nglycosylated site as shown in the ‘2fcb’ 3D structure (IMGT/3Dstructure-DB; Ehrenmann et al.
2010). As in humans, two YxxL signatures, separated by 11 amino acids and representing a
typical immunoreceptor tyrosine-based activation motif (ITAM; YxxLx(7–12)YxxL), are present
in the CYT region.
Similar to FcγRII, macaque FcγRI cDNA clones also show a typical human FcγRI
mRNA organization (Fig. 3.5). The obtained 1,027-bp-encoded 342-amino acid polypeptide
starts with a putatively partial leader region of 13 residues, followed by the extracellular region
consisting of three domains [D1], [D2], and [D3] and is 267 amino acids in length, ending with a
CO region (7AA), a TM region (23 AA) and a partial CYT region. As in humans, six cysteines
(C26 and C68, C107 and C151, as well as C195 and C243), each pair of which (1st-CYS 23 and
2nd-CYS 104 in the IMGT unique numbering; Lefranc et al., 2005) forms disulfide bonds of the
[D1], [D2] and [D3] domain, respectively, are conserved in macaques. However, only four
potential N-linked glycosylation sites, [D1] N44, [D2] N95, [D3] N6 and N80 (Table 3.3 and
Fig. 3.5), are present in macaques as compared to the seven present in humans.
Together, these results show that rhesus macaque FcγRII and FcγRI cDNA clones exhibit
the typical mRNA primary structure/organization of their corresponding human receptor.
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Fig. 3.6. Nucleotide and deduced amino acid sequences of rhesus macaque Fcγ receptor II
(FcγRII, CD32) (GenBank accession number: HQ423393). Nucleotides are numbered at right
and amino acids are numbered throughout. The amino acid numbering is in accordance with the
IMGT unique numbering system for Ig C-like domains (Lefranc et al., 2005). Following the Nterminal signal sequence (a 12 amino acid part is shown doubly underlined) is the extracellular
portion of ~180 amino acids in length. The predicted start site of the mature protein is indicated
by the number “1” below the amino acid A. +1, above the nucleotide sequence, indicates the start
of the extracellular chain. Underlined Cs (n=4) indicates cysteines that have the potential to form
intra-chain disulfide bonds. Potential N linked glycosylation sites (n=5; Caragea et al., 2007) (Nx-S/T; x denotes any amino acid) are represented by broken boxes, of which those with broken
double-line (n=2) denote potential N-linked glycosylation sites not recognized in humans. The
underlined sequence corresponds to the CO-TM region. Closed boxes illustrate the two YxxL
signatures, separated by 11 amino acids in the intracellular cytoplasmic tail, which represent a
typical immunoreceptor tyrosine-based activation motif (ITAM; YxxLx(7–12)YxxL) in the
molecule. The two over-line arrows at the beginning and the end of the nucleotide sequence
represent the binding regions and directions for the designed CD32.1 (forward) and CD32.8
(reverse) primers, respectively. The other two over-line arrows in the middle of the sequence
denote internal primers [CD32.3 (forward) and CD32.2 (reverse), in that order]. Arrowheads
indicate the allelic positions at which the polymorphic amino acids (represented by amino acids
displayed below and in parentheses) identified in this work are present. The closed black circle
indicates a functional polymorphic amino acid in human CD32 (131 H/R), known to define the
specificity of human CD32 for IgG2.
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3.3.2. The rhesus macaque CD64 and CD32 extracellular C-like, ligand-binding portion
shares high homology with that of human CD64 and, to a lesser degree, CD32, respectively
We compared the FcγRI and FcγRII deduced amino acid sequences obtained from all
nine macaques examined with the corresponding sequences in humans. The IMGT Collier de
Perles representation of CD32 and CD64 [D1] and [D2] domains are shown in Fig. 3.7. This
representation allows to locate amino acids within a topological context by bridging the gap
between linear amino acid sequences and 3D structures (Kaas et al., 2007). Figures 3.9, 3.10,
3.11, and 3.12 show that rhesus macaque deduced proteins display totally conserved intron–exon
boundaries and exhibit high homology in sequence compared to their human counterparts. For
the extracellular portion alone, amino acid comparisons between these two primate species
revealed a high level of similarity, which were ~88–90% for CD32 (18–22 changes in the entire
176-amino-acid extracellular region) and ~94–95% for CD64 (14–16 changes in the entire 267amino-acid extracellular region) (percentage ranged depending on the alleles considered in
comparison). For macaque CD32, these amino acid differences are distributed equally (n=8 to
11) between [D1] and [D2] domains (Fig. 3.10). However, for CD64, while each of the two first
domains [D1] and [D2] show relatively equivalent number (n=6 to 8) of amino acid
differences(compared to humans), its third domain [D3] displays the least change (n=2) (Fig.
3.9). The TM region in macaque CD32 and CD64 share ~83% (number of amino acid
differences, n=5) and 93% (n=2) identity with that in humans, respectively. Thus, the number of
macaque/human amino acid differences in these two receptors is substantially lower in the TM
region than in the C-like domains.No attempt was made for comparing the L or CYT region
sequences, as when designing primer sets, we did not aim to confirm the full length of the
receptors (several residues at L and CYT terminals were not present in the final cloning
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products). As mentioned above, two additional potentially glycosylated N are observed in
macaque CD32 (Fig. 3.6). In contrast, two residues of this type are replaced by other amino acids
in CD64 (Fig. 3.5). Furthermore, replacement of human [D2] T101 (148) in CD64 with A in
macaques results in breaking of the potential N-linked glycosylation motif of [D2] N99 in the
receptor. These amino acid changes are present in all animals examined, with the exception of
the polymorphic amino acid CD32 [D2] 77 (128 in sequence).
All but one of the human CD32a amino acids known to be crucial for IgG binding
(Maxwell et al., 1999) are conserved in macaque CD32. These residues include: [D2] K29 and
P30 (BC loop), S79 and D82 (D strand), and Y113 (FG loop) (113, 114, 130, 133, and 157 in
sequence, respectively), which presumably directly contact the IgG Fc ligand; [D2] L36, P87 and
I108 (115, 134, and 155 in sequence), which presumably have the ability to affect conformation
of the loops; [D2] H80 (131 in sequence) (D strand), the established low-responder polymorphic
allele (Fig. 3.6). The only exception is at position [D2] 81 (132 in sequence): it is L in humans
but M in macaques. [D2] M81 is found in all nine macaques examined. It is noteworthy that all
nine examined macaques display [D2] H80 (131 in sequence) (Fig. 3.10), the well known IgG2
low-responder polymorphic allele in humans (Warmerdam et al., 1991). Because no human
CD64a crystal structure has been solved to date (Ellsworth et al., 2010), and thus no specific
residues crucial for ligand binding have been established, it is not possible to identify potential
conserved IgG-binding amino acids in the macaque CD64 sequence. However, at least three
binding interface residues in [D2], W3, W26, and K77 (87, 110, 128 in sequence) found to be
totally invariant among all human FcγRs (Radaev et al., 2001), are completely conserved in all
nine macaque CD64 proteins (Fig. 3.9). These amino acids are also conserved in most macaque
CD32 proteins examined (Fig. 3.10).
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Table 3.3. Correspondence between sequence positions and IMGT unique numbering for potential N-linked glycosylation sites in
rhesus macaque FcγRsa.
CD32 domains
Position

[D1]

In sequences
61
In IMGT
97
Compared
Conserved
to human

CD64 domains

[D2]
128
77
Polymorphic

135
88
Polymorphic

[CYT]

[D1]

[D2]

142
95

213
10

42
44

142
95

178
6

223
80

Conserved

Conserved

Conserved

Conserved

Conserved

Conserved

a

[D3]

Abbreviation and full gene designations are the following: FcγRI: IgG Fc high affinity I receptor (CD64); FcγRII: IgG Fc low affinity

II receptor (CD32); FcγRIII: IgG Fc low affinity III receptor (CD16).
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Table 3.4. Location and type of allelic polymorphism present in rhesus macaque FcγRsa.
[D1] amino acid positions (number of animals)b
FcγR
(total novel
6
18
55
60
75
79
polymorphism)c (5)d (15.2) (90)
(96) (117) (121)
L/P
CD16 (2)
--------------------(1)
M/R
V/I
CD32 (9)
----------------(4)
(1)
V/G
Q/R
V/A
CD64 (3)
------------(1)
(1)
(1)

[D2] amino acid positions (number of animals)
93
119
125
126
128
133
(9)
(40)
(46)
(47)
(77)
(82)

140
(93)

-----

-----

-----

-----

-----

-----

-----

-----

T/P
(3)

A/T
(1)

K/I
(5)

S/A
(1)

N/K
(5)

N/D
(4)

Q/R
(4)

-----

-----

-----

-----

-----

-----

-----

-----

92
(8)
A/T
(2)

a

Abbreviation and full gene designations are the following: FcγRI: IgG Fc high affinity I receptor (CD64); FcγRII: IgG Fc low affinity

II receptor (CD32); FcγRIII: IgG Fc low affinity III receptor (CD16).
b

Number of individual animals (among of the nine animals examined) whose sequences exhibit polymorphism.

c

Number of novel allelic polymorphic amino acids that were identified in this work.

d

Numbers in parentheses indicate the IMGT positions per domain (Lefranc et al., 2005).
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Together, these data show that the extracellular C-like, ligand-binding portion of rhesus
macaque CD64 and CD32 shares extensive homology with that of human CD64 and, to a lesser
degree, CD32, respectively.

3.3.3. A relatively high level of intra-species polymorphism is present in macaque FcγR
sequences
Nine (M55R, V79I, T93P, A119T, K125I, S126A, N128K, N133D, and Q142R) or three
(V6G, Q18R, and V60A) allelic polymorphic residues were identified from all examined
macaque FcγRII or FcγRI alleles, respectively (Table 3.4). In CD64, all variable residues occur
in membrane-distal [D1], whereas in CD32, most (seven out of nine) allelic polymorphic sites
are clustered on a short segment in the membrane-proximal [D2] domain (Table 3.4, Fig. 3.10,
and Fig. 3.12). Unlike FcγRII and FcγRI, the macaque FcγRIII sequence and a number of its
allelic polymorphisms have recently been described (Miller et al., 2007; Rogers et al., 2006b). In
the present study, two previously unreported CD16 allelic variants at the amino acid level were
identified from the nine macaques examined: most macaques carry [D1] L117 (75 in sequence)
and [D2] A8 (92 in sequence), whereas one of the animals exhibits [D1] P117 and two animals
exhibit [D2] T8 in their CD16 domains (Table 3.4, Fig. 3.11, and Fig. 3.12).
Among the nine macaques examined, five (CD32) and three (CD64 and CD16) distinct
allelic sequences, differing by at least one amino acid, were recognized (Fig. 3.9 and 3.10, and
data not shown).
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Fig. 3.7. IMGT Colliers de Perles of rhesus macaque CD32 (FcγRII) C like [D1] (I), and [D2]
(II) as well as CD64 (FcγRI) C-like [D1] (III), [D2] (IV) and [D3] (V) domains (on one layer;
obtained with the IMGT/Collier-de-Perles tool in the IMGT/DomainGapAlign) (Ehrenmann et
al., 2010). Colliers de Perles is the 2D graphical representations of IG and TR V, C domains,
highlighting conserved amino acids. The conserved C (position 23), and C (position 104), are
indicated. Shaded circles or squares represent positions at which hydrophobic amino acids (I, V,
L, F, C, M, A) and W are found in more than 50% of analyzed IgSF sequences. The BC loop,
CD transversal strand, and FG loop are limited by amino acids displayed in squares. Hatched
circles indicate missing positions according to the IMGT unique numbering for C-DOMAIN and
C-LIKE-DOMAIN (Lefranc et al., 2005). Arrows indicate the beta-strand direction.
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Fig. 3.8. A phylogenetic tree indicating the amino acid sequence similarity among independent
allelic variants of macaque FcγR molecules identified in this study. Also included are a
representative human corresponding receptor and a computationally predicted CD32 and CD64like sequences (see Figures 3.5 and 3.6 for GenBank accession numbers of these sequences).
Phylogenetic distances were computed from the CD32 and CD64 amino acid sequences aligned
in Figures 3.6 and 3.5. For CD16, a representative human (“CD16aHu”; GenBank accession
number: AK291451.1) and macaque CD16 are included (“CD16Rogers2006”; GenBank
accession number: ABD83659). The numbers next to the branches indicate the percentage of
replicate trees. The evolutionary distance bar denotes the number of substitutions per site.
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Fig. 3.9. Alignment of the deduced amino acid sequences of rhesus macaque CD64 (FcγRI)
(GenBank accession numbers: HQ423394-HQ423396) (obtained by cloning and sequencing
whole blood cDNAs) with a human CD64a representative (shown as “Human”; GenBank
accession number: AK291451.1). The deduced amino acid sequences of the macaque CD64 are
compared and residues that differ from the human CD64a sequence are shown. Included are only
macaque sequences carrying independent allelic polymorphic amino acids (n=3), in which each
allele has a single polymorphic site or a unique combination of polymorphic sites. A
computationally predicted macaque CD64-“like” [“RhesusP”; GenBank accession number
(updated 6/1/2010): XR_013029] was also counted in. Hyphens illustrate identical residues and
dots represent the IMGT gaps (missing amino acids) inserted to maximize alignment.
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Fig. 3.10. Alignment of the deduced amino acid sequences of rhesus macaque CD32 (FcγRII)
(GenBank accession numbers: HQ423389-HQ423393) obtained by cloning and sequencing
whole blood cDNAs with a human CD32a representative (shown as “Human”; GenBank
accession number: BC020823.1). The deduced amino acid sequences of macaque CD32 are
compared and amino acids that differ from the human CD32a sequence are shown. Included are
only macaque sequences carrying independent allelic polymorphic amino acids (n=5), in which
each allele has a single polymorphic site or a unique combination of polymorphic sites. A
computationally predicted macaque CD32 [“RhesusP”; GenBank accession number (updated
6/1/2010): XM_001118066.2] was also counted in. Hyphens indicate identical residues and dots
represent the IMGT gaps (missing amino acids) inserted to maximize alignment. The broken-line
box represents the region where macaque polymorphic sites are clustered. The unbroken-line box
indicates the eight-amino acid stretch bearing multiple N substitutions (see text for details).
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Thus, these results suggest a relatively high level of intra-species heterogeneity of CD32
and, to a lesser extent, CD64 and CD16, in rhesus macaques.

3.3.4. Susscessful generation of recombinant FcγR gene cDNA constructs as well as their
cloning and expression vectors
The cDNAs that encode the extracellular domains of rhesus macaque CD64, CD32, and
CD16, were successfully annealed and amplified by PCRs or SOE-PCRs (Fig. 3.13). These
cDNA constructs were subsequently ligated properly into pCR2.1 TOPO TA cloning.
Sequencing-verified cloning vectors were digested with appropriate REs to release each FcγR,
which was subsequently subcloned into pcDNA3.1(+) (Invitrogen, Carlsbad, CA) on HindIII and
BamHI RE sites, downstream of and in-frame with the promoter sequence, yielding the
constructs pcDNA3-FcγRs-Hind-Bam (Fig. 3.3). Similar procedures were carried out for
pcDNA3.1(+) (Invitrogen, Carlsbad, CA) and NotI and XhoI REs, creating pcDNA3-FcγRs-NotXho recombinant expression vectors (Fig. 3.4). Additional expression plasmids, termed
P2561/2/3-FcγRs-Not-Xho, were also made by ligating the NotI-XhoI-digestive FcγR cDNAs
into P2561/2/3 plasmids excised with the same REs (Fig. 3.4).
The insert was verified for correct size and proper orientation by RE digestion (Fig.
3.13). RE analysis using EcoRI, HindIII and BamHI pair, as well as NotI and XhoI pair, revealed
agarose gel band(s) [a double band pattern was observed when the FcγR cDNAs also contained
the same RE site(s)] corresponding to the expected molecular weight/size of about 1.1, 0.9, or
0.8 kb for CD64, CD32, or CD16, respectively, indicating that each of the constructs has been
inserted into the expression vectors (Fig. 3.13). Selected recombinant plasmids were
subsequently produced in large quantities using EndoFree Plasmid Maxi kits (Qiagen Inc.,
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Fig. 3.11. Schematic representation illustrating the extracellular domain 1 ([D1], or EC1)
putative secondary structure of a representative sequence from each of three rhesus macaque
FcγR classes in alignment with those in humans: no variation at known human functional
positions is found in the animal molecules. (A) FcγRI (CD64), (B) FcγRII (CD32), (C) FcγRIII
(CD16). The black texts above each sequence secondary structure depict the variations found in
rhesus macaques, with the vertical arrows showing their relative positioning. Blue boxes,
residues involved in interdomain hinge packing; red boxes, putative Fc binding residues
(contacting B chain of IgG); blue star, predicted N-linked glycosylation site (human only); black
star, predicted N-linked glycosylation site. Rh, rhesus macaque; Hu, human. These
representations were constructed based on Radaev et al., 2001; Zhang et al., 2000; and Maxwell
et al., 1999.
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Fig. 3.12. Schematic representation illustrating the extracellular domain 2 ([D2], or EC2)
putative secondary structure of a representative sequence from each of three rhesus macaque
FcγR classes in alignment with those in humans: no variation at known human functional
positions is found in the animal molecules. (A) FcγRI (CD64), (B) FcγRII (CD32), (C) FcγRIII
(CD16). The black texts above each sequence secondary structure depict the variations found in
rhesus macaques, with the vertical arrows showing their relative positioning. Blue boxes,
residues involved in interdomain hinge packing; yellow boxes, putative Fc binding residues
(contacting A chain of IgG); red boxes, putative Fc binding residues (contacting B chain of IgG);
blue star, predicted N-linked glycosylation site (human only); black star, predicted N-linked
glycosylation site. Rh, rhesus macaque; Hu, human. These representations were constructed
based on Radaev et al., 2001; Zhang et al., 2000; and Maxwell et al., 1999.
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Fig. 3.13. Gel electrophoresis separation of DNA products resulting from PCR and SOE-PCR
annealing and amplification or digestion of clones of recombinant gene constructs of FcγRI (A),
FcγRII (B), and FcγRIII (C), as well as gel electrophoresis separation of DNA fragments
resulting from digestions of clones of recombinant FcγR gene constructs in pCR2.1 TOPO TA
cloning vector cut by EcoRI (D), in pCR2.1 TOPO TA cloning vector cut by NotI and XhoI (E),
and in P2561/2/3 expression vector cut by NotI and XhoI (F). PCR- and SOE-PCR-generated
products or fragments obtained from RE-digested DNA plasmids were separated on 1-2%
agarose gels, adjacent to DNA molecular weight standards. The gels were stained with ethidium
bromide and were visualized and photographed under UV light. RE digestions were used to
confirm that the recombinant gene constructs had each been inserted into correct region of the
vectors and in correct orientation (which were subsequently confirmed by DNA sequencing).
Number of lanes corresponding to each construct varies, as indicated by the horizontal lines. For
lanes with two bands, the above released band corresponds to the digested vector and the below
released band corresponds to the inserted DNA fragment. Lanes showing only one band (with
size similar to that of the relevant vector) correspond to clones without successful DNA ligation.
The DNA molecular weight standards are represented by lanes with multiple bands. Only
representative clones containing bands of the expected sizes are shown. The vertical arrows with
short notations show lanes corresponding to the indicated constructs.
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Valencia, CA), to be used for cellular transfection. DNA sequencing analysis confirmed the
accuracy and orientation of all these constructs in the expression vectors (data not shown).
Taken together, these data indicate that the FcγR cDNA genes were successfully
engineered into cloning and expression vector systems.

3.4. Discussion
The well-recognized protective nature of antibody responses in HIV-infection (Mascola
and Montefiori, 2010), along with the need to test candidate vaccines in the SIV-infected rhesus
macaque model, underscores the importance of characterizing Fc receptors in this species.
Indeed, recent findings indicate the importance of exploiting antibody responses that depend on
the interactions with Fc receptors to increase vaccine efficacy. Well-characterized anti-HIV
neutralizing monoclonal antibodies and even some non neutralizing antibodies show markedly
increased viral inhibitory activity when operating through an FcγR mediated mechanism (Forthal
and Moog, 2009). Using a different host-pathogen model system, it has been shown that antigenantibody complexes enhance antiviral cytotoxic T cell responses through FcγR-mediated binding
to dendritic cells (Michaud et al., 2010). Clearly, the breadth of FcγR functions appears more
extensive than what initially assumed. Therefore, the characterization of Fc receptors in rhesus
macaques is necessary to correctly and fully utilize this major animal model.
Although the FcγRII and FcγRI-“like” sequences have recently been predicted
computationally, results from our study provide the first analysis of FcγRII and FcγRI macaque
homologues along with their intraspecies allelic polymorphisms. The predicted cDNA structure
of the macaque CD32 and CD64 represents the typical primary structure of their human
counterparts, suggesting similar nature interactions with IgG molecules. Macaque FcγR exhibit
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characteristic FcγR structural features. In particular, the length of a domain and the number of
amino acids present between cysteine pairs, both of which are responsible for the folding pattern,
is shorter in FcγR (~88 and 42–44 residues, respectively) as compared to IG proteins (~110 and
no fewer than 80 residues, respectively) (Maxwell et al., 1999; Williams and Barclay, 1988). The
high amino acid sequence identity of the FcγR domains between humans and macaques is
consistent with the highly conserved nature of the individual C-like FcγR binding domains.
Nevertheless, not all amino acids from the Fc binding region and the interdomain region packing
are completely conserved in the macaque CD32 or CD64 sequences. One example is the addition
of two predicted N linked glycosylation sites at [D2] 77 and 88 in macaque CD32, and the lack
of three of these sites at [D1] 97, [D2] 88 and 99 in CD64, as compared to their human
counterparts. It is noteworthy that all these amino acid changes are recognized in the computerpredicted sequences, as well as in every individual animal examined, except for the polymorphic
[D2] 77. Given that N-glycosylation sites have the ability to affect structure/folding, cell-cell
adhesion, leukocyte expression patterns, and ligand-binding properties of FcγR (Rogers et al.,
2006; van Sorge et al., 2003), it might be predicted that these inter-species variations in
glycosylation pattern might have a functional consequence on macaque CD32 and CD64
proteins.
The majority of amino acids known to be crucial for CD32 ligand binding in humans
(Maxwell et al., 1999) are conserved in rhesus macaques. However, the human [D2] L81 is
substituted by M81 in all nine animals. As L and M are both amino acids with a hydrophobic
side chain and both favor the formation and stabilization of domain structures, it is reasonable to
speculate that no major alteration in the hydrophilic/hydrophobic profile results from this
change. Nevertheless, it is noteworthy that this position is located downstream next to the
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functionally polymorphic amino acid [D2] H/R80 (131). This residue defines the specificity of
CD32 for IgG in humans (Warmerdam et al., 1991). Interestingly, all nine macaques investigated
display H131, the IgG2 low-responder polymorphic allele. It remains to be seen, however, if this
substitution affects IgG-binding affinity and/or specificity of the receptor.
Because the C-terminal membrane-proximal [D2] domain is the principal IgG-binding
domain, its polymorphisms may influence binding properties. The N-terminal membrane-distal
[D1] domain, on the other hand, mainly plays a supporting role in domain–domain interaction;
thus, its variations might only affect the orientation of the spatial domain (Radaev and Sun,
2002). In macaque CD64 proteins, all four (including RhesusP) polymorphic amino acids occur
in [D1] (three in A strand and AB turn and the fourth one at position 93) (at amino acid 6–60),
whereas in CD32 proteins, most (seven of nine) allelic polymorphic sites are clustered on a short
segment in the middle of D2 (at amino acid 120–140 segment). Thus, these regions might be
capable of mutating easily, indicating the impact of the evolutionary forces and the active
functions of the receptors. In CD32 molecules, this short segment represents the type of smallregion, broad variation occurrence that might render the CD32 amino acid 120–140 segment a
mutation hot spot. Even more interesting is the presence of a shorter stretch of eight amino acids
located within another segment (residues 128 to 135): four of the eight residues are polymorphic,
three of these four polymorphic residues are N, and two of these three N residues are potential
glycosylated ones, thus indicating that this segment/stretch represents the most actively
functional and evolutionarily instable area of the molecule. Although the polymorphic variations
identified in the present study, including the two novel CD16 variants, are entirely located in the
ligand-binding regions, no single, specific variation is at a location known to be crucial for IgG
binding in the corresponding human molecules. However, even a single amino acid change may
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significantly alter the ligand-binding affinity of FcγR. IgG-FcγR interactions are complex and
multi-facial, and therefore, until binding studies are carried out, it is difficult to predict the
functional implications of these allelic variations.
Under natural evolutionary selection, polymorphisms, when occurring co-locally in both
FcγR molecules and their native Fc ligand within the binding areas, have the potential to
optimize functional activity and increase the binding fitness of both interacting players (Kim et
al., 2001). Also, because of the extensive contact surface and multiple interactive residues,
interactions between different FcRs and homodimeric Fc fragment of IgG (ligand) subclasses are
complex. For instance, both the CH2 and CH3 domains of IgGs are involved in binding, with
participated amino acids bind with different affinity depending on particular IgG subclass and
the corresponding FcγR class members (Shields et al., 2001; Burton and Woof, 1992).
Additionally, these interactions are asymmetrical (i.e. overlapping but not identical residues in
both Fc fragments may take part in binding). Recent work from our group demonstrates the
existence in macaques of a high level of IgA and IgG intra-species polymorphisms, particularly
in the IgG2 and IgG4 subclasses (Rogers et al., 2008; Scinicariello et al., 2004; Scinicariello and
Attanasio, 2001). The amino acid changes are primarily located at CH2 domain or the hinge
region, including the lower hinge where all FcγRs bind and are responsible for most of the IgG
effector functions and properties (Radaev and Sun, 2002). Thus, as both FcγR and IgG are highly
polymorphic in macaques, the binding fitness and effector functions associated with these
molecules might vary from individual to individual (i.e. intra-species) and might differ from
those present in humans (i.e. inter-species). In order to adequately assess the binding properties
and the ability to mediate effector functions of NHP FcγRs, therefore, not only the
polymorphism of FcγRs themselves are ascribed, but also their ligand IgG genetic heterogeneity
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must also be taken into account. Whether or not the sequence differences in FcγRs in rhesus
macques (compared to humans) might be compensated by substitutions in their corresponding
IgGs, leading to the unique properties and functions of the monkey IgG molecules, is difficult to
predict and remains to be experimentally determined. Additionally, since particular allelic
variations can be associated with disease susceptibility and/or severity and may influence the
outcome of treatment with monoclonal antibodies (van Sorge et al., 2003; Cartron et al., 2002),
this high heterogeneity characteristics must be considered when designing studies and
interpreting data obtained using macaques for assessing immunogenicity and protective efficacy
of HIV vaccines or vaccines for other infectious diseases, for studying the genetic basis of IgGmediated human diseases, and for evaluating Ab- or FcγR-derived immunotherapeutic
approaches.
In this study, we have successfully constructed recombinant cDNAs for all three classes
of rhesus macaque FcγRs through two expression vector systems. In the first system, each rhesus
macaque FcγR class cDNA was amplified by RT-PCRs and annealed by SOE-PCRs using
primers with restriction sites for HindIII and BamHI, followed by cloning into pCR2.1 TOPO
TA vector, and subsequent RE digestion verification and DNA sequencing confirmation. The
FcγR cDNA was then excised from pCR2.1 TOPO TA cloning vector with HindIII and BamHI
REs and engineered into expression vector pcDNA 3.1(+) (pre-digested with HindIII and BamHI
REs), which contains CMV promoter and poly(A) signal to drive FcγR expression. An
alternative system, where instead of HindIII and BamHI sites, NotI and XhoI RE sites were used.
This first system was applied for expression of rhesus macaque FcR genes recently identified in
our laboratory, including those encoding CD16 (Rogers et al., 2006) or the FcR for IgA (CD89)
(Rogers et al., 2008). Transfection with this vector into HeLa or COS-7 cells, however, failed to
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yield cell clones stably and/or sufficiently expressing recombinant FcγRs (Nguyen, D.C,
unpublished data). Therefore, we developed a second expression vector system, which was a
“combined” vector derived from the retrovirus vector pLXSN, containing LTR (as previously
described; Fig. 2.8), that allow for the inserted gene to integrate into the host cell chromosomes.
This vector was created by transferring a portion of the vector consisting of the FcR gene – as
well as pcDNA3.1(+) promoter and poly(A) signal – into the pLXSN vector. The use of this
“combined” vector, termed P2561/2/3, has previously proved to be capable of stably expressing
recombinant FcγRs (Rogers et al., 2008 and 2006). P2561/2/3 system used in the present study,
however, differs from the system previously used in our laboratory (Rogers et al., 2008 and
2006) by its unique RE sites. This improved expression vector system has also been used for
generation of recombinant IgGs, as described in the previous chapter.
Cloning procedures are often the “bottleneck” in the use of the recombinant DNA
method. Although in this study, no transfected cell clones were created at this time for evaluation
of production of recombinant FcγRs, the successful construction of expression vectors is an
important step before further studies can be undertaken. The gene expression cDNA constructs
created in this study, which were designed (through the design of the primers) to incorporate
unique [i.e. those are not present in FcγR genes, and rare (Persic et al., 1997)] NotI-XhoI
restriction sites outside the gene coding regions for FcγRs, capable of facilitating easy cloning
and exchange of IgSF gene constructs, can be readily cloned into another particular expression
plasmid vector using RE digestion-ligation. For instance, future studies using the vector systems
created from this study (and once protein FcγRs are produced) include those for mapping of
binding interaction with ligands (IgGs) to specific epitopes, for interactions of FcγRs with the
signaling chains, and for comparative studies of rhesus macaque/human IgG/FcγR interactions.
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CHAPTER 4
17β-ESTRADIOL RESTORES ANTIBODY RESPONSES
TO AN INFLUENZA VACCINE IN A POSTMENOPAUSAL MOUSE MODEL

(PARTIAL CONTENT OF THIS CHAPTER WAS PUBLISHED AS:
NGUYEN ET AL., VACCINE 2011;29:2515–8)

4.1. Summary
Post-menopausal women belong to an age group that is highly susceptible to influenza
infection and its most serious complications. Data on the immunogenicity of influenza vaccines
in these women is, however, limited. In this study, we assessed the antibody response to
influenza vaccination in a postmenopausal mouse model. An inactivated-detergent-split vaccine
from the A/New Caledonia/20/99 (H1N1) influenza virus strain was given to three groups of
mice: ovariectomized (OVEX), OVEX with 17β-estradiol replacement (OVEX + E2), and shamOVEX. The OVEX+ E2 group produced influenza virus-specific serum antibodies, including
neutralizing antibodies, at significantly higher levels (p < 0.001) than did OVEX mice. These
levels matched those observed in the sham-OVEX group, indicating that ovariectomy negatively
modulates the antibody response to the influenza vaccine, whereas 17β-estradiol replacement
restores this response to levels observed in intact animals. Our findings suggest that
immunogenicity and efficacy of influenza vaccines need to be evaluated in postmenopausal
women, including those receiving hormone replacement therapy.
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4.2. Introduction
Influenza remains a serious public health problem, which generates heavy burdens by
annual epidemics and sporadic pandemics (Fiore et al., 2010). In the United States, influenzaassociated hospitalizations increase with increasing age (Dao et al., 2010). Co-morbidities and
serious complications, including pneumonia, respiratory failure, and sepsis, are common in older
individuals (Lee et al., 2010). Post-menopausal women belong to the age group highly
susceptible to influenza complications. Currently, the most effective method in influenza control
and prevention is the use of vaccines (Fiore et al., 2010). In the elderly, because of poor immune
responses due to immunosenescence, the rate of immunization failure for influenza vaccines may
be as high as 50% (Gravenstein et al., 1989). Unlike other infections, such as bacterial infections
and sepsis, in which females are more resistant than males (Straub, 2007), women are more
susceptible than men to influenza virus infection (WHO, 2010).
Sex hormones are known to modulate the development and function of the immune
system (Karpuzoglu et al., 2009; Bouman et al., 2005). As compared to men and pre-menopausal
women, postmenopausal women and women subjected to surgical menopause are more
susceptible to some specific disorders, including infectious diseases, and exhibit T and B cell
impairment (Kumru et al., 2004). The use of hormone replacement therapy and estrogen
replacement therapy in postmenopausal women is associated with retaining or improving both B
and T cell immune functions, as well as with partly preventing or restoring some of the immune
impairments associated with the post-menopause status (Gameiro et al., 2010). However, the
modulatory effect of estrogen on immunity to human recommended vaccines, particularly after
menopause, is largely uncharacterized.
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We hypothesized that estrogen modulates the antibody response to influenza vaccine
preparations and tested this hypothesis in the present study.

4.3. Materials and methods
4.3.1. Mice, bilateral ovariectomy, and estrogen deliver
Pathogen-free adult (8–12 weeks of age) female BALB/c mice (Charles River
Laboratories, Inc., Wilmington, MA), were housed and maintained in a pathogen-free
environment on a phytoestrogen-free diet. The animals were divided into three groups: OVEX
(subjected to ovariectomy), OVEX+ E2 (supplemented with exogenous estrogen) and Intact
(sham-OVEX, not subjected to ovariectomy) (Fig. 4.1). Each group consisted of 23–24 mice, in
which half of the mice were immunized, and the other half served as control. Surgical
ovariectomy was performed under anesthesia to remove both left and right ovaries and animals
were allowed to recover for at least one week before initiation of the experiments. 17β-estradiol
(E2) (Sigma–Aldrich Corp., St. Louis, MO) was dissolved in 100% ethanol and diluted to its
final concentrations (1 nM) in phosphate-buffered saline (PBS). The animals received 1 nM E2
in drinking water (Gordon et al., 1986). The continuous delivery of E2 began after surgeries and
lasted until the conclusion of the experiment. All animals were housed and all experimental
procedures were carried out according to local and federal guidelines.

4.3.2. Immunization
Mice were immunized subcutaneously with a primary (Day 0) and booster (Day 28) 3 μg
dose of an inactivated-detergent split influenza vaccine containing 333 μg/ml of the surface
protein hemagglutinin (HA) of A/New Caledonia/20/99 virus (H1N1) obtained from Dr. David
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Burt (ID Biomedicals, now GlaxoSmithKline Biologicals, Canada). Serum samples were
collected at weeks 2–3 pre-immunization, immediately before vaccination (Day 0), 3 weeks after
the first (3rd week post-prime) and the second (3rd week post-booster) doses, and 3 (3rd month)
and 6 (6th month) months after the second dose (Fig. 4.2). Animals were monitored for adverse
reactions to immunization such as redness, swelling, or the formation of granulomas at the site of
injection.

4.3.3. Evaluation of specific serum antibody response
Antibody responses were evaluated by performing a set of assays using serum samples
collected at different time-points. The assays included enzyme-linked immunosorbent assay
(ELISA), HA-specific hemagglutination inhibition (HI), micro-neutralization (MN), and singleradial hemolysis (SRH). Individual serum samples were used for all assays, with the exception of
MN assay, for which pooled serum samples were used. The whole live homologous A/New
Caledonia/20/99 virus was used for HI and MN assays. Viruses were propagated in the allantoic
cavity of 10-day-old embryonated hens’ eggs at 34oC for 2 days. Virus stocks were aliquoted and
stored at −70 ◦C until use. ELISAs were performed to detect IgM, IgG, IgG1, and IgG2a specific
for viral HA by standard end-point dilution as previously described (Katz et al., 1997). Test sera
were treated with receptor-destroying enzyme (RDE; purified neuraminidase from Vibrio
cholerae, Denka Seiken Co. Ltd., Tokyo, Japan). Control negative mouse sera (five to seven
samples) were included in each ELISA to establish negative endpoint cut-offs. Titers for immune
sera were calculated as the reciprocal of the highest dilution of test sera that gave an absorbance
reading value greater than twice the mean absorbance with one standard deviation of the control
sera at an equivalent dilution. A four-fold or two-fold increase in titer, for individual and pooled
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Fig. 4.1. Grouping of animals. Numbers denote individual animal numbering (for label purpose).

Fig. 4.2. Immunization and blood collection timeline.
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serum comparison, respectively, was considered statistically significant for specific
enhancement. Sera were tested for HI antibody using whole live homologous A/New
Caledonia/20/99 virus (8 HA units per 50 μl PBS), by a standard HI assay (Stephenson et al.,
2004). A four-fold or greater increase in HI titer was considered indicative of significant
enhancement.
Neutralizing antibody activity was determined according to the MN assay as previously
described (Stephenson et al., 2004). The presence of viral protein was detected by ELISA with a
monoclonal antibody to the influenza A NP (Katz et al., 1997). MN titers were expressed as
reciprocal of the highest dilution of serum that gave 50% neutralization of 100 TCID50 of virus
in Marbin Darby canine kidney cells. Sera were considered positive for antibody if titers of ≥80
were obtained in both assays; a fourfold or greater increase in MN titer was considered indicative
of specific enhancement. The SRH assay was performed using chicken red blood cells as
previously described (Stephenson et al., 2004). A 25% erythrocyte suspension was coated with
an amount of 5,000 HAU per ml of homologous A/New Caledonia/20/99 virus. Plates were
prepared by incorporating 0.6 ml of virus-treated erythrocytes together with 8.4 ml of 1% melted
agar (Sigma–Aldrich Co., St. Louis, MO). An SRH zone of 25mm2 was considered protective
(to 50% subjects) and an increase of equal or greater than 50% in the zone represented a
significant antibody rise.

4.3.4. Data analysis
Serum HI antibody titers underwent log 2 transformation; the initial serum dilution was
1/10, and undetectable titers were assigned a value of 5. Comparison of Ig titers was referred to
log10 transformation of ELISA end-point titers. The SPSS program (SPSS Inc., Chicago, IL)
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version 12 was used for statistical analysis. Analysis among multi-group data was carried out
using ANOVA, followed by Tukey’s honestly significant differences test, or Tamhane’s T2 test
when the test of homogeneity of variances (Levene’s statistic) indicated that the variance
between the groups was not equal. Non-parametric data were compared by Mann–Whitney Utest after Kruskal–Wallis analysis of variance. The null hypothesis was rejected at p > 0.05.

4.4. Results
All immunized mice produced anti-HA specific IgG and IgM responses following the
primary dose. Antibody titers substantially increased after the booster dose (Fig. 4.3), with IgG
being the predominant antibody class observed. The rise in specific antibody titers of both Ig
classes post-prime was specific (from four- to seven-fold and significantly higher with p < 0.001)
in the OVEX+ E2 and Intact when compared to the OVEX mice. Antibody levels increased
substantially post-booster immunization (p < 0.001). No significant difference (p = 0.557) in
antibody titers was observed between the OVEX+ E2 and Intact mouse groups for both time
points and for both Ig classes. Specific IgG1 and IgG2a subclass antibodies were substantially
induced. IgG1 levels were in general higher than IgG2a levels, regardless of the presence of E2.
No statistically significant change was observed in titer for all three groups of mice of the same
time points within each subclass of Ig.
Animals from all groups generated a limited, but detectable HI antibody titers 3 weeks
post-primary immunization. After the boosting dose, however, serum HI antibody titers
dramatically increased (up to 128-fold) for all groups (Fig. 4.3). At this time point, the titers from
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Fig. 4.3. Specific protective antibodies were induced and restored in the presence of 17βestradiol (E2) through six months after the boosting immunization. Titers expressed as values of
mean log2 (for HI titer) or mean log10 (for ELISA IgM/IgG titers)±standard deviation (SD); titers
of 2.33 (mean log2) and 2.00 (mean log10) for HI titer and ELISA IgM/IgG titers, respectively,
were the detection limit. ¥No statistically significant change was observed in titer for all three
groups of mice at the same time points within each subclass of Ig. *Changes in titer of the
OVEX+ E2 and Intact groups of mice as compared to that of the OVEX group of mice
[specifically increased, and with statistical significance (p < 0.05)] and of the OVEX+ E2 and
Intact groups of mice as compared to each other [no statistically significant change (p > 0.5)]; all
considered at the same time point. */¥Increase in titer with (p < 0.05; OVEX+ E2 group) and
without (p > 0.05; Intact group) statistical significance as compared to the OVEX group of mice.
§

Pooled sera (no SD and no statistical comparison).
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the OVEX+ E2 and Intact mouse groups were similar, and at least four-fold higher than those
from the OVEX group (p = 0.001). As a four-fold increase in HI titer is considered protective,
our results demonstrate a specific and significant elevation of HI antibody levels in the OVEX+
E2 and Intact mice as compared to the OVEX group. Results from the SRH assay show that the
hemolytic areas produced by the OVEX+ E2 or Intact sera were 62% and 65% greater than those
obtained with OVEX sera respectively, while these two former areas differed only by 2% and the
unvaccinated sera yielded no hemolytic zone (Fig. 4.4).
Together, these results show the presence of similar antibody levels in the OVEX+ E2
and Intact groups, and the presence of significantly higher antibody levels in these groups as
compared to the OVEX group.
Maintenance of long-term vigorous immune responses is important for overall vaccine
efficacy. Therefore, we evaluated anti HA antibody titers produced three and six months after the
booster immunization using the same set of assays used to detect antibody levels at earlier time
points. Fig. 4.3 and Table 4.1 show the level and kinetics of these responses. IgG levels peaked
three months post boost for HI and MN antibodies, whereas IgM reached maximum levels threeweek post-boost, with no exceptions for all groups. Influenza virus-specific serum antibodies
were present three and six months post-boost regardless of the presence of estrogen (Fig. 4.3).
IgG1 and IgG2a levels were maintained through six months after the boosting immunization.
Again, antibody responses were not significantly different (p > 0.05) between the OVEX+ E2
and Intact groups, but were specifically and significantly higher (p < 0.001) than those in the
OVEX group three and six months post-boost. Similarly, results from SRH assay showed a
significantly higher antibody levels in the OVEX+ E2 and Intact groups as compared to the
OVEX group: the hemolytic area produced by the OVEX+ E2 or Intact sera was greater than that
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yielded by the OVEX sera by 66% and 68%, respectively (for the three-month time point), and
by 74% and 87%, respectively (for the six-month time point); all these zones were greater than
25 mm2 (data not shown). No significant differences between the OVEX+ E2 and the Intact
groups (their hemolytic areas differed by 1% or 7% at three- and six-month, respectively) were
seen. Results from the SRH assay cannot be used to obtain quantitative determinations.
However, SRH results were used to confirm the finding that the OVEX+ E2 group produced
antibody responses at levels produced by the Intact group.
All tested serum antibody (IgG, IgM, HI, and MN) titers at all times points from all
control (unvaccinated) mice of the three groups were below detectable level (data not shown).
Together, these results suggest that exogenous administration of estrogen restores
production of specific antibody responses, but does not influence the TH1/TH2 pattern, at least up
to six months after administration of the booster dose.

4.5. Discussion
Gender dimorphism in responses against pathogens and in autoimmune diseases has been
observed in both humans and rodent models (Klein et al., 2010; McCombe et al., 2009). Indeed,
the presence of estrogen and androgen receptors on progenitor and mature cells of the immune
system suggests an important role for sex hormones in hematopoiesis and development of innate
and adaptive immunity (Cunningham and Gilkeson, 2010; Rahman and Christian, 2007). The
influence of 17β-estradiol on B-cell activity and development of antibody-mediated autoimmune
diseases has been characterized (Grimaldi et al., 2005). However, it is recognized that
information on the role that 17β-estradiol play in the modulation of antibody responses to
vaccines is limited (Klein et al., 2010). Results from our study directly indicate a modulatory role

210

Fig. 4.4. Effect of 17β-estradiol (E2) on influenza-specific antibody production as measured by Single Radial Hemolysis (SRH) assay.
Specific antibodies were restored in the presence of estrogen from three weeks through six months after the boosting immunization.
BALB/c mice were s.c. immunized with monovalent influenza vaccine antigen of A/New Caledonia/20/99 (H1N1) virus strain. Serum
samples were collected one-, three-, and six-months after the boost (Two-Dose Vaccination) immunization. Agarose gels were used
and results are read directly by measuring diameter of lysis ring that is directly proportional to the concentration of antibodies in test
sera. Each sample was tested in duplicate.
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Table 4.1. Neutralizing antibody titers in ovariectomized (OVEX) mice, OVEX mice subjected
to 17β-estradiol (E2) replacement (OVEX + E2) and Intact mice.
MN titer
Mouse groupa

Three months post-

Six months post-

2nd vaccine dose

2nd vaccine dose

OVEXb

640c

320

OVEX + E2b

5,120d

2,560d

Intactb

5,120d

2,560d

a

Each group of 11–12 BALB/c mice were s.c. immunized with 3 μg/dose of the HA antigen.

b

All MN assays used pooled sera (no SD).

c

Titers expressed as the reciprocal of the highest dilution of serum that gave 50% neutralization

of 100 TCID50 of virus in MDCK cells.
d

Increased in titer of equal or greater than fourfold as compared to the OVEX group of mice of

the same time course and of less than fourfold as compared to each other indicated with this
same note (d).
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for E2 replacement on the response to an influenza vaccine in a post-menopausal animal model.
In a similar model, E2 replacement resulted in improved protection against herpes simplex virus2 (HSV-2) genital challenge as compared to placebo and progesterone (Bhavanam et al., 2008)
and estrogen administered in conjunction with a specific vaccine HSV-2 improved protection
(Pennock et al., 2009). Thus, it is reasonable to postulate that postmenopausal women might
respond differently to vaccine administration and that E2 replacement might up-modulate
responses to vaccines in these women.
The ability of E2 to restore specific anti-influenza HA antibody responses, which provide
the essential protective role in influenza infection, in ovariectomized animals could be related to
up-modulation of TH2 activity, as estrogen is known to exhibit reciprocal regulatory effects on T
helper cells by inhibiting TH1 cytokine production and promoting that of TH2 cells (Salem,
2004). Alternatively, this finding could be a result of the skewed-TH2 responses that are known
to be produced by Balb/c mice (Sacks et al., 2008). In our study, although anti-HA specific IgG1
(TH2-related) was higher than IgG2a (TH1-related) and anti-HA specific IgG1 increased earlier
than IgG2a in all groups of mice, neither ovariectomy nor E2 levels had an effect on IgG1/IgG2a
levels. The mechanisms underlying the ability of estradiol to up-modulate the response to the
influenza vaccine are most likely complex and may involve pathways mediated by estrogen
receptors as well as receptor independent pathways. Clarification of these mechanisms, as well
as assessment of protective efficacy through challenge studies, will provide insight for the design
of estradiol-based intervention strategies to increase the efficacy of influenza vaccines in
postmenopausal women.
The incidence of influenza infection, as well as related morbidity and mortality, may
differ between males and females, are often related to age and may vary between countries. For
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example, the outcome of influenza virus infection is generally worse for females, but the
magnitude of these differences varies across geographical regions (WHO, 2010). Most reports of
cases of seasonal influenza do not analyze data for sex differences, and when sex differences are
analyzed there is no assessment of the interaction between sex and age. Although humoral
immune responses to influenza vaccines have been found to be consistently higher in women
than in men, clinical studies focusing on the effectiveness of these vaccines do not assess neither
the role of sex nor the interaction between sex and age (Klein et al., 2010). Thus, studies carried
out in animal models provide needed insight to understand the role that menopause plays in the
response to vaccines. As life expectancy increases worldwide, the size of the postmenopausal
population will increase accordingly. At the same time, influenza epidemics and pandemics are
expected to continue representing a major global health threat. Older individuals are known to be
at risk of serious influenza-associated complications while, at the same time, responding poorly
to vaccines. Postmenopausal women would have the added disadvantage of impaired responses
caused by a changing hormonal environment. Therefore, results from our study highlight the
importance of taking into account the postmenopausal status when evaluating vaccine efficacy
and designing strategies to control epidemic and pandemic influenza.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS

Phylogenetically positioned closely to humans, rhesus macaques are being increasingly
used as an animal model for studies involving a variety of human diseases, as well as for
assessing Ab-based therapeutics and vaccines, especially for HIV/AIDS research (Staprans et
al., 2010; Hérodin et al., 2005). The design and interpretation of experimental data related to
these studies often require the evaluation of humoral responses and are typically based on the
assumption that rhesus macaque Ab molecules and their interactions with Fc receptors mimic
those present in humans. This assumption has not been fully evaluated. The information
available on rhesus macaque Ab molecules and corresponding Ig Fc receptors is steadily
increasing (Warncke et al., 2012; Jacobsen et al., 2011; Rogers et al., 2008, 2006a, and 2004;
Scinicariello et al., 2004; Scinicariello and Attanasio, 2001; Calvas et al., 1999). The findings
that rhesus macaques exhibit a high level of Ab constant region polymorphism (Rogers et al.,
2008; Scinicariello et al., 2004; Scinicariello and Attanasio, 2001) suggest that their
interactions with corresponding FcRs might be heterogenous, and that the structural and
functional properties of their Ab products may not be of direct equivalence of those in humans.
Indeed, recent data demonstrated a direct correlation of key amino acid differences with distinct
functional activities (including ADCC and CDC) and FcγR binding affinity of the human and
cynomolgus IgG subclasses (Warncke et al., 2012; Jacobsen et al., 2011). However, the IgG
effector functions and pathogen clearance mechanisms in this model are largly unexplored –
mostly due to lack of specific Ab reagents. In this study, we have engineered and produced
recombinant IgG chimeras that were able to specifically recognize the NIP and were bound by
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affinity purified goat anti-monkey IgG(H+L) Abs. These recombinant Abs would be powerful
new tools for evaluation of various IgG functional properties, including activation of cellkilling mechanisms through binding with FcγRs such as ADCC, CDC, and phagocytosis, as
well as other Ig characteristics, such as their half-life and protease susceptibility.
To assess their ability in triggering specific effector functions, these recombinant IgG
molecules will be subjected to FcγR binding and other immune cell-related studies (Fig. 5.1).
Such FcγR binding properties and effector functional activities of these NIP-rhIgG chimeras
will be assessed in in vitro studies using methods established in our laboratory (Rogers et al.,
2006). For these purpose, we retained the murine Ig V gene directed against the NIP hapten, an
established specificity for Ig effector functions studies. HeLa cell lines expressing rhesus
macaque FcγRs already generated (Rogers et al., 2006; Rogers et al., 2004) or to be generated
(using the expression vector systems described in this dissertation) will be used in these
functional studies. We expect these rhesus macaque recombinant IgG subclasses to exhibit the
effector functions of the related appropriate human IgG CH regions, including FcγR binding
and activation of relevant immune effector cells. We also predict some binding affinity and
effector functional differences that might result from distint amino acid sequences of IgG
subclasses among these two species. Confirmation of the presence and potency of such IgG
effector functions with these newly created chimeric recombinant Abs will allow for their
better use in further studies.
Monoclonal Abs capable of specifically recognizing each of the rhesus macaque IgG
subclasses represent valuable tools for further characterization of Ab responses and vaccine
efficacy in this model. The relative level of IgG subclasses synthesized and present in rhesus
macaque serum, which provide insights into the mechanisms that drive Ab production in this
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model, remain unknown. Given the availability of the cloning and expression plasmids
containing the CH2/CH3 exon cDNA constructs (coding for the Fc region) created in this study,
murine mAbs able to specifically recognize rhesus macaque IgG subclass Fc regions may be
rapidly generated. Such Ab generation can be completed through DNA immunization of mice, an
approach previously described by our group (Attanasio et al., 1997) (Fig. 5.1). Resultant murine
mAbs can then be utilized to define the relative IgG isotype expression levels in normal and
SIV/SHIV-infected rhesus macaque individuals.
In this study, we have developed a flexible vector system and strategies for cloning and
expression of Ig genes in order to produce in mammalian cells functional Igs, including those
from NHP animals. As presented in the present study, complete, fully assembled IgG Abs that
retain original antigenic specificity can be created and produced from separate IgH and IgL
chains. This Ig expression system is uselful for engineering Abs with desired properties to be
used to assess the IgG structure-function relationship or to evaluate vaccines or Ab-based
therapeutic development. For example, the system might be used to enable generation of novel
Abs with V domains of particular specificity, including clinically relevant specificity – instead of
the NIP, such as those specific to antigens originated from SIV, HIV, or influenza viruses
[including the lethal H5N1 (Simmons et al., 2007)], as well as from Mycobacterium tuberculosis
(Fig. 5.1). These agents can be simply created by exchanging the Ig V gene of interest with that
of the system. Such recombinant IgG variants might even be used for passive transfer or
SIV/HIV challenge studies in rhesus macaques. Such in vivo evaluation will provide insights not
only to better define the interplay between the humoral immune system and the cell-based
effector innate immunity, but also to clarify the role of specific Ab-dependent cell-killing
effector functions in in vivo protection against these pathogens (including HIV, SIV, and
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influenza virus antigens). Those studies would, in turn, provide insights related to the in vivo
administration of therapeutic Abs.
Through genetic manipulation of Ig (not necessarily IgG) CH region genes, the effector
functions of recombinant Abs can be modified to allow for desired immune effector responses
while retaining antigen binding potency and specificity. To this end, the recombinant plasmid
constructs created in this study may be subjected to manipulation for IgG-related basic and
applied research purposes, including evaluating the pharmacologic values of recombinant Abs in
the rhesus macaque model. Modifications could also be adapted to generate recombinant Abs
with additional V and/or C functional properties, as well as for optimization (enhancement or
neutralization) of particular Fc-mediated effector functions or other functional activities, to be
used in Ab–antigen interaction studies or as therapeutic agents (Fig. 5.1). Moreover, such
materials and approaches can be utilized for studying IgG structure/function relationships, such
as changes in FcγR binding affinity due to amino acid differences by intra-species allelic
polymorphisms in CH domains or in the hinge region. These constructs might also be used for
production of well-conserved, immunogenic protein antigens for vaccine studies as well.
In light of the finding that despite the extensive sequence identity and almost complete
overlap of amino acids involved in Ab Fc binding, human and macaque CD16 molecules differ
as it relates to number of isoforms (no CD16b has been identified in macaques) and cell-type
expression patterns (as compared to human neutrophils, known to express CD16, rhesus
macaque neutrophils do not appear to express this protein) (Rogers et al., 2006b), and that distint
FcγR expression patterns and different binding properties between cynomolgus and human
FcγRs and IgGs molecules have been recently revealed (Warncke et al., 2012; Jacobsen et al.,
2011), further characterizations of FcγR classes in rhesus macaques are necessary. The cellular
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expression patterns of the rhesus macaque FcγRs identified in this dissertation – including CD64
and CD32 receptors – have been partially completed (Nguyen, D.C, unpublished data). As
previously discussed, the results obtained with genetic characterization of FcγRs validate rhesus
macaques as an animal model for vaccine development and Ab response studies, while at the
same time, underscoring the need to take into account their high degree of genetic heterogeneity
when designing experimental protocols for such studies. These results were also the basis for
creation of recombinant FcγR cDNA molecules.
A major application using a cloned (recombinant) DNA molecule is the expression of it
into a recombinant protein product. Our long term goals upon identification of the rhesus
macaque homologues of human FcγR molecules at the genetic level are to characterize those
molecules at the protein level, including determining their expression patterns on leukocyte
populations and binding properties to both human and rhesus macaques IgG subclasses. As
discussed previously, FcγRs vary in their affinity for different IgG subclasses. Moreover,
interspecies differences between Igs as well as between FcRs of NHP models as opposed to
humans might lead to variation in types immune effector responses induced by immune
complexes (ICs)-FcRs (Warncke et al., 2012; Jacobsen et al., 2011). These differences might be
ascribed onto different host defense strategies and disease susceptibility or progression of the
rhesus macaque model against invading pathogens. Better understanding of these responses
would serve to improve interpretation of immunology-related studies conducted in these models,
particularly in rhesus macaques. Such studies could provide valuable insight for development of
therapeutic agents directed at Ig and their Fc cell surface receptors. Therefore, it is important to
develop expression systems for FcγRs and assays for binding affinity of cell bound receptors
(and possibly, secreted FcγR portions), particularly given the fact that it is currently unknown
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whether or at what extent human IgGs bind rhesus macaque effector cells. Recombinant forms of
rhesus macaque FcγRs must, thus, be engineered. The first step towards these goals is to create
recombinant FcγR cDNA constructs and incorporated them into cloning and expression vectors.
We have employed the expression system and strategies developed and validated in this study to
successfully create such FcγR cDNA constructs and vectors. Indeed, our strategies can also be
adapted to be used for other rhesus macaque or other NHP IgSF molecule members as well.
The recombinant IgG chimeras, as well as the cDNA plasmid vectors of IgG subclasses
and corresponding FcγR molecules created in this study, therefore, represent both the
foundations and the fundamental tools for further studies about IgG effector functions and Ab
structure-function relationship in the rhesus macaque model (Fig. 5.1). Such studies will further
validate and improve the use of rhesus macaques as a valuable model for studies that require
assessment of IgG and FcγR functional properties and their interactions.
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